<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="pmc-domain-id">3416</journal-id><journal-id journal-id-type="pmc-domain">molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430496</article-id><article-id pub-id-type="pmcid-ver">PMC12430496.1</article-id><article-id pub-id-type="pmcaid">12430496</article-id><article-id pub-id-type="pmcaiid">12430496</article-id><article-id pub-id-type="doi">10.3390/molecules30173506</article-id><article-id pub-id-type="publisher-id">molecules-30-03506</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Quinazolines [<italic toggle="yes">a</italic>]-Annelated by Five-Membered Heterocycles: Synthesis and Biological Activity</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Lipunova</surname><given-names initials="GN">Galina N.</given-names></name><xref rid="af1-molecules-30-03506" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0177-1582</contrib-id><name name-style="western"><surname>Nosova</surname><given-names initials="EV">Emiliya V.</given-names></name><xref rid="af1-molecules-30-03506" ref-type="aff">1</xref><xref rid="af2-molecules-30-03506" ref-type="aff">2</xref><xref rid="c1-molecules-30-03506" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9140-358X</contrib-id><name name-style="western"><surname>Charushin</surname><given-names initials="VN">Valery N.</given-names></name><xref rid="af1-molecules-30-03506" ref-type="aff">1</xref><xref rid="af2-molecules-30-03506" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Dembinski</surname><given-names initials="R">Roman</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-30-03506"><label>1</label>Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences, 22 S. Kovalevskaya St./20 Akademicheskaya St., Ekaterinburg 620137, Russia; <email>lipunova@ios.uran.ru</email> (G.N.L.); <email>charushin@ios.uran.ru</email> (V.N.C.)</aff><aff id="af2-molecules-30-03506"><label>2</label>Department of Organic and Biomolecular Chemistry, Ural Federal University, 19 Mira St., Ekaterinburg 620002, Russia</aff><author-notes><corresp id="c1-molecules-30-03506"><label>*</label>Correspondence: <email>emilia.nosova@yandex.ru</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>30</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496502</issue-id><elocation-id>3506</elocation-id><history><date date-type="received"><day>09</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>23</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 16:25:51.440"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="molecules-30-03506.pdf"/><abstract><p>This review covers article and patent data obtained mostly within the period 2013&#8211;2024 on the synthesis and biological activity of quinazolines [<italic toggle="yes">a</italic>]-annelated by five-membered heterocycles. Pyrrolo-, (iso)indolo-, pyrazolo-, indazolo-, (benz)imidazo-, (benz)thiazolo-, and triazolo- [<italic toggle="yes">a</italic>]quinazoline systems have shown multiple potential activities against numerous targets. We highlight that most research efforts are directed to design of anticancer, antibacterial, anti-inflammatory, and other agents of azolo[<italic toggle="yes">a</italic>]quinazoline nature. This review emphases both the medicinal chemistry aspects of pyrrolo[<italic toggle="yes">a</italic>]-, (iso)indolo[<italic toggle="yes">a</italic>]-, and azolo[<italic toggle="yes">a</italic>]quinazolines and the comprehensive synthetic strategies of quinazolines annelated at the N(1)&#8211;C(2) bond from the perspective of drug development and discovery.</p></abstract><kwd-group><kwd>pyrroloquinazolines</kwd><kwd>indoloquinazolines</kwd><kwd>azoloquinazolines</kwd><kwd>biological activity</kwd><kwd>advanced synthesis</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Science and Higher Education of the Russian Federation</funding-source><award-id>FEUZ-2023-0021</award-id><award-id>FUWM-2024-0009</award-id></award-group><funding-statement>Funding from Ministry of Science and Higher Education of the Russian Federation, projects FEUZ-2023-0021 (<named-content content-type="citation"><xref rid="sec1-molecules-30-03506" ref-type="sec">Section 1</xref></named-content>, <named-content content-type="citation"><xref rid="sec2-molecules-30-03506" ref-type="sec">Section 2</xref></named-content>, <named-content content-type="citation"><xref rid="sec5-molecules-30-03506" ref-type="sec">Section 5</xref></named-content> and <named-content content-type="citation"><xref rid="sec6-molecules-30-03506" ref-type="sec">Section 6</xref></named-content>) and FUWM-2024-0009 (<named-content content-type="citation"><xref rid="sec3-molecules-30-03506" ref-type="sec">Section 3</xref></named-content> and <named-content content-type="citation"><xref rid="sec4-molecules-30-03506" ref-type="sec">Section 4</xref></named-content>).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-30-03506"><title>1. Introduction</title><p>Quinazoline and quinazolinone are medicinally important nitrogen heterocycles, exhibiting diverse biological activities [<xref rid="B1-molecules-30-03506" ref-type="bibr">1</xref>,<xref rid="B2-molecules-30-03506" ref-type="bibr">2</xref>]. The varied and complex effects that quinazoline compounds have on different biological systems have made them interesting for drug researchers who want to uncover all possible medical uses they might offer [<xref rid="B3-molecules-30-03506" ref-type="bibr">3</xref>]. More than 150 naturally occurring alkaloid molecules contain the quinazolinone structure either by itself or within conjugated systems; most natural products of fused quinazoline origin are [<italic toggle="yes">b</italic>]-annelated quinazolines [<xref rid="B4-molecules-30-03506" ref-type="bibr">4</xref>].</p><p>Quinazolinone natural products display a wide range of medicinal properties, including antibacterial. One of them, Luotonin A (<xref rid="molecules-30-03506-f001" ref-type="fig">Figure 1</xref>), proved to exhibit significant cytotoxicity toward the murine leukemia P-388 cell line (IC<sub>50</sub> = 1.8 &#956;g/mL); this agent acts as a topoisomerase-I inhibitor [<xref rid="B5-molecules-30-03506" ref-type="bibr">5</xref>]. Vasicinone (<xref rid="molecules-30-03506-f001" ref-type="fig">Figure 1</xref>), another natural alkaloid isolated from <italic toggle="yes">P. nigellastrum</italic>, is a potential agent for Parkinson&#8217;s disease and possibly other oxidative stress-related neurodegenerative disorders [<xref rid="B4-molecules-30-03506" ref-type="bibr">4</xref>]. Indolo[<italic toggle="yes">b</italic>]quinazoline tryptanthrin (<xref rid="molecules-30-03506-f001" ref-type="fig">Figure 1</xref>) exhibits a broad spectrum of biological activities and can act as an anti-inflammatory, anticancer, antibacterial, antifungal, antiviral, and antitubercular agent, as well as other uses [<xref rid="B4-molecules-30-03506" ref-type="bibr">4</xref>]. Rutaecarpine (<xref rid="molecules-30-03506-f001" ref-type="fig">Figure 1</xref>) is a naturally occurring pentacyclic indolopyridoquinazolinone alkaloid extracted from the traditional Chinese herb <italic toggle="yes">Evodia rutaecarpa</italic>. It has long been utilized in folk medicine for alleviating symptoms related to headaches, gastrointestinal disturbances, and various other illnesses. Building upon its medicinal potential, numerous therapeutic agents have since been developed targeting inflammation, atherosclerosis, Alzheimer&#8217;s disease, cancerous tumors, and fungal infections [<xref rid="B4-molecules-30-03506" ref-type="bibr">4</xref>]. Considering the directions of quinazolines modification for potential use in medicinal chemistry, in some cases, chemists designed the angular counterparts of [<italic toggle="yes">b</italic>]-annelated quinazoline biologically active compounds.</p><p>Annelated quinazolines synthesized by various methods have gained significant attention from researchers worldwide due to their diverse and beneficial health-related characteristics [<xref rid="B6-molecules-30-03506" ref-type="bibr">6</xref>,<xref rid="B7-molecules-30-03506" ref-type="bibr">7</xref>]. The intensive utilization of the quinazoline core for designing and synthesizing novel antibacterial agents has recently received considerable attention. Review article [<xref rid="B5-molecules-30-03506" ref-type="bibr">5</xref>], devoted to antibacterial activity of various 4(3<italic toggle="yes">H</italic>)-quinazolinone derivatives, discloses some data on thiazolo[3,4-<italic toggle="yes">a</italic>]quinazolinones active against <italic toggle="yes">B. subtilis</italic> and SAR studies on [1,2,4]-triazolo[<italic toggle="yes">a</italic>]quinazolines. Scientists combine parts from different active molecules, like quinazolines, using special techniques to create new hybrid compounds that work better and stronger [<xref rid="B8-molecules-30-03506" ref-type="bibr">8</xref>].</p><p>The introduction of new approaches to the design of biologically active derivatives with improved properties stimulates the development of modern synthetic strategies, such as green chemistry techniques, one-pot processes, and other rational methods. One-pot synthesis procedures of quinazoline derivatives, emerging as a highly efficient and sustainable strategy for the preparation of novel bioactive compounds, are summarized in the review [<xref rid="B9-molecules-30-03506" ref-type="bibr">9</xref>].</p><p>Quinazolines [<italic toggle="yes">c</italic>]-annelated by five- and six-membered heterocycles were analyzed recently [<xref rid="B10-molecules-30-03506" ref-type="bibr">10</xref>]. Different triazoloquinazoline derivatives were overviewed [<xref rid="B11-molecules-30-03506" ref-type="bibr">11</xref>], and it was stated that the condensation of 2-hydrazino-3<italic toggle="yes">H</italic>-quinazolin-4-ones with carbonic acids represents the most common synthetic approach to 1,2,4-triazolo[4,3-<italic toggle="yes">a</italic>]quinazolines, whereas their isomers, [1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolines, are obtained by cyclocondensation of <italic toggle="yes">N</italic>-cyanoimido(dithio)carbonates with 2-hydrazinobenzoic acid. A variety of biological applications of triazoloquinazolines and imidazoquinazolines are highlighted in the book chapters [<xref rid="B12-molecules-30-03506" ref-type="bibr">12</xref>,<xref rid="B13-molecules-30-03506" ref-type="bibr">13</xref>]. Synthesis and bioactivity evaluation of some pyrazolo[<italic toggle="yes">c</italic>]quinazolines were described in reviews [<xref rid="B14-molecules-30-03506" ref-type="bibr">14</xref>,<xref rid="B15-molecules-30-03506" ref-type="bibr">15</xref>].</p><p>The annelation of an additional ring at the N(1)&#8211;C(2) bond represents a crucial modification of quinazolines that enables fine-tuning of their biological activity. Consequently, [<italic toggle="yes">a</italic>]-annelated quinazolines attract substantial interest owing to their notable pharmacological properties. To date, compounds of this type have not been introduced into medical practice. Vaskevych et al. [<xref rid="B16-molecules-30-03506" ref-type="bibr">16</xref>] provided the comprehensive analysis of quinazolin-4-one heteroanalogues as biologically relevant substances and drugs. They paid special attention to cyclizations of alkenyl(alkynyl)-functionalized quinazolinones into pyrrolo-, thiazolo-, and imidazo[<italic toggle="yes">a</italic>]- and [<italic toggle="yes">b</italic>]-annelated quinazolin-4-ones; structural and electronic effects of reagents on the regio- and stereoselectivity of the cyclizations were elucidated, and relevant reaction mechanisms were clarified.</p><p>In this review, we focus on the medicinal chemistry aspects of various quinazolines [<italic toggle="yes">a</italic>]-annelated by five-membered heterocycles (<xref rid="molecules-30-03506-f002" ref-type="fig">Figure 2</xref>), encompassing both synthetic pathways and biological activities. We compile relevant literature reports within the context of drug development and discovery efforts.</p><p>A wide variety of methods are essential for constructing such annelated systems. Traditional methods for cyclocondensation may work well but also come with some drawbacks and limitations. Innovative syntheses utilizing appropriate reagents, multicomponent reactions, intramolecular C&#8211;H amidations, <italic toggle="yes">N</italic>-arylation/2-amidation cascades, along with metal-free, catalyst-free eco-friendly strategies, are becoming increasingly prevalent.</p></sec><sec id="sec2-molecules-30-03506"><title>2. Pyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolinones</title><p>In review article [<xref rid="B17-molecules-30-03506" ref-type="bibr">17</xref>], one section focuses on pyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolines, detailing their synthesis strategies and providing illustrative examples. Following this publication, numerous research teams began synthesizing similar compounds and evaluating their biological effects, with particular emphasis placed on structural derivatives of Luotonin and Vasicinone.</p><p>Rasapalli et al. [<xref rid="B18-molecules-30-03506" ref-type="bibr">18</xref>] investigated the cyclizations of quinazolinonyl enone <bold>1</bold>, using super acids, to access the C-aryl luotonins via the intermediacy of tricyclic ketones. It was found that depending on substoichiometric amounts of TfOH in TFA as a solvent the cyclization of quinazolinonyl enone <bold>1</bold> proceeds with the formation of [<italic toggle="yes">a</italic>]- or [<italic toggle="yes">b</italic>]-annelated quinazolinones <bold>2</bold> or <bold>3</bold> as triflate salts of the enol tautomers (<xref rid="molecules-30-03506-sch001" ref-type="fig">Scheme 1</xref>). It was found that in a more acidic medium, compound <bold>2</bold> is capable of effective conversion to regioisomer <bold>3</bold>. Based on data from quantum chemical calculations, the probable mechanism for the formation of regioisomeric tricyclic enols was discussed, and it was suggested that the cyclization process follows an aza-Nazarov pathway.</p><p>In subsequent work [<xref rid="B19-molecules-30-03506" ref-type="bibr">19</xref>], the same team successfully developed a facile one-pot synthesis of novel angular luotonins <bold>5a</bold>&#8211;<bold>l</bold> via a methanesulfonic acid mediated aza-Nazarov&#8211;Friedlander cyclization sequence of quinazolinonyl enones <bold>1a</bold>&#8211;<bold>l</bold> (<xref rid="molecules-30-03506-sch002" ref-type="fig">Scheme 2</xref>). Optimal conditions for the formation of tricyclic enols <bold>4</bold> with a yield of up to 59% were selected, and two-step synthesis of polycyclic compounds <bold>5</bold> was carried out without isolation of intermediates <bold>4</bold>. The structure of polycyclic compounds <bold>5f</bold> and <bold>5k</bold> was confirmed by X-ray data.</p><p>A series of angular luotonins <bold>5a</bold>&#8211;<bold>l</bold> were assayed as topo-I inhibitors at four different concentrations (0.1, 1.0, 10, and 100 &#956;M), camptothecin (CPT, at 1 &#956;M) was used as the standard. Pentacyclic derivatives <bold>5</bold> proved to be weak inhibitors of human topoisomerase I compared to CPT, despite their nearly planar structure [<xref rid="B19-molecules-30-03506" ref-type="bibr">19</xref>], which can be effectively incorporated into specific binding sites on the target biomolecules.</p><p>Vaskevych et al. [<xref rid="B20-molecules-30-03506" ref-type="bibr">20</xref>] developed an efficient approach to 1-(hydroxymethyl)-2,3-dihydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(1<italic toggle="yes">H</italic>)-ones <bold>7</bold>, the method is based on oxidative cyclization of 2-(3-butenyl)quinazolin-4(3<italic toggle="yes">H</italic>)-ones <bold>6</bold> initiated by iodosobenzene bis(trifluoroacetate) (PIFA) (<xref rid="molecules-30-03506-sch003" ref-type="fig">Scheme 3</xref>). The reaction proceeds with high regioselectivity when 2.5 eq of PIFA are used in 2,2,2-trifluoroethanol (TFE) solution at 0 &#176;C over 24 h. Quinazolinone derivatives <bold>6</bold> were obtained in good yields (63&#8211;91%) in two stages: acylation of anthranilamides with &#945;-allylacetyl chloride and subsequent thermal cyclocondensation. The structure of compounds <bold>7</bold> was confirmed by spectral data, including X-ray for derivative <bold>7f</bold>. Compounds <bold>7</bold> represent a new class of vasicinone analogs.</p><p>Arylsulfenylation (selenylation) of 2-(3-butenyl)quinazolin-4(3<italic toggle="yes">H</italic>)-ones <bold>6</bold> in nitromethane in the presence of an equimolar amount of lithium perchlorate proceeds as an electrophilic cyclization involving N(1) or N(3) atoms of quinazolone core to yield 1-arylthio(selenyl)methyl substituted angular-annulated 2,3-dihydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(1<italic toggle="yes">H</italic>)-ones <bold>8</bold> as major products and isomeric linear-annulated 2,3-dihydropyrrolo[2,1-<italic toggle="yes">b</italic>]quinazolin-9(1<italic toggle="yes">H</italic>)-one derivatives <bold>9</bold> as minor products (<xref rid="molecules-30-03506-sch003" ref-type="fig">Scheme 3</xref>) [<xref rid="B21-molecules-30-03506" ref-type="bibr">21</xref>].</p><p>Vaskevych et al. developed a selective synthetic approach to pyrroloquinazolinones based on the proton- and halogen-induced electrophilic cyclization of 2-(3-butenyl)quinazolin-4(3<italic toggle="yes">H</italic>)-ones <bold>6</bold> [<xref rid="B22-molecules-30-03506" ref-type="bibr">22</xref>]. Several protic acids (HCl, CF<sub>3</sub>CO<sub>2</sub>H, H<sub>2</sub>SO<sub>4</sub>, polyphosphoric acid, CF<sub>3</sub>SO<sub>3</sub>H) were tested, and trifluoromethanesulfonic acid was chosen as the most efficient reagent. Compounds <bold>6a</bold>&#8211;<bold>h</bold> dissolved in CF<sub>3</sub>SO<sub>3</sub>H at room temperature were converted into 1-methyl-2,3-dihydropyrrolo[2,1-<italic toggle="yes">b</italic>]quinazolin-9(1<italic toggle="yes">H</italic>)-ones <bold>10a</bold>&#8211;<bold>h</bold> with high chemoselectivity and in excellent yields (<xref rid="molecules-30-03506-sch004" ref-type="fig">Scheme 4</xref>). The linear structure was confirmed by XRD data using compound <bold>10g</bold> as an example.</p><p>Iodine, bromine, NIS, and NBS were used as halogenating agents in the synthesis of pyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolinones <bold>12</bold> and <bold>13</bold>. The reaction of compounds <bold>6a</bold>&#8211;<bold>h</bold> with 3 equiv. of iodine in acetic acid followed by the treatment with sodium iodide led to pyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolinonium salts <bold>11a</bold>&#8211;<bold>h</bold>, which when treated with sodium acetate gave 1-iodomethyl-substituted pyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolinones <bold>12a</bold>&#8211;<bold>h</bold> in an overall yield of up to 80% (<xref rid="molecules-30-03506-sch004" ref-type="fig">Scheme 4</xref>). The selective cyclization of compounds <bold>6</bold> using bromine failed due to the formation of bromination products at the double bond of quinazolinones <bold>6</bold>. The iodination of substrates <bold>6a</bold>&#8211;<bold>e</bold> with 1 eq of NIS in acetonitrile solution at 0 &#176;C allows one-step preparation of target products <bold>12a</bold>&#8211;<bold>e</bold> in high yields. The treatment of <bold>6a</bold>&#8211;<bold>e</bold> with NBS under the same conditions led to the formation of 1-bromomethyl-substituted pyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolinones <bold>13a</bold>&#8211;<bold>e</bold>.</p><p>Singh et al. developed a highly regioselective synthesis of tetrahydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(1<italic toggle="yes">H</italic>)-one derivatives <bold>16</bold>, using such building blocks as <italic toggle="yes">N</italic>&#8242;-aryl benzohydrazides <bold>14</bold> and cyclopropane aldehydes <bold>15</bold> [<xref rid="B23-molecules-30-03506" ref-type="bibr">23</xref>]. Optimal conditions for the annulation of <italic toggle="yes">N</italic>&#8242;-phenyl-2-aminobenzohydrazide <bold>14a</bold> with aldehydes <bold>15</bold> were found. The process was realized in DCM in the presence of PTSA (30 mol%) as a catalyst at room temperature. Presented easily scaled reaction follows a domino sequence of imination/intramolecular cycling/nucleophilic ring opening. The transformation proceeds via the formation of an intermediate imine species, which subsequently engages in intramolecular cyclization. The resulting dihydroquinazolin-4-one then experiences nucleophilic ring opening, followed by cyclization involving the nitrogen atom of the quinazoline ring. Interaction of differentially substituted cyclopropane aldehydes <bold>15a</bold>&#8211;<bold>j</bold> with <italic toggle="yes">N</italic>-phenylbenzohydrazide <bold>14a</bold> yielded a series of tetrahydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(1<italic toggle="yes">H</italic>)-ones <bold>16aa</bold>&#8211;<bold>ja</bold> as two diastereoisomers (trans and cis) in an overall yield of 78&#8211;85% (<xref rid="molecules-30-03506-sch005" ref-type="fig">Scheme 5</xref>).</p><p>The universality of the reaction involving <italic toggle="yes">N</italic>&#8217;-aryl-substituted anthranyl hydrazides <bold>14a</bold>&#8211;<bold>f</bold> was studied by their interaction with 4-methoxyphenyl-cyclopropane aldehyde <bold>15a</bold> [<xref rid="B23-molecules-30-03506" ref-type="bibr">23</xref>]. The formation of tetrahydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(<italic toggle="yes">1H</italic>)-ones <bold>16ab</bold>&#8211;<bold>ag</bold> was also shown as <italic toggle="yes">trans</italic> and <italic toggle="yes">cis</italic> isomers with the same ratio, except <bold>16ag</bold>, and an overall yield of 78&#8211;81% (<xref rid="molecules-30-03506-sch006" ref-type="fig">Scheme 6</xref>). It should be noted that <italic toggle="yes">N</italic>-benzyl anthranilamide and <italic toggle="yes">N</italic>-phenyl anthranilamide participate in the reaction with <bold>15a</bold>, which also led to the formation of tetrahydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(<italic toggle="yes">1H</italic>)-ones in good yields. The relative configuration of both the diastereomers (cis and trans) was established based on the nuclear Overhauser effect (NOE) experiment data of <bold>16aa</bold> and <bold>16aa&#8242;</bold> and was supported by the X-ray analysis of both diastereomers <bold>16ag</bold>.</p><p>Grinev et al. described the preparation of 1-R-4,5-didihydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>17a</bold>,<bold>b</bold> by the reaction of 2-(aminomethyl)aniline with furanones at heating in aprotic solvents (benzene, toluene) with azeotropic removal of eliminated water (<xref rid="molecules-30-03506-sch007" ref-type="fig">Scheme 7</xref>) [<xref rid="B24-molecules-30-03506" ref-type="bibr">24</xref>].</p></sec><sec id="sec3-molecules-30-03506"><title>3. Indolo[1,2-<italic toggle="yes">a</italic>]quinazolinones and Isoindolo[2,1-<italic toggle="yes">a</italic>]quinazolinediones</title><p>Indoles are widely found in pharmaceuticals and nature products; the indole-containing quinazoline derivatives were reported as protein kinase CK2 inhibitors and poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors [<xref rid="B25-molecules-30-03506" ref-type="bibr">25</xref>]. Isoindoloquinazolines have been shown to be Tumor Necrosis Factor-alpha (TNF-<italic toggle="yes">&#945;</italic>) inhibitory [<xref rid="B26-molecules-30-03506" ref-type="bibr">26</xref>].</p><p>Synthetic approaches to bioactive indolo[1,2-<italic toggle="yes">a</italic>]quinazolinones are limited. Kotipalli et al. developed an easy and convenient two-step method for the synthesis of indolo[1,2-<italic toggle="yes">a</italic>]quinazolinone derivatives, starting from 2-iodobenzamides <bold>18</bold> and indole derivatives [<xref rid="B27-molecules-30-03506" ref-type="bibr">27</xref>]. The first step involves the <italic toggle="yes">N</italic>-arylation of indole by 2-iodobenzamide derivatives via Ullman coupling. Optimal conditions for this stage were found, which allowed obtaining 2-(1<italic toggle="yes">H</italic>-indol-1-yl)-<italic toggle="yes">N</italic>-substituted benzamide derivatives <bold>19</bold> in up to 85% yield. The second step involves intramolecular C&#8211;H amidation using a palladium catalyst and AgOAc as oxidant and proceeds in toluene at 100 &#176;C in the presence of TFA (<xref rid="molecules-30-03506-sch008" ref-type="fig">Scheme 8</xref>). The series of indolo[1,2-<italic toggle="yes">a</italic>]quinazolinone derivatives <bold>20</bold> with different substituents R, R<sup>1</sup>, R<sup>2</sup> was obtained. It was shown that long alkyl chain in R<sup>1</sup> or the <italic toggle="yes">p</italic>-methoxy group in the aryl fragment leads to a decrease in yield to 30&#8211;34%; in the case R = NO<sub>2</sub>, the cyclization does not occur.</p><p>Abe et al. reported a self-relay copper (I)-catalyzed Ullmann <italic toggle="yes">N-</italic>arylation/2-amidation cascade to form functionalized indolo[1,2-<italic toggle="yes">a</italic>]quinazolinones <bold>23</bold> in one-pot from easily available 2-bromobenzamides <bold>21</bold> with indoles <bold>22</bold> in high yields [<xref rid="B28-molecules-30-03506" ref-type="bibr">28</xref>] (<xref rid="molecules-30-03506-sch009" ref-type="fig">Scheme 9</xref>). It was found that the optimal conditions for the cascade are the following: the presence of CO<sub>2</sub>Me group at the position 3 of indole, the use of CuBr as a catalyst, Cs<sub>2</sub>CO<sub>3</sub> as a base and DMSO as a solvent, boiling for 16 h. It was also shown that in the case R = NO<sub>2</sub> or R<sup>1</sup> = <italic toggle="yes">t</italic>-Bu indolo[1,2-<italic toggle="yes">a</italic>]quinazolinones could not be obtained even under boiling for 72 h. The authors discuss the proposed process pathways and note that methyl carboxylate could act as activating group in this Ullmann <italic toggle="yes">N</italic>-arylation/2-amidation cascade.</p><p>Badigenchala et al. developed a transition-metal- and base-free approach to indolo[1,2-<italic toggle="yes">a</italic>]quinazolinones [<xref rid="B29-molecules-30-03506" ref-type="bibr">29</xref>]. It was demonstrated that <italic toggle="yes">N</italic>-iodosuccinimide (NIS) can be used for intramolecular cross-coupling of C(sp<sup>2</sup>)&#8211;H and N&#8211;H bonds, leading to the formation of indolo[1,2-<italic toggle="yes">a</italic>]quinazolinones <bold>25</bold> (<xref rid="molecules-30-03506-sch009" ref-type="fig">Scheme 9</xref>). Optimal cyclization conditions were found for 2-(1<italic toggle="yes">H</italic>-indol-1-yl)-<italic toggle="yes">N</italic>-methylbenzamide, and the effect of substituents R, R<sup>1</sup>, R<sup>2</sup> on reaction ability was studied. It was shown that the presence of strong electron withdrawing (R<sup>2</sup> = 5-NO<sub>2</sub>, 7-azaindole derived) or bulky (R = <italic toggle="yes">t</italic>-Bu) group suppressed the reaction completely. Gram scale synthesis has been performed to examine the synthetic utility of the protocol.</p><p>Jiang et al. described Pd-catalyzed domino synthesis of 5-amine-indolo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>27</bold> from readily available 2-aminobenzonitriles <bold>26</bold> and 2-(2-bromophenyl)acetonitriles (<xref rid="molecules-30-03506-sch010" ref-type="fig">Scheme 10</xref>) [<xref rid="B30-molecules-30-03506" ref-type="bibr">30</xref>]. The approach involves a Buchwald&#8211;Hartwig type coupling and a base-promoted intramolecular nucleophilic reaction. It was found that in the case of EWG = COOEt, the yield of products <bold>27</bold> is reduced to 55&#8211;62%, and in the case of R = CF<sub>3</sub>, to 37%.</p><p>One approach to the synthesis of isoindoloquinazolinediones is based on a multi-component reaction (MCR) of isatoic anhydride <bold>28</bold>, amines and 2-formylbenzoic acid under different conditions (<xref rid="molecules-30-03506-sch011" ref-type="fig">Scheme 11</xref>). The reaction was carried out by heating the reagents in acetic acid at 110 &#176;C, aliphatic and aromatic amines were used, the highest yields of 6,6a-dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-diones <bold>29</bold> were obtained for the more nucleophilic aliphatic amines [<xref rid="B31-molecules-30-03506" ref-type="bibr">31</xref>]. Reddy et al. [<xref rid="B32-molecules-30-03506" ref-type="bibr">32</xref>] described the faster and greener synthesis of the analogues of compounds <bold>29</bold> via a &#946;-cyclodextrin-mediated MCR of the same reagents in water under microwave irradiation.</p><p>Esmaeili-Marandi et al. [<xref rid="B33-molecules-30-03506" ref-type="bibr">33</xref>] described novel 1,2,3-triazole-containing isoindolo[2,1-<italic toggle="yes">a</italic>]-quinazolines via a convenient three-step reaction starting from isatoic anhydride <bold>28</bold>. Interaction of <bold>28</bold> with 1-aminoprop-2-yne in water at room temperature gives 2-amino-<italic toggle="yes">N</italic>-(prop-2-yn-1-yl)benzamide, which further undergoes cyclization into isoindolo[2,1-<italic toggle="yes">a</italic>]-quinazoline <bold>30</bold> in the presence of TsOH (20 mol%) in EtOH under reflux (<xref rid="molecules-30-03506-sch011" ref-type="fig">Scheme 11</xref>). Product <bold>30</bold> was readily converted to the target compound <bold>31</bold> via click reaction with organic azides, obtained from the corresponding benzyl halogenides and sodium azide.</p><p>Mahdavi et al. developed a four-step effective and simple synthetic approach for the synthesis of novel isoinodolo[2,1-<italic toggle="yes">a</italic>]quinazolino[1,2-<italic toggle="yes">c</italic>]quinazolinones <bold>33</bold> (<xref rid="molecules-30-03506-sch012" ref-type="fig">Scheme 12</xref>) [<xref rid="B34-molecules-30-03506" ref-type="bibr">34</xref>], the method can be extended for the preparation of a library of potentially bioactive compounds. Reaction of isatoic anhydride <bold>28</bold> and amines led to various 2-aminobenzamide derivatives, and their interaction with <italic toggle="yes">o</italic>-nitrobenzaldehyde and subsequent reduction of nitro group resulted in the formation of 2-(2-aminophenyl)-3-R-2,3-dihydroquinazolin-4<italic toggle="yes">(</italic>1<italic toggle="yes">H)</italic>-ones <bold>32</bold>. Optimal conditions for the reaction of compounds <bold>32</bold> with 2-formylbenzoic acid were found: boiling in dry ethanol in the presence of <italic toggle="yes">p</italic>-toluenesulfonic acid (<italic toggle="yes">p</italic>-TSA) and tetrabutylammonium bromide (TBAB) at a ratio of <italic toggle="yes">p</italic>-TSA/TBAB = 0.5 [<xref rid="B34-molecules-30-03506" ref-type="bibr">34</xref>].</p><p>Recently, performing metal-catalyst-free green and efficient synthesis in water has become more popular because it is good for the environment and sustainable. Madhubabu et al. [<xref rid="B35-molecules-30-03506" ref-type="bibr">35</xref>] developed a short and efficient metal free, catalyst-free greener approach for the synthesis of dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-dione derivatives <bold>34</bold> in water (<xref rid="molecules-30-03506-sch013" ref-type="fig">Scheme 13</xref>). Isatoic anhydride, an amine, and 3-bromoisobenzofuran-1(3<italic toggle="yes">H</italic>)-one served as starting materials. A mixture of water and polyethylene glycol 400 (PEG-400) in a ratio of 4:1 provided the most efficient solvent system. After completing the reaction, the product underwent filtration, and the recovered solvent could be effectively reused multiple times without noticeable loss of activity compared to fresh solvent. This reliable methodology tolerates both aliphatic and aromatic amines and exhibits exceptional scalability.</p><p>Abbasian et al. [<xref rid="B36-molecules-30-03506" ref-type="bibr">36</xref>] reported the synthesis of dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-diones <bold>35</bold> using the catalyst on silica-based ordered mesoporous material (SBA-15) functionalized by imidazolium ionic liquid sulfonic acid (ImIL-Sul-SBA-15) (<xref rid="molecules-30-03506-sch013" ref-type="fig">Scheme 13</xref>). The reaction between isatoic anhydride <bold>28</bold>, amines, and substituted 2-formylbenzoic acids was conducted in the ethanol&#8211;water mixture (1:1) in the presence of ImIL-Sul-SBA-15 (20 mol%) at 50 &#176;C for 1 h. Once the reaction finished, a mixture containing desired product <bold>35</bold> along with the catalyst (ImIL-Sul-SBA-15) was filtered out. Then, this solid was cleaned with ethanol to remove the product, leaving behind just the catalyst. Testing demonstrated that the catalyst maintained its efficiency and could be recycled up to six consecutive cycles without experiencing any noticeable loss in catalytic activity. Benefits include easy recovery of the catalyst, quick reaction time, and high yields of the final product.</p><p>Rayatzadeh et al. described the synthesis of a series of 6,6<italic toggle="yes">a</italic>-dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-dione derivatives <bold>36</bold> using sulfonic acid functionalized nanoporous silica (SBA-Pr-SO<sub>3</sub>H) as a reusable catalyst (<xref rid="molecules-30-03506-sch013" ref-type="fig">Scheme 13</xref>) [<xref rid="B37-molecules-30-03506" ref-type="bibr">37</xref>]. Derivatives <bold>36</bold> were obtained via a two-step process, once the reaction was completed, the catalyst was separated, and the final products were isolated by recrystallization from ethanol. Key advantages are high yields and easy purification process.</p><p>The synthesis of isoindoloquinazolinediones <bold>38</bold> was carried out in a single step starting from 2-aminobenzamides <bold>37</bold> and 2-formylbenzoic acid, conditions for cyclization were selected (<xref rid="molecules-30-03506-sch014" ref-type="fig">Scheme 14</xref>) [<xref rid="B38-molecules-30-03506" ref-type="bibr">38</xref>,<xref rid="B39-molecules-30-03506" ref-type="bibr">39</xref>,<xref rid="B40-molecules-30-03506" ref-type="bibr">40</xref>]. Devi et al. [<xref rid="B38-molecules-30-03506" ref-type="bibr">38</xref>] used a mixture of choline chloride (ChCl) and TsOH as promising green deep eutectic solvent. The reaction proceeds rapidly (15 min) at room temperature leading to dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazolin-5,11-diones <bold>38a</bold>&#8211;<bold>g</bold> in high yields.</p><p>Lohar et al. developed an efficient and green mechanochemical method for the synthesis of isoindolo[2,1-<italic toggle="yes">a</italic>]quinazolines <bold>38a</bold>,<bold>b</bold>,<bold>d</bold>,<bold>e</bold>,<bold>g</bold>&#8211;<bold>o</bold> via 2,2,2-trifluoroethanol (TFE)-catalyzed liquid-assisted grinding (LAG) (<xref rid="molecules-30-03506-sch014" ref-type="fig">Scheme 14</xref>) [<xref rid="B40-molecules-30-03506" ref-type="bibr">40</xref>]. A mixture of equimolar amounts of reagents and TFE was ground together for 9&#8211;11 min at room temperature; the progress of the reaction was monitored by TLC, compounds <bold>38a</bold>,<bold>b</bold>,<bold>d</bold>,<bold>e</bold>,<bold>g</bold>&#8211;<bold>o</bold> were isolated in high yields.</p><p>Dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazolin-5,11-diones <bold>39</bold> were prepared by cyclization in the xylene/acetic acid mixture at reflux for 3&#8211;5 h and isolated as racemates (<xref rid="molecules-30-03506-sch014" ref-type="fig">Scheme 14</xref>). The authors of [<xref rid="B39-molecules-30-03506" ref-type="bibr">39</xref>] performed a prediction of biological activity profile of compound <bold>39a</bold> and concluded that this quinazolinone derivative can affect many molecular targets within cells, promising for design new anticancer and antiparasitic drugs, as well as agents for neurodegenerative diseases therapy. Thus, 6<italic toggle="yes">aS</italic>-enantiomer of annelated quinazoline <bold>39a</bold> can block the TDP1 and ELG1 protein, suppress the ATG4B protease function. The racemic mixture of the tetracyclic compound <bold>39a</bold> is toxic for cardiomyocytes, it can decompose the TDP-43 protein, inhibit the DNA repair systems.</p><p>A series of 6-(arylamino)-6,6<italic toggle="yes">a</italic>-dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazolin-5,11-diones <bold>41a</bold>&#8211;<bold>g</bold> was synthesized through iodine-catalyzed reaction of <italic toggle="yes">N</italic>&#8217;-aryl-2-aminobenzohydrazides <bold>40</bold> and 2-formylbenzoic acid in ionic liquid (<xref rid="molecules-30-03506-sch015" ref-type="fig">Scheme 15</xref>) [<xref rid="B41-molecules-30-03506" ref-type="bibr">41</xref>]. The structure of the compounds was confirmed by X-ray data, for compound <bold>41b</bold> as an example. The reaction was shown to be chemoselective, the interaction of unsubstituted 2-aminobenzohydrazide with 2-formylbenzoic acid under the same conditions gave 5<italic toggle="yes">H</italic>-phthalazino[1,2-<italic toggle="yes">b</italic>]quinazoline.</p><p>A fast and eco-friendly technique was created to prepare a series of important, versatile isoindolo[2,1-<italic toggle="yes">a</italic>]quinazolines <bold>43</bold> with multiple functions for biology research (<xref rid="molecules-30-03506-sch015" ref-type="fig">Scheme 15</xref>) [<xref rid="B42-molecules-30-03506" ref-type="bibr">42</xref>]. The reaction of 2-aminobenzhydrazide <bold>42</bold> (R = H) with 2-formylbenzoic acid was studied under solvent free conditions using graphene oxide (GO) as mild heterogeneous carbocatalyst. Optimal conditions have been identified, expanding the scope of 2-aminobenzohydrazides. It has been demonstrated that 2-aminobenzamides give high yield of products <bold>43</bold> under the same conditions. The structures of compounds <bold>43</bold> have been validated through X-ray analysis for two compounds <bold>43</bold> (R = NHPh, R<sup>1</sup> = H, and R = CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>-4-Me, R<sup>1</sup> = 3-Cl). The GO nanosheets were prepared from natural graphite powder. A possible reaction mechanism with GO as catalyst was discussed, it was noted that the acidity of GO plays an important role in the studied transformation.</p><p>Guo et al. [<xref rid="B43-molecules-30-03506" ref-type="bibr">43</xref>] reported the synthesis of dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazolin-5,11-diones <bold>45</bold> without using 2-formylbenzoic acid. The preparation process includes palladium-catalyzed three-component carbonylative cyclization of 2-aminobenzamides <bold>42</bold> with 2-bromobenzaldehydes <bold>44</bold> under an atmospheric pressure of carbon monoxide (<xref rid="molecules-30-03506-sch016" ref-type="fig">Scheme 16</xref>). Optimal synthetic conditions, including selection of catalyst, ligand, base, and solvent, were found, and broad substrate scope was demonstrated. A plausible mechanism involves a palladium-catalyzed cyclocondensation/cyclocarbonylation sequence: initially, the oxidative addition of Pd(0) to 2-(2-bromophenyl)tatrehydroquinazolin-4-one, which is formed in situ via the cyclocondensation of 2-aminobenzamide <bold>42</bold> with 2-bromobenzaldehyde <bold>44</bold> under basic conditions, gives rise to a palladium complex. Next, the insertion of CO into the C&#8211;Pd bond of this complex affords an acylpalladium complex, which then eliminates HBr regioselectively to yield cyclopalladium intermediate under the promotion of the base. Finally, reductive elimination delivers <bold>45</bold> and regenerates the Pd(0) species. It is also possible that the intramolecular nucleophilic attack of NH on the carbonyl group of acylpalladium complex gives product <bold>45</bold> and the active Pd(0) species. According to Guo et al. [<xref rid="B43-molecules-30-03506" ref-type="bibr">43</xref>], this method works well with different types of chemical groups, uses easily available ingredients, demonstrates high regioselectivity, and is straightforward to perform.</p><p>Kolotaev et al. [<xref rid="B44-molecules-30-03506" ref-type="bibr">44</xref>] described synthetic approaches to dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazolin-5,11-diones, containing hydroxamic acids, as potential HDAC/VEGFR inhibitors. The first method involved the alkylation of the tetracyclic derivatives <bold>46</bold>, <bold>47</bold> obtained by the interaction of substituted anthranilamides and 2-formylbenzoic acids, with ethyl 6-bromohexanoic acid (<xref rid="molecules-30-03506-sch017" ref-type="fig">Scheme 17</xref>). An attempt to obtain tetracyclic quinazolines <bold>48</bold> from NH-derivatives <bold>46a</bold>,<bold>b</bold> was unsuccessful. In the case of hydroxy derivatives <bold>47a</bold>,<bold>b</bold>, the alkylation in the presence of cesium carbonate in DMF resulted in the selective formation of products <bold>49a</bold>,<bold>b</bold> in good yields.</p><p>Another approach was selected for the synthesis of dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazolin-5,11-diones <bold>48a</bold>,<bold>b</bold> (<xref rid="molecules-30-03506-sch018" ref-type="fig">Scheme 18</xref>). The reaction between isatoic anhydride <bold>28</bold> and ethyl 6-aminohexanoic acid led to substituted anthranilamide, which further converted into <italic toggle="yes">N</italic>-substituted tetracycles <bold>48a</bold>,<bold>b</bold> under the action of 2-formylbenzoic acids. The reaction of compounds <bold>48a</bold>,<bold>b</bold> with hydroxylamine enabled the synthesis of the expected derivatives <bold>50a</bold>,<bold>b</bold>, wherein hydroxamic acids were linked to tetracyclic quinazolinone-containing fragments via a spacer able to occupy the enzyme channel.</p><p>Mondal et al. described one-pot synthesis of isoindole-fused quinazolin-4-ones in the presence of an acid catalyst [<xref rid="B45-molecules-30-03506" ref-type="bibr">45</xref>]. Interaction of substituted anthranilamides <bold>51a</bold>&#8211;<bold>d</bold> with <italic toggle="yes">o</italic>-phthalaldehyde in methanol and 2 N HCl in 3:1 ratio at room temperature led to the formation of range of isoindolo[2,1-<italic toggle="yes">a</italic>]quinazolin-5(11<italic toggle="yes">H</italic>)-ones <bold>52a</bold>&#8211;<bold>d</bold> (<xref rid="molecules-30-03506-sch019" ref-type="fig">Scheme 19</xref>). It should be noted that compound <bold>52a</bold> was isolated from the reaction mixture as the salt <bold>52a</bold>&#183;HCl, and <bold>52a</bold> was obtained only after the treatment with sodium bicarbonate solution. The structure of <bold>52a</bold>&#183;HCl was confirmed by X-ray data; the tetracyclic skeleton is planar, and the hydrogen bonding of the amide hydrogen through a water molecule forms a network in the solid. Derivatives <bold>52b</bold>&#8211;<bold>d</bold> were isolated from the reaction as major products.</p><p>Moreover, Mondal et al. [<xref rid="B45-molecules-30-03506" ref-type="bibr">45</xref>] performed the mechanistic study under deuterated solvent and revealed that the reaction proceeds through intramolecular 1,3-hydride shift. In addition to benzamides <bold>51a</bold>&#8211;<bold>d</bold>, various other amides such as 2-aminobenzenesulfonamide and 2-aminotetrahydrobenzothiophenamide were involved in this reaction, leading to corresponding analogs of compounds <bold>52</bold> with similarly high yields. Importantly, the type of substituents present in the amide group has little effect on the yield of the final products, thereby providing significant latitude for varying the structure of the bicyclic core. Additionally, this method could potentially be applied to many different variations of <italic toggle="yes">o</italic>-phthaldialdehyde compounds.</p></sec><sec id="sec4-molecules-30-03506"><title>4. Pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines and Indazolo[2,3-<italic toggle="yes">a</italic>]quinazolines</title><p>In the review article [<xref rid="B14-molecules-30-03506" ref-type="bibr">14</xref>], some data on the synthetic approaches and bioactivity of pyrazoloquinazolines in which the pyrazole ring is attached to different edges of pyrimidine core are discussed. Regarding the synthesis of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines, two strategies were reported: the interaction of 2-hydrazinylbenzoic acid with 3-oxoalkanenitrile in the presence of CH<sub>3</sub>COOH [<xref rid="B46-molecules-30-03506" ref-type="bibr">46</xref>] and the three-component reaction of 3(5)-amino-4-phenylpyrazole with aromatic aldehydes and cyclohexanone in acetic acid [<xref rid="B47-molecules-30-03506" ref-type="bibr">47</xref>]. Some pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines were described as negative allosteric modulators of metabotropic glutamate receptors [<xref rid="B48-molecules-30-03506" ref-type="bibr">48</xref>], other tricyclic derivatives exhibit the topoisomerase-1 inhibitory activity [<xref rid="B49-molecules-30-03506" ref-type="bibr">49</xref>]. Example synthesis of indazoloquinazoline system with <italic toggle="yes">a</italic>, <italic toggle="yes">b</italic>, or <italic toggle="yes">c</italic> patterns of annelation of indazole fragment to quinazoline core are provided in the micro-review [<xref rid="B50-molecules-30-03506" ref-type="bibr">50</xref>].</p><p>A series of new manuscripts on pyrazolo[1,5-<italic toggle="yes">a</italic>] and indazolo[2,3-<italic toggle="yes">a</italic>]quinazolines have been published more recently. Zhang et al. [<xref rid="B51-molecules-30-03506" ref-type="bibr">51</xref>] presented a convenient and simple synthetic procedure for obtaining several pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones <bold>54</bold> via copper-catalyzed cascade reactions of 2-bromobenzoates <bold>53</bold> with 1<italic toggle="yes">H</italic>-pyrazol-5-amines under ligand-free conditions in water (<xref rid="molecules-30-03506-sch020" ref-type="fig">Scheme 20</xref>). This method is based on commercially available starting materials; water is used as solvent, so the procedure responds to the urgent need for &#8220;greener&#8221; and &#8220;cleaner&#8221; chemistry.</p><p>Gnanasekaran et al. [<xref rid="B52-molecules-30-03506" ref-type="bibr">52</xref>] incorporated 2-fluoroaroyl chlorides <bold>55</bold> into reaction with 5-aminopyrazoles (<xref rid="molecules-30-03506-sch020" ref-type="fig">Scheme 20</xref>). The formation of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones <bold>56</bold> is described as two-step sequence: initial acylation of the C5 amino group of the pyrazole was performed in DMF at &#8722;10 &#176;C and further heating to 140 &#176;C, then S<sub>N</sub>Ar ring closure between N1 of the pyrazole and the 2-fluoroarylamide was performed. Products <bold>56</bold> were obtained in high yields regardless of the nature of substituents.</p><p>An efficient method for the synthesis of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>58</bold>, indazolo[2,3-<italic toggle="yes">a</italic>]quinazoline <bold>59</bold>, and 10-azaindazolo[2,3-<italic toggle="yes">a</italic>]quinazoline <bold>60</bold> was described using various 2-fluorobenzaldehydes <bold>57</bold> interacting with 1<italic toggle="yes">H</italic>-pyrazol-3-amines or 1<italic toggle="yes">H</italic>-indazol-3-amine (and its 7-aza derivative) under metal-free conditions (<xref rid="molecules-30-03506-sch021" ref-type="fig">Scheme 21</xref>) [<xref rid="B53-molecules-30-03506" ref-type="bibr">53</xref>]. The process involves an intermolecular condensation step followed by a metal-free base-promoted intramolecular C&#8211;N coupling reaction. This methodology opens wide opportunities for preparation of various polycyclic quinazoline derivatives. Significantly, the bromine atom remains unaffected throughout the reaction process, allowing its subsequent utilization for additional chemical modifications or transformations.</p><p>Gao et al. [<xref rid="B54-molecules-30-03506" ref-type="bibr">54</xref>] developed regioselective synthesis of indazolo[2,3-<italic toggle="yes">a</italic>]quinazolines <bold>62</bold> via a sequential annulation and dehydrogenative aromatization of cyclohexanones <bold>61</bold> (<xref rid="molecules-30-03506-sch022" ref-type="fig">Scheme 22</xref>). The reaction is carried out in 1-methyl-pyrrolidin-2-one (NMP) as a solvent in the presence of iodine and sulfur at 120 &#176;C for 20 h. A control experiment verified the sequential nature of the process steps. This reaction demonstrates broad compatibility across various types of aminoindazole compounds, encompassing those derived from aromatic and heterocyclic aldehydes, along with diversely functionalized cyclohexanones. Furthermore, this methodology has been successfully employed for the preparation of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives <bold>63</bold>.</p><p>A series of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines and their aza-analogues were synthesized and studied as inhibitors of histone lysine demethylase 4D (KDM4D) [<xref rid="B55-molecules-30-03506" ref-type="bibr">55</xref>]. Initially, Fang et al. performed molecular docking for 30 compounds, two tricyclic derivatives showed an inhibition rate greater than 50% against KDM4D at a concentration of 10 &#181;M. One of the leading compounds was pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivative (<bold>A</bold>); its activity was measured towards three additional KDM enzymes (KDM2B, KDM3B, and KDM5A), and excellent selectivity toward KDM4D was demonstrated. Structural modifications focusing on three fragments of compound <bold>A</bold> (highlighted in green color) led to the synthesis of a series of derivatives <bold>64a</bold>&#8211;<bold>t</bold>. These derivatives were prepared by reacting 2-chloroacetyl chlorides, derived from either benzoic acid or picolinic acid, with corresponding 3-amino-<italic toggle="yes">1H</italic>-pyrazole-4-carbonitriles (<xref rid="molecules-30-03506-f003" ref-type="fig">Figure 3</xref>).</p><p>All target compounds were initially tested for their inhibitory activity against KDM4D at a concentration of 10 &#956;M. Only three compounds (<bold>64p</bold>, <bold>64r</bold>, and <bold>64s</bold>) exhibited higher potencies compared to <bold>A</bold>. For these three compounds, IC<sub>50</sub> values were determined, derivative <bold>64r</bold> was chosen as lead compound (<xref rid="molecules-30-03506-t001" ref-type="table">Table 1</xref>). Moreover, quinazoline <bold>64r</bold> exhibits good selectivity for KDM4D; molecular docking was used to predict the binding model of compound <bold>64r</bold> in the active pocket of KDM4D (<xref rid="molecules-30-03506-f004" ref-type="fig">Figure 4</xref>).</p><p>Kov&#225;cs et al. [<xref rid="B56-molecules-30-03506" ref-type="bibr">56</xref>] reported the synthesis of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives through the reaction of 2-hydrazinobenzenecarboxylic acids or their esters (compounds <bold>65</bold>) with &#945;-oxo-cyanides (<xref rid="molecules-30-03506-sch023" ref-type="fig">Scheme 23</xref>). Refluxing a mixture of compound <bold>65</bold> and 4-oxotetrahydrothiophene-3-carbonitrile in ethanol led to the formation of 6,7-dihydro-<italic toggle="yes">5H,9H</italic>-thieno[3&#8242;,4&#8242;:3,4]pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>66</bold>, which were subsequently converted into amines <bold>67</bold>.</p><p>Interaction of 2-oxocyclopentanecarbonitrile (n = 1) or 2-oxocyclohexanecarbonitrile (n = 2) with arylhydrazines <bold>65</bold> in ethanol afforded a series of novel tetracyclic pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives <bold>68</bold>, the reduction of the latter leads to formation of amines <bold>69</bold>. Notably, when R<sup>2</sup> = Me, Br or R<sup>5</sup> = Me, the yield of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives <bold>66</bold> and <bold>68</bold> significantly decreased, and their corresponding amines <bold>69</bold> were not detected.</p><p>5-Substituted pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines were synthesized and evaluated as ligands of GABA<sub>A</sub> receptor [<xref rid="B57-molecules-30-03506" ref-type="bibr">57</xref>], only one compound showed receptor recognition in the nanomolar range. To find derivatives with higher activity, novel 3- and/or 8-substituted pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines were synthesized [<xref rid="B58-molecules-30-03506" ref-type="bibr">58</xref>]. Using a copper-catalyzed tandem reaction, appropriate 2-bromo-4-R-benzaldehyde and 5-amino-<italic toggle="yes">1H</italic>-pyrazole-4-carbonitrile, 3-cyanoderivatives <bold>70a</bold>&#8211;<bold>c</bold> were isolated in low yields (<xref rid="molecules-30-03506-sch024" ref-type="fig">Scheme 24</xref>). Later [<xref rid="B59-molecules-30-03506" ref-type="bibr">59</xref>], derivative <bold>70b</bold> was obtained in 55% yield by fusion of 5-amino-<italic toggle="yes">1H</italic>-pyrazole-4-carbonitrile with 2-chlorobenzaldehyde at 160 &#176;C for 6 h. Interaction of ethyl 1-(3-methoxyphenyl)-5-aminopyrazole-3-carboxylate <bold>71</bold> with formaldehyde or paraformaldehyde in an acidic medium afforded 8-methoxy-pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline <bold>72a</bold>; however, separation it from its 6-methoxy isomer was difficult. The key intermediate <bold>72a</bold> was synthesized in higher yield from 2-carboxy-5-methoxyphenylhydrazine via intermediate 8-methoxy-pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>73</bold>, <bold>74</bold>, and <bold>75</bold> (<xref rid="molecules-30-03506-sch024" ref-type="fig">Scheme 24</xref>). Derivative <bold>72a</bold> and ethyl pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline-3-carboxylate <bold>72b</bold> were hydrolyzed to give the respective 3-carboxylic acids <bold>76a</bold>,<bold>b</bold>, which were further transformed into 3-ester derivatives <bold>77a</bold>&#8211;<bold>e</bold> and <bold>78a</bold>&#8211;<bold>c</bold>. Finally, compounds <bold>77a</bold>,<bold>b</bold>,<bold>d</bold> were converted into the corresponding 4,5-dihydroderivatives <bold>79a</bold>,<bold>b</bold>,<bold>d</bold>.</p><p>The in vitro study of the BZ site/GABA<sub>A</sub>-R binding affinity of synthesized pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines derivatives <bold>72</bold>, <bold>77</bold>, <bold>78</bold> showed that the new compounds have binding recognition in the nanomolar range (3.16 &lt; Ki (nM) &lt; 529.3) at fixed concentrations of 10 &#956;M, raising the subnanomolar affinity value of 0.27 nM for compound <bold>77b</bold> (<xref rid="molecules-30-03506-t002" ref-type="table">Table 2</xref>). The pharmacological tests evidenced for compound <bold>77b</bold> a profile of positive allosteric modulator with anxiolytic and antihyperalgesic activity, lacking toxicity when tested in human neuronal-like cells and in vivo models.</p><p>In the next work of the same team [<xref rid="B60-molecules-30-03506" ref-type="bibr">60</xref>], modification of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>77</bold> was performed by shortening or removing the linker between aryl(hetaryl) ring and the pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline core, 3-aryl(hetaryl)-pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>82</bold> and 3-(hetero)aroyl-pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>83</bold> were developed. Cyclization of hydrazinobenzoic acid with appropriate propanenitrile resulted in the formation of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines bearing at position 3 (hetero)aryl group (compounds <bold>80a</bold>&#8211;<bold>e</bold>) or (hetero)aroyl group (compounds <bold>80f</bold>&#8211;<bold>h</bold>) (<xref rid="molecules-30-03506-sch025" ref-type="fig">Scheme 25</xref>). Treatment of compounds <bold>80a</bold>&#8211;<bold>e</bold> with LiAlH<sub>4</sub> in anhydrous THF followed by oxidation led to 3-(hetero)aryl derivatives <bold>82a</bold>&#8211;<bold>e</bold>. Compounds <bold>80f</bold>&#8211;<bold>h</bold> were transformed into 3-(hetero)aroylpyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>83a</bold>&#8211;<bold>c</bold> via intermediate chloroquinazolines <bold>81</bold>.</p><p>The synthesis of compounds <bold>82f</bold>&#8211;<bold>i</bold> was accomplished using the Suzuki cross-coupling based on halogenated derivatives <bold>86a</bold>,<bold>b</bold>, which were obtained from 8-methoxypyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline <bold>85</bold> (<xref rid="molecules-30-03506-sch025" ref-type="fig">Scheme 25</xref>). The starting quinazolinone <bold>84</bold> was synthesized by decarboxylation of derivative <bold>73</bold>. Derivative <bold>76a</bold> used for the preparation of quinazolines <bold>82f</bold> and <bold>83d</bold>&#8211;<bold>g</bold> (<xref rid="molecules-30-03506-sch025" ref-type="fig">Scheme 25</xref>). Treating 3-(hetero)aroyl-pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>83a</bold>,<bold>b</bold>,<bold>d</bold>&#8211;<bold>g</bold> with sodium borohydride complex (NaBH<sub>3</sub>CN) in AcOH allowed obtaining their dihydro analogs <bold>87a</bold>,<bold>b</bold>,<bold>d</bold>&#8211;<bold>g</bold>.</p><p>All target compounds were previously evaluated for their ability to displace [<italic toggle="yes">3H</italic>]flumazenil (Ro-151788) from its specific binding to Bz receptors in bovine membrane samples. Electrophysiological studies on recombinant &#945;1&#42933;2&#947;2L GABA<sub>A</sub> receptors were carried out for more promising compounds <bold>82d</bold>&#8211;<bold>f</bold>, <bold>83a</bold>&#8211;<bold>d</bold>, <bold>86f</bold>,<bold>g</bold>, <bold>87a</bold>,<bold>b</bold>,<bold>d</bold>. Quinazolines <bold>82</bold> bearing Ar/Het group could not modulate the GABA<sub>A</sub> function, but they were found to act as null modulators or antagonists. Among aroyl/Het derivatives <bold>83a</bold> and <bold>83b</bold> can modulate the GABA<sub>A</sub> receptor in an opposite manner: <bold>83b</bold> enhances and <bold>83a</bold> reduces the variation of the chlorine current. The most potent derivative <bold>87d</bold> reached a maximal activity at 1 &#956;M (+54%) and enhanced the chlorine current at &#8805;0.01 &#956;M. Moreover, compound <bold>83g</bold> demonstrated the ability to antagonize the full agonist diazepam.</p><p>Guerrini et al. [<xref rid="B61-molecules-30-03506" ref-type="bibr">61</xref>] evaluated the effect of the shift of the methoxy group from position 8 to position 6, with the same (hetero)aryl ester groups at position 3. 6-Acetyl-7-(2-dimethylaminovinyl)pyrazolo[1,5-<italic toggle="yes">a</italic>]pyrimidine 3-cyano or 3-ethoxycarbonyl <bold>88a</bold>,<bold>b</bold>, obtained according to the described method [<xref rid="B62-molecules-30-03506" ref-type="bibr">62</xref>], were used for the synthesis of 3,6-disubstituted pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines. Boiling of these compounds in an acetic buffer solution led to the formation of 6-hydroxypyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>89a</bold>,<bold>b</bold>, whose alkylation yielded derivatives <bold>90a</bold>,<bold>b</bold> (<xref rid="molecules-30-03506-sch026" ref-type="fig">Scheme 26</xref>). Compound <bold>90b</bold> was hydrolyzed to produce the corresponding 3-carboxylic acid, which was esterified to ethers <bold>91a</bold>&#8211;<bold>c</bold>, and then reduced to 4,5-dihydroderivatives <bold>92a</bold>&#8211;<bold>d</bold>. Compound <bold>90a</bold> under the treating with hydroxylamine hydrochloride in ethanol and potassium carbonate, followed by cyclization was transformed into 3-(5-methyl-1,2,4-oxadiazol-3-yl)-derivative <bold>93</bold>. To prepare derivatives <bold>96a</bold>,<bold>b</bold>, compounds <bold>89a</bold> and <bold>90a</bold> were converted into 3-carboxyamide derivatives <bold>94a</bold>,<bold>b</bold>, which upon reaction with dimethylformamide-di-<italic toggle="yes">tert</italic>-butylacetate (DMF-DtBA) in toluene formed acylamidines <bold>95a</bold>,<bold>b</bold>. Boiling these acylamidines with hydrazine hydrate yielded compounds <bold>96a</bold>,<bold>b</bold>. 3-Iodo-6-benzyloxypyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline <bold>97</bold> was obtained from compound <bold>89b</bold> after decarboxylation, alkylation, and iodination (<xref rid="molecules-30-03506-sch026" ref-type="fig">Scheme 26</xref>).</p><p>Novel 3,6-disubstituted pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>89</bold>&#8211;<bold>94</bold>, <bold>96</bold>, <bold>97</bold> were studied as ligands to GABA<sub>A</sub> receptor. The GABA<sub>A</sub>-binding affinity of compounds was evaluated for their ability to displace [<sup>3</sup>H]flumazenil (Ro-151788) from its specific binding in a bovine membrane. From the obtained results, it follows that the compounds demonstrated the percent of inhibition of specific [3H]Ro15-1788 binding at 10 &#956;M concentration from 1% to 43.7%, iodine-containing compound <bold>97</bold> showed the highest inhibition (43.7%), quinazoline <bold>89b</bold> demonstrated 32% inhibition (<xref rid="molecules-30-03506-t003" ref-type="table">Table 3</xref>). Drawing upon both experimental evidence and computational molecular modeling analyses conducted on compound <bold>91b</bold>, the researchers inferred that relocating substituent groups from position 8 to position 6 plays a critical role in achieving effective ligand-receptor interactions.</p><p>New 8-methoxypyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>98a</bold>&#8211;<bold>i</bold> and their dihydro derivatives <bold>99a</bold>&#8211;<bold>i</bold> bearing the amide fragment at the position 3 were synthesized [<xref rid="B63-molecules-30-03506" ref-type="bibr">63</xref>] as analogues of 8-methoxypyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline 3-ester [<xref rid="B57-molecules-30-03506" ref-type="bibr">57</xref>,<xref rid="B58-molecules-30-03506" ref-type="bibr">58</xref>], 3-(hetero)aroyl and 3-(hetero)aryl derivatives [<xref rid="B60-molecules-30-03506" ref-type="bibr">60</xref>] identified as modulators of GABA<sub>A</sub> receptors. 8-Methoxypyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline-3-carboxylic acid <bold>78a</bold> after the treatment with thionyl chloride or trichloroacetonitrile/PPh<sub>3</sub> in CCl<sub>4</sub> led to the formation of Het-C(O)Cl intermediate, which without isolation interacted with the appropriate amine, giving compounds <bold>98a</bold>&#8211;<bold>i</bold>, which were transformed into the corresponding 4,5-dihydroderivatives <bold>99a</bold>&#8211;<bold>i</bold> by the treatment with sodium cyanoborohydride (NaBH<sub>3</sub>CN) in acetic acid (<xref rid="molecules-30-03506-f005" ref-type="fig">Figure 5</xref>).</p><p>All the new compounds <bold>98a</bold>&#8211;<bold>i</bold> and <bold>99a</bold>&#8211;<bold>i</bold> have been evaluated in vitro for their ability to modulate the chlorine current on recombinant GABA<sub>A</sub> receptors of the &#945;1&#946;2&#947;2L type (expressed in frog oocytes of the <italic toggle="yes">Xenopus laevis</italic> species). Two groups of compounds were identified from electrophysiological test: positive modulators agonists (<bold>98e</bold>,<bold>h</bold>,<bold>i</bold> and <bold>99e</bold>,<bold>h</bold>) and null modulators antagonist (<bold>98a</bold>,<bold>b</bold>,<bold>d</bold>,<bold>f</bold>,<bold>g</bold> and <bold>99a</bold>&#8211;<bold>d</bold>,<bold>f</bold>,<bold>g</bold>).</p><p>In the next work [<xref rid="B64-molecules-30-03506" ref-type="bibr">64</xref>], new 8-chloropyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives <bold>100</bold>&#8211;<bold>107</bold> (<xref rid="molecules-30-03506-f005" ref-type="fig">Figure 5</xref>) were presented as GABA<sub>A</sub> receptor modulators. Their syntheses resemble those illustrated in <xref rid="molecules-30-03506-sch024" ref-type="fig">Scheme 24</xref> and <xref rid="molecules-30-03506-sch025" ref-type="fig">Scheme 25</xref>. Compounds <bold>100</bold>&#8211;<bold>107</bold> underwent molecular dynamics simulations performed on an isolated segment of the GABA<sub>A</sub> receptor protein located between &#945; and &#947; chains, where the benzodiazepine-binding site is identified. Using the &#8216;Proximity Frequencies&#8217; model (PF), Crocetti et al. [<xref rid="B63-molecules-30-03506" ref-type="bibr">63</xref>] predicted that compounds <bold>100a</bold>, <bold>103a</bold>, and <bold>106b</bold> belong to the agonist class with 93.1% probability. On the contrary, derivatives <bold>101c</bold>, <bold>103c</bold>, and <bold>107</bold> fall into the antagonist class, with 62&#8211;73% prediction. Thus, two types of compounds occupy different areas in the binding site. The virtual prediction for <bold>106b</bold> and <bold>107</bold> as agonist and antagonist, respectively, was confirmed through electrophysiological assays.</p><p>3,8-Disubstituted pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline <bold>108</bold>&#8211;<bold>113</bold> (<xref rid="molecules-30-03506-f006" ref-type="fig">Figure 6</xref>), bearing oxygen or nitrogen function at position 8, were synthesized and studied as GABA<sub>A</sub> receptor modulators [<xref rid="B65-molecules-30-03506" ref-type="bibr">65</xref>]. The synthesis is based on approaches presented in <xref rid="molecules-30-03506-sch024" ref-type="fig">Scheme 24</xref> and <xref rid="molecules-30-03506-sch025" ref-type="fig">Scheme 25</xref>.</p><p>Compounds <bold>108</bold>&#8211;<bold>113</bold> were screened through electrophysiological techniques on recombinant &#945;1&#946;2&#947;2L-GABA<sub>A</sub> receptors expressed in <italic toggle="yes">Xenopus laevis</italic> oocytes, some compounds exhibited certain ability to bind the receptor. The most promising electrophysiological results were obtained for compounds <bold>108d</bold>, <bold>109a</bold>, <bold>109b</bold>, and <bold>112</bold>. Among the 3-iododerivatives, compound <bold>108d</bold>, which does not modulate the chlorine current, was evaluated for its ability to antagonize the full agonist lorazepam (1 &#956;M). Compounds <bold>109a</bold> and <bold>112</bold> were found to exhibit agonist profile while quinazolines <bold>109b</bold> and <bold>108d</bold> act as antagonists. Molecular modelling studies and Hierarchical Cluster Analysis (HCA) data have collocated these ligands in the class corresponding to their pharmacological profile (<xref rid="molecules-30-03506-f007" ref-type="fig">Figure 7</xref>).</p><p>A large series (102 compounds) of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives were designed and synthesized to investigate their activity as SIRT6 activators [<xref rid="B66-molecules-30-03506" ref-type="bibr">66</xref>]. SIRT6 is a particularly important member of Sirtuins and has emerged as a novel therapeutic target for various diseases. Previously [<xref rid="B67-molecules-30-03506" ref-type="bibr">67</xref>], a 2-methyl-5-(4-methylpiperazin-1-yl)pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline <bold>(Hit41)</bold> had been found as a new SIRT6 de-fatty-acylation activator. Zhang et al. [<xref rid="B66-molecules-30-03506" ref-type="bibr">66</xref>] discovered highly active SIRT6 de-fatty-acylation activators by structural modifications of Hit41, focusing on expanding substituents at positions 2 (R<sup>1</sup>) and 5 (R<sup>2</sup>) of the pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline scaffold. Three series of derivatives were synthesized (<xref rid="molecules-30-03506-sch027" ref-type="fig">Scheme 27</xref>): <bold>115a</bold>&#8211;<bold>117a</bold> (R<sup>1</sup> = H); <bold>115b</bold>&#8211;<bold>117b</bold> (R<sup>1</sup> = Me); <bold>115c</bold>&#8211;<bold>117c</bold> (R<sup>1</sup> = <italic toggle="yes">t</italic>Bu). In each series, R<sup>2</sup> represented a broad set of Ar or Het substituents (number indicated in parentheses). Chlorinated precursors <bold>114a</bold>&#8211;<bold>c</bold>, obtained using one of the approaches shown in <xref rid="molecules-30-03506-sch024" ref-type="fig">Scheme 24</xref>, were used as starting materials.</p><p>Fluor de Lys (FDL) assays were performed for compounds <bold>115</bold>&#8211;<bold>117</bold>, for some compounds additional calculations were made to determine the concentration of the compound (&#956;M) at which the compound can increase the enzymatic activity by 50% values (EC<sub>1.5</sub>), structure&#8211;activity relationship (SAR) was studied. A set of novel SIRT6 activators was obtained (13 compounds with EC<sub>1.5</sub> &lt; 50.79 &#956;M); among them, 2-methyl-<italic toggle="yes">N</italic>-(4-phenoxyphenyl)pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5-amine <bold>116b(q)</bold> is the most potent one, which exhibited excellent defatty-acylation activation activity against SIRT6 (EC<sub>1.5</sub> 1.85 &#177; 0.41 &#956;M and EC<sub>50</sub> 11.15 &#177; 0.33 &#956;M). Notably, that the calculated EC<sub>1.5</sub> value for Hit41 is only 49.30 &#177; 0.74 &#956;M. The bioactivity of <bold>116b(q)</bold> was further verified by differential scanning fluorimetry (DSF) and surface plasmon resonance (SPR) assays. Molecular docking showed that the pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline <bold>116b(q)</bold> formed a hydrogen bond with Val115 and four &#960;&#8211;&#960; interactions with Phe64, Phe82, and Phe86; <bold>116b(q)</bold> can significantly improve the thermal stability of SIRT6 protein and inhibit the PI3K/Akt signaling pathway in mouse embryonic fibroblasts (MEFs), thereby inhibiting the proliferation of MEFs. As a result, Zhang et al. [<xref rid="B66-molecules-30-03506" ref-type="bibr">66</xref>] discovered a new potent SIRT6 activator, which can be taken as a lead compound for later studies.</p><p>A library of new pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline compounds substituted at positions 3, 7, or 8 was synthesized and their anti-inflammatory activity was studied [<xref rid="B68-molecules-30-03506" ref-type="bibr">68</xref>]. The key intermediates <bold>118a</bold>&#8211;<bold>d</bold>, <bold>120a</bold>&#8211;<bold>e</bold>, and <bold>122</bold> were obtained by the condensation of disubstituted 2-hydrazinobenzoic acid with ethoxymethylene-malononitrile, ethyl-2-cyano-3-ethoxyacrylate, and 3-oxo-2-(3-thienyl)proponitrile, respectively (<xref rid="molecules-30-03506-sch028" ref-type="fig">Scheme 28</xref>). Acid hydrolysis of nitriles <bold>118</bold> yielded amides <bold>119</bold>, while carboethoxy derivatives <bold>120</bold> were converted into unsubstituted counterparts <bold>121</bold>. Pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>118</bold>&#8211;<bold>122</bold> were subjected to further transformations, and 45 compounds were synthesized for screening. For example, from derivative <bold>119a</bold>, a series of 5-alkoxy-substituted pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>123a</bold>&#8211;<bold>i</bold> was prepared, the compound <bold>123c</bold> was oxidized to yield sulfoxide <bold>124</bold> and then sulfone <bold>125</bold>, whereas <bold>123b</bold> was transformed into 3-(1,2,4-triazole) derivative <bold>126</bold> (<xref rid="molecules-30-03506-sch028" ref-type="fig">Scheme 28</xref>).</p><p>Compounds <bold>123</bold>&#8211;<bold>126</bold> were tested for their ability to inhibit lipopolysaccharide (LPS)-induced nuclear factor &#954;B (NF-&#954;B) transcriptional activity in human THP-1Blue monocytic cells. Only 13 compounds were able to inhibit NF-&#954;B activity with IC<sub>50</sub> &lt; 50 &#956;M, two of them showed the highest activity: <bold>123i</bold> (5-[(4-sulfamoylbenzyl)oxy]pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline-3-carboxamide) and <bold>124</bold> (5-[(4-(methylsulfinyl)benzyloxy]pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline-3-carboxamide). Pharmacophore mapping of potential targets and molecular modeling allowed to conclude that these compounds could effectively bind to extracellular signal-regulated kinase 2 (ERK2), p38&#945;, and c-Jun N-terminal kinase 3 (JNK3) with the highest complementarity to JNK3. Moreover, compounds <bold>123i</bold> and <bold>124</bold> exhibited micromolar binding affinities for JNK1, JNK2, and JNK3. Obtained results [<xref rid="B68-molecules-30-03506" ref-type="bibr">68</xref>] demonstrate the potential for developing lead anti-inflammatory drugs of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline nature.</p><p>Kumar et al. presented the synthesis of tetracyclic hybrid structures <bold>127</bold>&#8211;<bold>132</bold>, combining pyrazolo[3,4-<italic toggle="yes">b</italic>]pyridine and pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline fragments, and data of their biological activity [<xref rid="B69-molecules-30-03506" ref-type="bibr">69</xref>]. Reaction of 3-amino-pyrazolo[3,4-<italic toggle="yes">b</italic>]pyridine-5-carboxylate <bold>127</bold> with 2-fluorobenzaldehyde resulted in the formation of ethyl pyrido[2&#8242;,3&#8242;:3,4]pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline-8-carboxylate <bold>128</bold> in 89% yield. Hydrolysis of compound <bold>128</bold> under alkaline conditions produced carboxylic acid derivative <bold>129</bold>, which upon reaction with various substituted anilines, cyclic secondary amines, and primary aliphatic amines led to the corresponding amide-substituted pyridopyrazolo-quinazolines <bold>130a</bold>&#8211;<bold>f</bold>, <bold>131a</bold>&#8211;<bold>d</bold>, and <bold>132a</bold>&#8211;<bold>h</bold> (<xref rid="molecules-30-03506-sch029" ref-type="fig">Scheme 29</xref>). In all cases, the reaction between <bold>129</bold> and amines was carried out in the presence of benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP).</p><p>Pyridopyrazolo-quinazolines <bold>128</bold>&#8211;<bold>132</bold> were evaluated for antibacterial activity against Gram-positive and Gram-negative bacterial strains, compounds <bold>129</bold>, <bold>130a</bold>, <bold>130c</bold>, <bold>130f</bold>, <bold>131a</bold>, <bold>132c</bold>, <bold>132f</bold>, and <bold>132h</bold> exhibited promising antibacterial activity against various bacterial strains (<xref rid="molecules-30-03506-t004" ref-type="table">Table 4</xref>). Compound <bold>129</bold> showed high antibacterial (MIC 3.9 &#956;g/mL) and broad-spectrum anti-biofilm activity. Compounds <bold>129</bold> and <bold>132b</bold> also showed good antifungal activity against various <italic toggle="yes">Candida</italic> strains. Compound <bold>129</bold> was found to be promising as a broad-spectrum biofilm inhibitor both against bacterial pathogens and against <italic toggle="yes">C. albicans</italic> MTCC3017. Further, compound <bold>129</bold> reduced the ergosterol content in three <italic toggle="yes">Candida</italic> strains (<italic toggle="yes">C. albicans</italic> MTCC227, <italic toggle="yes">C. albicans</italic> MTCC1637, and <italic toggle="yes">C. albicans</italic> MTCC3017). Both compound <bold>129</bold> and Miconazole showed the same amount of inhibition of ergosterol content in <italic toggle="yes">C. albicans</italic> MTCC227, modelling studies were also performed for validation. Compounds <bold>131d</bold>, <bold>132a</bold>, <bold>132b</bold>, and <bold>132d</bold> exhibited inhibition &gt; 90% against MCF7 (breast) cancer cell line; compounds <bold>130d</bold>, <bold>131a</bold>, <bold>132a</bold>, <bold>132b</bold>, <bold>132f</bold>, and <bold>132g</bold> exhibited inhibition &gt; 90% against SKOV3 (ovarian) cancer cell line, Doxorubicin was used as a standard.</p><p>Synthesis and insecticidal activities of polysubstituted 4,5-dihydropyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>133</bold>&#8211;<bold>136</bold> (<xref rid="molecules-30-03506-sch030" ref-type="fig">Scheme 30</xref>) were described [<xref rid="B70-molecules-30-03506" ref-type="bibr">70</xref>,<xref rid="B71-molecules-30-03506" ref-type="bibr">71</xref>,<xref rid="B72-molecules-30-03506" ref-type="bibr">72</xref>]. 5,5-Disubstituted 4,5-dihydropyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivative <bold>133a</bold>, obtained by interaction of 5-amino-1<italic toggle="yes">H</italic>-phenylpyrazole with dialkyl bromomalonate, exhibited promising insecticidal activity against <italic toggle="yes">P. xylostella</italic> [<xref rid="B70-molecules-30-03506" ref-type="bibr">70</xref>]. Later, the same team [<xref rid="B71-molecules-30-03506" ref-type="bibr">71</xref>] performed some modifications of compound <bold>133a</bold>: substituents in benzene ring (direction A), position 3 of the pyrazole ring (direction B), position 5 of the quinazoline ring (direction C), synthesized three series of novel 4,5-dihydropyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives (<bold>133</bold>&#8211;<bold>135</bold>). Afterwords, an expanded series of analogues <bold>136</bold> was obtained [<xref rid="B72-molecules-30-03506" ref-type="bibr">72</xref>].</p><p>Insecticidal activities of compounds <bold>133</bold>&#8211;<bold>135</bold> against insect pests <italic toggle="yes">P. xylostella</italic>, <italic toggle="yes">S. frugiperda</italic>, and <italic toggle="yes">S. invicta</italic> were evaluated. The most compounds exhibited good (&gt;50% mortality) to excellent (100% mortality) insecticidal effect against <italic toggle="yes">P. xylostella</italic>; fifteen compounds from the series showed significant mortality rate &gt; 50% at 100 mg/L, and nine compounds were able to show mortality rate &gt; 50% at 25 mg/L, with LC<sub>50</sub> values found to be 3.87&#8211;24.35 mg/L. Compound <bold>133</bold> (R<sup>1</sup> = CF<sub>3</sub>, Cl, R<sup>2</sup> = Me) exhibited the best insecticidal activity; its LC<sub>50</sub> value against <italic toggle="yes">P. xylostella</italic> (3.87 mg/L) was comparable to that of <bold>indoxacarb</bold> (4.82 mg/L), which is one of the major commercial pesticides to control <italic toggle="yes">P. xylostella.</italic> Insecticidal activities of compounds <bold>133a</bold> and <bold>135</bold> (X = NH, 2-Cl-5-Me-thiazole) against <italic toggle="yes">S. frugiperda</italic> (mortality rate 79.63% and 72.12%) were comparable to that of <bold>fipronil</bold> (mortality rate 68.44%). The compounds <bold>133</bold> (R<sup>1</sup> = CF<sub>3</sub>, Cl, R<sup>2</sup> = Me) and <bold>135</bold> (X = O, R = Me) showed high insecticidal activities against <italic toggle="yes">S. invicta</italic> (mortality rate 96.67% and 95.56%) comparable to that of <bold>fipronil</bold> (mortality rate 100%) after 5 days of treatment at 1.0 mg/L. Moreover, electrophysiological studies indicated that compound <bold>136</bold> (R<sup>1</sup> = CO<sub>2</sub>Me, R<sup>2</sup> = H, R<sup>3</sup> = CN) could act as a potent GABA receptor antagonist (2 &#956;&#924;, inhibition 68.25%).</p></sec><sec id="sec5-molecules-30-03506"><title>5. Imidazo[1,2-<italic toggle="yes">a</italic>]quinazolines, Benzimidazo[1,2-<italic toggle="yes">a</italic>]quinazolines</title><p>Synthetic approaches to imidazoquinazolines, in which imidazole cycle is attached to c, b or g edges of quinazoline core, as well as to benzo[4,5]imidazo[1,2-<italic toggle="yes">c</italic>]- and benzo[4,5]imidazo[1,2-<italic toggle="yes">a</italic>]quinazolines are described in book chapter [<xref rid="B13-molecules-30-03506" ref-type="bibr">13</xref>]. Two main approaches to [<italic toggle="yes">a</italic>]-annelated derivatives are used: condensation of 2-aminobenzimidazole with various aromatic aldehydes bearing Hal or NO<sub>2</sub>; and intramolecular C&#8211;N bond formation. This section of the current manuscript contains data on the synthesis and biological activity of imidazo- and benzimidazo[<italic toggle="yes">a</italic>]quinazolines, which were not included in the book chapter [<xref rid="B13-molecules-30-03506" ref-type="bibr">13</xref>] or appeared later.</p><p>Annareddygari et al. [<xref rid="B53-molecules-30-03506" ref-type="bibr">53</xref>] developed an efficient method for the synthesis of benzo[4,5]imidazo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>137</bold> from different 2-fluoro-benzaldehydes with 2-aminobenzimidazole (its 7-aza derivative) under metal-free conditions in high yields (<xref rid="molecules-30-03506-sch031" ref-type="fig">Scheme 31</xref>). The process includes an intermolecular condensation followed by metal-free base-promoted intramolecular C&#8211;N coupling reaction.</p><p>Using this approach, a series of trisubstituted benzo[4,5]imidazo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>138</bold> was obtained to study their anti-fungal activities against six plant pathogenic fungi and analyze SAR [<xref rid="B73-molecules-30-03506" ref-type="bibr">73</xref>]. It was found that compound <bold>138</bold> (R = R<sup>1</sup> = H) demonstrated broad-spectrum antifungal activities with EC<sub>50</sub> = 4.43 &#956;g/mL.</p><p>Microwave-assisted synthesis of 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>140</bold> was presented <bold>[<xref rid="B74-molecules-30-03506" ref-type="bibr">74</xref>]</bold>. The reaction of 2-bromocyclohex-1-ene carbaldehydes (<bold>139a</bold>&#8211;<bold>c</bold>) and 2-aminobenzimidazoles in the presence of both base and magnesium sulfate under microwave irradiation led to the formation of derivatives <bold>140</bold> in 58&#8211;70% yields (<xref rid="molecules-30-03506-sch032" ref-type="fig">Scheme 32</xref>).</p><p>In the next work [<xref rid="B75-molecules-30-03506" ref-type="bibr">75</xref>], 2-bromocyclohex-1-enecarbaldehydes <bold>139a</bold>&#8211;<bold>c</bold> were incorporated into the reaction with 4,7-dimethoxy-<italic toggle="yes">1H</italic>-benzimidazole-2-amine under optimized conditions (microwave irradiation) for the obtaining tetrahydrobenzo[4,5]imidazo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>141</bold> and subsequent oxidation (<xref rid="molecules-30-03506-sch032" ref-type="fig">Scheme 32</xref>). It was demonstrated that 4,7-dimethoxy-1<italic toggle="yes">H</italic>-benzimidazole-2-amine also interacts effectively with 2-bromobenzaldehydes <bold>143</bold> with the formation of benzimidazo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>144</bold>. Oxidation of quinazoline-fused dimethoxybenzimidazoles <bold>141</bold> and <bold>144</bold> was conducted using ceric ammonium nitrate (CAN) in the MeCN/H<sub>2</sub>O medium. The corresponding benzo[4,5]imidazo[1,2-<italic toggle="yes">a</italic>]quinazoline-8,11-diones <bold>142</bold> and <bold>145</bold> were obtained in good yields.</p><p>Dao et al. [<xref rid="B76-molecules-30-03506" ref-type="bibr">76</xref>] reported the synthesis of 1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>147</bold> from &#42933;-bromo-&#945;,&#42933;-unsaturated amides and benzimidazole via copper powder catalyzed C&#8211;N coupling and subsequent C&#8211;N bond formative cyclization by C&#8211;H activation under microwave irradiation conditions (<xref rid="molecules-30-03506-sch033" ref-type="fig">Scheme 33</xref>). Interaction of amide <bold>146</bold> with imidazole under the same conditions led to the formation of 1,2,3,4-tetrahydroimidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5-one <bold>148</bold>. It was also demonstrated that benzamides <bold>149</bold> under similar conditions allowed to obtain benzimidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>150a</bold>&#8211;<bold>c</bold> (<xref rid="molecules-30-03506-sch033" ref-type="fig">Scheme 33</xref>). This reaction provides the first known way to make these unique hybrid nitrogen-containing structures using common starting materials.</p><p>Heterogeneous amorphous Cu&#8211;MOF-74 catalyst was developed for C&#8211;N coupling reaction and applied for the synthesis of benzimidazo/imidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>151a</bold>,<bold>b</bold> [<xref rid="B77-molecules-30-03506" ref-type="bibr">77</xref>] (<xref rid="molecules-30-03506-sch033" ref-type="fig">Scheme 33</xref>). Ma et al. demonstrated that crystalline Cu&#8211;MOF-74 can be used as a catalyst precursor to synthesize aCu-MOF-74 under the action of alkali and high temperature in the reaction solution, and then it acts as a true heterogeneous catalyst to catalyze C&#8211;N coupling between 2-iodobenzamides <bold>149</bold> and benzimidazole/imidazole, which gives higher isolated yields. The catalyst can be simply removed after the reaction and reused up to six times without losing much effectiveness.</p><p>An approach based on the Ullman coupling of 2-chlorobenzamide <bold>149d</bold> with imidazole followed by oxidative ring formation was used for the synthesis of imidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5-one <bold>152</bold> [<xref rid="B78-molecules-30-03506" ref-type="bibr">78</xref>] (<xref rid="molecules-30-03506-sch034" ref-type="fig">Scheme 34</xref>). When 4-phenylimidazole was applied, the yield of compound <bold>153</bold> was only 23%, while functionalization of derivative <bold>152</bold> by palladium-catalyzed direct C&#8211;H arylation with bromobenzene led to the formation of 2-phenyl-4-ethyl-imidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5-one <bold>153</bold> in 55% yield.</p><p>Rapid and efficient microwave-assisted metal-free base-mediated synthetic approach to the series of benzimidazo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>156</bold> (15 compounds) (<xref rid="molecules-30-03506-sch034" ref-type="fig">Scheme 34</xref>) from readily available building blocks was developed [<xref rid="B13-molecules-30-03506" ref-type="bibr">13</xref>,<xref rid="B79-molecules-30-03506" ref-type="bibr">79</xref>]. In the presence of groups X = NO<sub>2</sub> or R = 5-Br in the aldehyde <bold>155</bold>, the yields of compounds <bold>156</bold> decreased to 38% and 44%, respectively. This method uses easy-to-get starting materials, works with many different substrates, is simple to carry out, and allows making various benzimidazo[1,2-<italic toggle="yes">a</italic>]quinazoline compounds without needing metals.</p><p>One more strategy for the synthesis of imidazole[1,2-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones was described [<xref rid="B80-molecules-30-03506" ref-type="bibr">80</xref>]. Interaction of isatoic anhydride <bold>28</bold> with <italic toggle="yes">o</italic>-chlorobenzyl amine gave 2-amino-<italic toggle="yes">N</italic>-(2-chlorobenzyl)benzamide, which under the reaction with CS<sub>2</sub> in the alkali medium was converted into 3-(2-chlorobenzyl)-2-thioxo-2,3-dihydroquinazolin-4(1<italic toggle="yes">H</italic>)-one <bold>157</bold> (<xref rid="molecules-30-03506-sch035" ref-type="fig">Scheme 35</xref>). Heating this compound with a mixture of POCl<sub>3</sub> and PCl<sub>5</sub> yielded the corresponding 2-chloro derivative <bold>158</bold>, which upon reaction with 2,2-dimethoxyethylamine in the presence of NEt<sub>3</sub> afforded 4-(2-chlorobenzyl)imidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(<italic toggle="yes">4H</italic>)-one <bold>159</bold>. The structure of compound <bold>159</bold> was confirmed by various spectroscopic methods including X-ray crystallography.</p><p>In the next work [<xref rid="B81-molecules-30-03506" ref-type="bibr">81</xref>] 4-(2-chlorobenzyl)imidazolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-one <bold>159</bold> was functionalized at imidazole cycle by the Vilsmeier&#8211;Haack reaction with DMF and POCl<sub>3</sub> and then reductive amination with a secondary amine reagent to obtain compounds <bold>161a</bold>&#8211;<bold>e</bold> (<xref rid="molecules-30-03506-sch035" ref-type="fig">Scheme 35</xref>). Second series of 4-(2-chlorobenzyl)imidazole[1,2-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones (<bold>164</bold>, 27 compounds) was synthesized based on 2-amino-3-(2-chlorobenzyl)quinazolin-4(3<italic toggle="yes">H</italic>)-one <bold>162</bold>, obtained from chloro derivative <bold>158</bold> in the reaction with <italic toggle="yes">p</italic>-methoxy-benzylamine. Removing the benzyl group, cyclizing <bold>162</bold> with ethyl bromopyruvate and condensing with amine compounds led to the formation of compounds <bold>164</bold> in good yields (<xref rid="molecules-30-03506-sch035" ref-type="fig">Scheme 35</xref>).</p><p>Imidazoquinazolinone derivatives <bold>161</bold> and <bold>164</bold> were studied as allosteric inhibitors of SHP2 phosphatase, in vitro enzymatic assays were conducted. The inhibitory activities of <bold>161</bold> and <bold>164</bold> against SHP2 protease at 100 &#956;M and 200 &#956;M were evaluated; results demonstrated that most of the compounds have certain inhibitory activity against SHP2 protease. Imidazoquinazolinones <bold>161a</bold> (22.14% inhibition) and <bold>164</bold> (R = 4-HO-piperidinyl) (29.81% inhibition) showed better inhibition of SHP2 protein activity than SHP244 as a positive control, (14.95% inhibition) at 100 &#956;M. The in vitro cytotoxicity of 100 &#956;M concentrations of compounds <bold>161</bold>, <bold>164</bold> towards the melanoma cell line A375 was evaluated; according to results, compared with SHP244 and sorafenib (inhibition 13.81% and 14.79%), most of the compounds showed significant cytotoxicity to A375. Among them, <bold>161a</bold> (76.15% inhibition) and <bold>164</bold> (R = <italic toggle="yes">m</italic>-CF<sub>3</sub>-aniline) (27.93% inhibition) showed effective activity (<xref rid="molecules-30-03506-t005" ref-type="table">Table 5</xref>). The IC<sub>50</sub> values were also measured for the series of compounds, and generally it was shown that, compared with SHP244, the tumor cell activity of <bold>161</bold> and <bold>164</bold> compounds is significantly better than enzyme activity. The docking studies revealed that C=O groups of imidazoquinazolinones form hydrogen bond interactions with Lys274 and His84, respectively (<xref rid="molecules-30-03506-f008" ref-type="fig">Figure 8</xref>).</p><p>Ghashghaei et al. [<xref rid="B82-molecules-30-03506" ref-type="bibr">82</xref>] presented selective multiple multicomponent Groebke&#8211;Blackburn&#8211;Bienaym&#233; reaction (GBBR), which allows to obtain imidazoazines by acid-catalyzed interaction of &#945;-aminoazines, aldehydes and isocyanides. Thus, diaminoquinazoline <bold>165</bold> underwent a regioselective GBBR providing mono-adduct <bold>166</bold> at components ratio 1:1:1 (<xref rid="molecules-30-03506-sch036" ref-type="fig">Scheme 36</xref>). In a different reaction, substrate <bold>165</bold> afforded the symmetrical bis-adduct <bold>167</bold> (components ratio 1:2:2). Moreover, a second GBBR, performed upon <bold>166</bold>, gave the non-symmetrical compound <bold>168</bold> (components ratio 1:1:1). This method can be widely applied and create complicated molecules selectively, adjustably, and directly.</p><p>Annareddygari et al. [<xref rid="B53-molecules-30-03506" ref-type="bibr">53</xref>] developed the general approach to azoloquinazolines. Thus, the reaction of 2-aminobenzothiazole with 2-fluorobenzaldehyde led to the formation of benzo[4,5]thiazolo[3,2-<italic toggle="yes">a</italic>]quinazoline (<bold>169</bold>) in 73% yield under the optimized conditions (<xref rid="molecules-30-03506-sch037" ref-type="fig">Scheme 37</xref>).</p><p>The series of thiazolo[3,2-<italic toggle="yes">a</italic>]quinazolin-5-one derivatives <bold>172a</bold>&#8211;<bold>f</bold> containing a sulfonamide group on C7 was described [<xref rid="B83-molecules-30-03506" ref-type="bibr">83</xref>]. Interaction of chlorosulfonyl-substituted benzoyl halogenides <bold>170a</bold>&#8211;<bold>d</bold> with aminothiazoles led to the formation of amides <bold>171</bold> (<xref rid="molecules-30-03506-sch037" ref-type="fig">Scheme 37</xref>). The treatment them with amine under mild conditions and subsequent cyclization under reflux in DMF or diphenyl ether allowed to obtain thiazolo[3,2-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>172a</bold>&#8211;<bold>f</bold>. The influence of substituent R<sup>1</sup> and the nature of halogen on the yield of target products has been analyzed.</p></sec><sec id="sec6-molecules-30-03506"><title>6. Triazolo[<italic toggle="yes">a</italic>]quinazolines</title><sec id="sec6dot1-molecules-30-03506"><title>6.1. [1,2,4]-Triazolo[4,3-a]quinazolines</title><p>Book chapter [<xref rid="B12-molecules-30-03506" ref-type="bibr">12</xref>] discloses approaches to triazolo[<italic toggle="yes">a</italic>]- and triazolo[<italic toggle="yes">c</italic>]-annelated quinazolines based on traditional transformations of chloroquinazolines, condensations between quinazoline and azide or nitrile, copper-catalyzed alkyne-azide cycloaddition reaction, multicomponent reactions, and microwave-assisted procedures. In the book chapter [<xref rid="B12-molecules-30-03506" ref-type="bibr">12</xref>], some data on biological activity was also presented. The current section of the manuscript contains data on the synthesis and biological activity of triazolo[<italic toggle="yes">a</italic>]quinazolines, which were not included in the book chapter [<xref rid="B12-molecules-30-03506" ref-type="bibr">12</xref>] or appeared later.</p><p>A series of 5-substituted-[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolines <bold>173</bold> was synthesized, and anticonvulsant activity was tested [<xref rid="B84-molecules-30-03506" ref-type="bibr">84</xref>]. Among the compounds, <bold>173</bold> 5-heptyloxy-derivative was found to be especially potent (ED<sub>50</sub> = 39.4 mg/kg, PI = 8.3). Continuing research in this direction, the same team has presented a new series of 4-aryl-[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(<italic toggle="yes">4H</italic>)-ones <bold>175</bold> and <bold>176</bold>, 1-substituted derivatives <bold>177</bold>&#8211;<bold>180</bold> (<xref rid="molecules-30-03506-sch038" ref-type="fig">Scheme 38</xref>), and evaluated their anticonvulsant [<xref rid="B85-molecules-30-03506" ref-type="bibr">85</xref>] and antidepressant activities [<xref rid="B86-molecules-30-03506" ref-type="bibr">86</xref>]. In these compounds, an aryl substituent is introduced into the NH group of quinazolin-4(<italic toggle="yes">3H</italic>)-one, unlike derivatives <bold>173</bold>, while the triazole ring is modified. 2-Hydrazino-3-phenyl-2,3-dihydroquinazolin-4(<italic toggle="yes">1H</italic>)-one derivatives <bold>174</bold>, obtained by slightly modifying a previously reported method [<xref rid="B87-molecules-30-03506" ref-type="bibr">87</xref>], were used as starting materials for the synthesis of [1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(<italic toggle="yes">4H</italic>)-ones <bold>175</bold>&#8211;<bold>180</bold>. The treatment of derivatives <bold>174</bold> with formic acid under reflux overnight led to 4-aryl-[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones <bold>175</bold> (24 compounds). The 4-aryl-[1,2,4]tetrazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(<italic toggle="yes">4H</italic>)-ones <bold>176</bold> (23 compounds) were obtained by reaction <bold>174</bold> with NaNO<sub>2</sub> in 10% HCl. To obtain the target compounds <bold>177</bold>&#8211;<bold>180</bold>, derivative <bold>174</bold> was reacted with diethyl oxalate, urea, carbon disulfide, and acetic acid, respectively (<xref rid="molecules-30-03506-sch038" ref-type="fig">Scheme 38</xref>). The amido derivative <bold>177</bold> was obtained by treating ethoxycarbonyl derivative <bold>176</bold> with aqueous ammonia.</p><p>Compounds <bold>175</bold>&#8211;<bold>180</bold> were evaluated for their anticonvulsant activity and neurotoxicity by maximal electroshock (MES) and rotarod neurotoxicity tests [<xref rid="B85-molecules-30-03506" ref-type="bibr">85</xref>]. The compounds were dissolved in DMSO and Kunming mice in the 18&#8211;22 g weight range were used. According to preliminary data, 11 compounds from the series of <bold>175</bold> possessed anticonvulsant activity against MES-induced seizures at a dose of 100 mg/kg, and five of these (R = <italic toggle="yes">o</italic>(<italic toggle="yes">m</italic>,<italic toggle="yes">p</italic>)-Cl, <italic toggle="yes">p</italic>-Br, 3,4-Me<sub>2</sub>) were found to remain active at a dose of 30 mg/kg. Further studies demonstrated that two derivatives <bold>175</bold> (R = <italic toggle="yes">p</italic>-Cl and <italic toggle="yes">p</italic>-Br) displayed wide spectrum activity in several models (<xref rid="molecules-30-03506-t006" ref-type="table">Table 6</xref>), exhibited wide margin of safety with a protective index (PI) exceeding one for existing drugs (&gt;25.5 and &gt;26.0), and showed significant oral activity against MES-induced seizures in mice, with ED<sub>50</sub> 88.02 and 94.60 mg/kg, respectively.</p><p>Compounds <bold>175</bold>&#8211;<bold>180</bold> were evaluated for antidepressant activities in mice [<xref rid="B86-molecules-30-03506" ref-type="bibr">86</xref>]. Most of them showed antidepressant activity in the forced swimming test (FST). It was found that three compounds from the series of <bold>176</bold> (R = <italic toggle="yes">o</italic>-F, <italic toggle="yes">m</italic>-Me and <italic toggle="yes">p</italic>-Me) at a dose of 50 mg/kg significantly reduced the immobility time in the FST. Compound <bold>176</bold> (R = <italic toggle="yes">p</italic>-Me) proved to be the most active, the immobility time decreased by 82.69% at 50 mg/kg dose (<xref rid="molecules-30-03506-t006" ref-type="table">Table 6</xref>). Also, this substance did not change normal behavior in tests, and its positive impact was like the antidepressant fluoxetine.</p><p>1-Methyl[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones <bold>182</bold>, <bold>183</bold> were obtained by the reaction of 2-hydrazinoquinazolin-4(3<italic toggle="yes">H</italic>)-ones <bold>181a</bold>,<bold>b</bold> with acetylacetone (<xref rid="molecules-30-03506-sch039" ref-type="fig">Scheme 39</xref>) [<xref rid="B90-molecules-30-03506" ref-type="bibr">90</xref>]. Notably, the 7-hydrazinocarbonyl group in quinazolin-4(3<italic toggle="yes">H</italic>)-one <bold>181a</bold> is transformed into a pyrazole derivative, which can be replaced by amine with the amide formation.</p><p>1-Substituted-[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones, bearing at position 4 pyridine-4-yl (<bold>185a</bold>&#8211;<bold>e</bold>) or <italic toggle="yes">p</italic>-nitrophenyl (<bold>186a</bold>&#8211;<bold>e</bold>) fragment (<xref rid="molecules-30-03506-sch039" ref-type="fig">Scheme 39</xref>) were described [<xref rid="B91-molecules-30-03506" ref-type="bibr">91</xref>,<xref rid="B92-molecules-30-03506" ref-type="bibr">92</xref>]. Compounds <bold>185a</bold>&#8211;<bold>d</bold> and <bold>186a</bold>&#8211;<bold>d</bold> were obtained by the reaction of 2-hydrazino-3-R-quinazolin-4(3<italic toggle="yes">H</italic>)-one <bold>184</bold> with the corresponding acid as one carbon donor, whereas interaction of <bold>184</bold> with chloroacetyl chloride in glacial acetic acid was used for the preparation of compounds <bold>185e</bold> and <bold>186e</bold>. Both series of derivatives have been evaluated for their in vivo antihistaminic and sedative&#8211;hypnotic activities. The protection against histamine-induced bronchospasm on conscious guinea pigs method was adopted to determine the antihistaminic potential of the test compounds. All compounds exhibit significant antihistaminic activity, the percentage protection for compounds <bold>185a</bold>&#8211;<bold>e</bold> is 69&#8211;73%, and for derivatives <bold>186a</bold>&#8211;<bold>e</bold> 68&#8211;71.6%. The highest activity was shown by derivatives <bold>185a</bold> and <bold>186a</bold>. Sedative-hypnotic activity was determined by measuring the reduction in motor activity. The results showed that almost all the test compounds were found to exhibit mild activity (less than 10%).</p><p>The synthesis, crystal structure, DFT study, and molecular docking of two new 4-(2-chlorobenzyl)-containing [1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones (<bold>189</bold>, <bold>190</bold>) were presented [<xref rid="B93-molecules-30-03506" ref-type="bibr">93</xref>,<xref rid="B94-molecules-30-03506" ref-type="bibr">94</xref>]. Both derivatives were synthesized according to <xref rid="molecules-30-03506-sch040" ref-type="fig">Scheme 40</xref> starting from the corresponding 4(<italic toggle="yes">3H</italic>)-quinazolinone-3-[(2-chlorophenyl)methyl]-2-hydrazonyl <bold>187</bold>, obtained via hydrazinolysis of quinazoline thione <bold>157</bold> (see <xref rid="molecules-30-03506-sch035" ref-type="fig">Scheme 35</xref>). The structures of derivatives <bold>189</bold> and <bold>190</bold> have been confirmed by X-ray diffraction data. The crystal structures of <bold>189</bold>, <bold>190</bold> were compared with the conformers optimized by DFT calculation, and they were found to be consistent. Studies on the molecular electrostatic potential and frontier molecular orbital (FMO) of <bold>189</bold> show that this compound has a certain nucleophilic reactivity and large hardness.</p><p>Molecular docking study for compound <bold>189</bold> demonstrated the formation of seven hydrogen bonds with SHP2 protein, indicating that this compound has a better binding effect with SHP2 [<xref rid="B93-molecules-30-03506" ref-type="bibr">93</xref>]. Molecular docking of <bold>190</bold> suggests favorable interactions with SHP2 protein [<xref rid="B94-molecules-30-03506" ref-type="bibr">94</xref>]. The SHP2 enzyme inhibitory activity of <bold>190</bold> was evaluated at 10 &#956;M, (<bold>SHP244</bold> was used as a reference compound [<xref rid="B95-molecules-30-03506" ref-type="bibr">95</xref>]) and it was shown that activity (inhibition rate 12.40%) was lower than that of <bold>SHP244</bold> (19.67%). The antitumor activity of compound <bold>190</bold> was evaluated in human hepatoma cells SMMC7721, human melanoma cells A375 and human breast cancer cells MCF-7 using an MTT assay (<bold>SHP244</bold> was used as a reference compound). It was found that the IC<sub>50</sub> values were 757, 70.19 and &gt;1000 &#956;M, respectively. Compound <bold>190</bold> has better selectivity for melanoma cells. The antitumor activity of <bold>190</bold> was better than that of the reference compound in SMMC7721 and A375, which may be due to <bold>190</bold> has better physical and chemical properties.</p><p>A series of [1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(<italic toggle="yes">4H</italic>)-one derivatives were synthesized and studied as SHP2 protein inhibitors [<xref rid="B95-molecules-30-03506" ref-type="bibr">95</xref>]; among them, compound SHP244 showed good results. Continuing these studies, new groups of [1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(<italic toggle="yes">4H</italic>)-ones (compounds <bold>192(1</bold>&#8211;<bold>28)</bold>, <bold>193a</bold>,<bold>b</bold>, <bold>195a</bold>&#8211;<bold>c</bold>) were obtained through modification of the SHP244 structure at positions 1 and 4 (<xref rid="molecules-30-03506-sch041" ref-type="fig">Scheme 41</xref>) [<xref rid="B81-molecules-30-03506" ref-type="bibr">81</xref>]. The benzene ring in the triazole cycle was replaced with a nitrogen-containing side chain to enhance the binding effect with the receptor and the 2-chlorobenzene ring was replaced with an aromatic ring containing different substituents to investigate the effect of this part of the structure on the activity.</p><p>The inhibitory activities of triazoloquinolinone derivatives <bold>192</bold>, <bold>193</bold>, and <bold>195</bold> against SHP2 protease at 100 mM and 200 mM were evaluated in vitro. Self-isolated and purified SHP2 was used as the target protein, and SHP244 was used as a positive control. It was shown that most compounds have certain inhibitory activity against SHP2 protease. Compared with SHP244, some compounds show similar or higher sensitivity to SHP2, which indicates that the modification of the three parts of SHP244 has a profound influence on the activity. For example, compound <bold>193b</bold> (28.20% inhibition) and compound <bold>195b</bold> (26.38% inhibition) showed better SHP2 protein inhibitory activity than comparable structures at 100 mM, and better than SHP244 (23.52% inhibition). To study the antitumor activity of the compounds <bold>192</bold>, <bold>193</bold>, <bold>195</bold>, SHP244, and sorafenib were used as positive controls, and the MTT method was used to evaluate the in vitro cytotoxicity of the compounds 100 mM on the melanoma cell line A375 (<xref rid="molecules-30-03506-t006" ref-type="table">Table 6</xref>). Compared with SHP244 and sorafenib, most of the compounds showed significant cytotoxicity to A375, such as <bold>192(5)</bold> (27.02% inhibition) and <bold>192(21)</bold> (29.60% inhibition). Metabolic stability of compound <bold>192(22)</bold> in human and rat liver microsome in vitro was studied, SHP244 was used as a positive control. It was found that this compound showed considerable stability in human and rat liver microsomes, and the clearance rate for both human and rat liver microsomes was less than 9.6 (mL/min/mg) with similar remaining (82.0% and 78.9%, t<sub>1/4</sub> 60 min). At the same time, t<sub>1/2</sub> are both greater than 145 min, which is much greater than t<sub>1/2</sub> of SHP244 for human and rat liver microsomes (14.2 and 12.2 min). Docking studies of the compound <bold>195c</bold> was performed, and it was shown that C(O) group of 2-(pyrrolidin-1-yl)acetyl fragment and nitrogen of triazole cycle form hydrogen with the amino acid residues Asn281 and Tyr80, respectively (<xref rid="molecules-30-03506-f009" ref-type="fig">Figure 9</xref>).</p><p>Some [1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-one derivatives exhibit other types of biological activity. Thus, compounds <bold>196a</bold>&#8211;<bold>c</bold> (<xref rid="molecules-30-03506-f010" ref-type="fig">Figure 10</xref>) were screened for their in vitro antimicrobial and antitubercular activities against pathogenic strain [<xref rid="B96-molecules-30-03506" ref-type="bibr">96</xref>]. Compounds were obtained by the reaction of 3-aryl-2-hydrazinoquinazolines with carbon disulfide in good yields. Compound <bold>196b</bold> was found to be nearly equipotent with Ciprofloxacin against both Gram-positive and Gram-negative bacteria (<italic toggle="yes">P. aeruginosa</italic> and <italic toggle="yes">S. aureus</italic>) with MIC 2.6 &#956;g/mL and demonstrated very promising antifungal activity against <italic toggle="yes">A. niger</italic> with MIC 2.6 &#956;g/mL. The anti-tubercular activity of compounds <bold>196</bold> reveal that compound <bold>196b</bold> showed better activity than the other compounds with a MIC of 5.2 &#956;g/mL against <italic toggle="yes">M. tuberculosis</italic> H<sub>37</sub>Rv.</p><p>A 3D similarity-based virtual screen to search for ligands of Toll-like receptor (TLR7), an important target for drug discovery, was performed [<xref rid="B97-molecules-30-03506" ref-type="bibr">97</xref>]. Six new compounds were identified as interesting initial hit compounds that can act as TLR7 antagonists with micromolar potencies, as determined using a reporter assay. Among them, [1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-one <bold>197</bold> (<xref rid="molecules-30-03506-f010" ref-type="fig">Figure 10</xref>), possessing good solubility, was progressed into biological evaluation and showed antagonistic activity (IC<sub>50</sub> = 185 &#956;M).</p><p>A series of 1-aryl-[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>198</bold> (11 derivatives) designed as conformationally restricted of CA-4 (well-known antimitotic agent) analogues was synthesized to study their biological efficiency toward tubulin polymerization, their cytotoxicity toward various cancer cell lines, and their antivascular effects [<xref rid="B98-molecules-30-03506" ref-type="bibr">98</xref>]. Derivatives <bold>198</bold> were obtained by the reaction of 3-benzyl(methyl)-2-hydrazino-quinazolinones with corresponding aryl aldehydes followed by oxidative cyclization. Only two of them (<bold>198a</bold>,<bold>b</bold>) were potent in vitro tubulin polymerization inhibitors with IC<sub>50</sub> values of 4.26 and 0.15 mM respectively, but only the <italic toggle="yes">N</italic>-methyl substituted counterpart <bold>198b</bold> displayed strong growth inhibitions toward the NCI-60 human cancer cell lines panel. This compound has shown remarkable activity in the HUVEC shape change assays as cell invasion and endothelial tube formation experiments which are good indicators for potential in vivo antivascular activity. These results suggest that compound <bold>198b</bold> might be lead compound for the development of novel vascular disrupting agents and is promising candidates for in vivo evaluation.</p><p>Triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5-one derivative <bold>199</bold> demonstrated potent NF-&#954;B inducing kinase (NIK) inhibitory effect with IC<sub>50</sub> values of 103.4 &#177; 5.1 &#956;M and 57% [<xref rid="B99-molecules-30-03506" ref-type="bibr">99</xref>]. Identification of new NIK inhibitors by discriminatory analysis-based molecular docking was performed, 70 compounds from different classes were selected and tested by the NIK adenosine triphosphate (ATP) consumption essay for NIK inhibitory activities. Three of them, including derivative <bold>199</bold>, have an inhibiting rate over 50%.</p><p>Identification of a new heterocyclic scaffold for inhibitors of the Polo-Box Domain of Polo-like Kinase 1 (PBD of Plk1) was performed [<xref rid="B88-molecules-30-03506" ref-type="bibr">88</xref>]. A small chemical library of &#8764;400 drug-like molecules was screened for the ability to bind to the PBD of Plk1. Among four hits identified was triazoloquinazolinone <bold>200</bold> (<xref rid="molecules-30-03506-f011" ref-type="fig">Figure 11</xref>), which inhibited PBD binding in the ELISA assay with an IC<sub>50</sub> of 4.38 &#956;M. When compared to the previously characterized phosphopeptide, PLHSpT (IC<sub>50</sub> of 14.74 &#956;M), the affinity of the compound <bold>200</bold> is anticipated to be at least threefold higher than that of peptide. To find compounds with improved characteristics within this series, a large range of triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>201</bold> (147 derivatives) was synthesized by modifying different fragments of structure <bold>200</bold>. All derivatives were obtained through the reaction of 3-R-2-hydrazino-quinazolinones with carbon disulfide. Various substituents were introduced as R<sup>1</sup> groups (7(8,9)-F, 7-Br, 7-I, 7-Me, 7-NHAc, 7-NMe<sub>2</sub>) and aza-analogues of the phenyl ring were also introduced. Many alkyl, heteroalkyl, and arylalkyl modifications of the R<sup>2</sup> group (phenylethyl in compound <bold>200</bold>) were included.</p><p>All compounds were evaluated for their efficacy against the full-length human Plk1 in an ELISA assay and for their in vitro physiochemical properties. Variation of substituent R<sup>2</sup> (in the case R<sup>1</sup> and R<sup>3</sup> = H) demonstrated that compound containing R<sup>2</sup> = Pr exhibited the best inhibitory activity (IC<sub>50</sub> of 1.03 &#956;M). Replacing R<sup>3</sup> in this compound with 2-oxo-2-phenylethyl led to a sharp decrease in inhibitory activity (IC<sub>50</sub> &gt; 50 &#956;M). Variation of substituent R<sup>1</sup> (with R<sup>2</sup> = Ph and R<sup>3</sup> = H) resulted in changes in inhibitory activity ranging from IC<sub>50</sub> 1.54&#8211;30.71 &#956;M. As a result, it was found that derivative <bold>201a</bold> demonstrated the best efficacy against the full-length human Plk1 in an ELISA assay (<xref rid="molecules-30-03506-t006" ref-type="table">Table 6</xref>). Furthermore, the MeS-containing prodrug derivatives <bold>202</bold> exhibited potent inhibition of mitotic progression and cellular proliferation, while their metabolic stability was thoroughly evaluated.</p></sec><sec id="sec6dot2-molecules-30-03506"><title>6.2. [1,2,4]-Triazolo[1,5-a]quinazolines</title><p>Book chapter [<xref rid="B12-molecules-30-03506" ref-type="bibr">12</xref>] discloses approaches to triazolo[<italic toggle="yes">a</italic>]-annelated quinazolines based on traditional transformation of chloroquinazolines, condensations between quinazoline and azide, copper-catalyzed alkyne-azide cycloaddition reaction, through the coupling of dialkyl/phenyl <italic toggle="yes">N</italic>-cyanoimidocarbonates with the substituted 2-hydrazinobenzoic acids. Some data on biological activity was also provided in the book chapter [<xref rid="B12-molecules-30-03506" ref-type="bibr">12</xref>]. The current section of the manuscript contains data on the synthesis and biological activity of triazolo[<italic toggle="yes">a</italic>]quinazolines, which were not included in the book chapter [<xref rid="B12-molecules-30-03506" ref-type="bibr">12</xref>] or appeared later.</p><p>An approach based on the Ullman coupling of 2-chloroarylamides <bold>203</bold> with triazoles followed by oxidative ring formation was applied for the synthesis of [1,2,4]-triazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>204</bold> and their aza-analogs <bold>205</bold> (<xref rid="molecules-30-03506-sch042" ref-type="fig">Scheme 42</xref>) [<xref rid="B78-molecules-30-03506" ref-type="bibr">78</xref>].</p><p>Efficient method was developed for the synthesis of [1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>206</bold> from 2-fluoro benzaldehydes <bold>57</bold> with 1<italic toggle="yes">H</italic>-1,2,4-triazol-3-amine under metal-free conditions in high yields (<xref rid="molecules-30-03506-sch042" ref-type="fig">Scheme 42</xref>) [<xref rid="B53-molecules-30-03506" ref-type="bibr">53</xref>]. The process includes an intermolecular condensation followed by metal-free base-promoted intramolecular C&#8211;N coupling reaction. It is worth mentioning that the bromine atom stays intact during the reaction and can later be modified or used in additional steps.</p><p>2-(4-Chlorophenyl)[1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazoline <bold>207</bold>, obtained by the reaction of 2-chlorobenzaldehyde with substituted 1<italic toggle="yes">H</italic>-1,2,4-triazol-5-amine (<xref rid="molecules-30-03506-sch042" ref-type="fig">Scheme 42</xref>), was evaluated for its in vitro anticancer activity against liver cancer HepG2 and breast cancer MCF7 cell lines, unfortunately, the compound demonstrated low activity [<xref rid="B100-molecules-30-03506" ref-type="bibr">100</xref>].</p><p>The synthesis of [1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolinone derivatives <bold>209</bold> and <bold>211</bold> by reaction of hydrazononitriles with hydroxylamine hydrochloride in presence of sodium acetate was described [<xref rid="B101-molecules-30-03506" ref-type="bibr">101</xref>] (<xref rid="molecules-30-03506-sch043" ref-type="fig">Scheme 43</xref>). The influence of the nature of the heterocyclic fragment in hydrazononitriles <bold>208</bold> has been demonstrated. Benzimidazolyl-containing hydrazono-nitrile <bold>208a</bold> reacts with hydroxylamine hydrochloride upon boiling in DMF for 3 h leading to triazolo[1,5-<italic toggle="yes">a</italic>]quinazolinone <bold>209</bold>, whereas <bold>208b</bold> containing a benzothiazole fragment under the same conditions forms an amidoxime derivative <bold>210</bold> that did not cyclize even over a longer period (48 h). However, heating compound <bold>210</bold> in glacial acetic acid at reflux yielded the cyclized product <bold>211</bold> in good yield.</p><p>2-Phenoxybenzo[<italic toggle="yes">g</italic>][1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-one <bold>212</bold> was synthesized in good yield by the reaction of diphenyl-<italic toggle="yes">N</italic>-cyanoimidocarbonate with hydrazinonaphthoic acid (<xref rid="molecules-30-03506-sch044" ref-type="fig">Scheme 44</xref>) [<xref rid="B102-molecules-30-03506" ref-type="bibr">102</xref>]. Alkylation, chlorination and thionation of the lactam group in this compound led to the range of derivatives <bold>213</bold>&#8211;<bold>215</bold>. Compounds <bold>212</bold>&#8211;<bold>215</bold> were characterized by NMR and HREI-MS analyses.</p><p>A series of 2-methylthio-benzo[<italic toggle="yes">g</italic>][1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>216</bold>, obtained according to <xref rid="molecules-30-03506-sch044" ref-type="fig">Scheme 44</xref>, was tested against a variety of Gram-positive bacterial species, Gram-negative bacteria and against ten types of fungi [<xref rid="B103-molecules-30-03506" ref-type="bibr">103</xref>]. Most derivatives showed significant antimicrobial activity against six bacterial and six fungal strains. Al-Salahi et al. [<xref rid="B104-molecules-30-03506" ref-type="bibr">104</xref>] concluded that the promising compounds could be employed as useful scaffolds for building of new derivatives with more potent antimicrobial effects.</p><p>Various substituted 1,2,4-triazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>217</bold>&#8211;<bold>220</bold> (<xref rid="molecules-30-03506-f012" ref-type="fig">Figure 12</xref>) were synthesized <bold>[<xref rid="B104-molecules-30-03506" ref-type="bibr">104</xref>]</bold>, and evaluation of their biological effects on heart rate and blood pressure was performed. Compounds <bold>217</bold> were obtained by interaction of the corresponding 2-hydrazino-benzoic acid with diphenyl-<italic toggle="yes">N</italic>-cyanoimidocarabonate, the modification of structure <bold>217</bold> led to triazoloquinazolines <bold>218</bold>&#8211;<bold>220</bold>. The structures of derivatives <bold>217b</bold>, <bold>217d</bold> and 2-benzyloxy-1,2,4-triazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5-one was confirmed later by X-ray data [<xref rid="B7-molecules-30-03506" ref-type="bibr">7</xref>,<xref rid="B105-molecules-30-03506" ref-type="bibr">105</xref>].</p><p>In vivo antihypertensive activity study of the compounds <bold>217</bold>&#8211;<bold>220</bold> was performed for rats and mice. The results demonstrated that derivatives <bold>217a</bold>,<bold>c</bold> and <bold>218b</bold> were found to increase the heart rate (33, 14, and 40%, respectively), whereas derivatives <bold>217d</bold> and <bold>218a</bold> decrease the heart rate (23 and 15%, respectively). Moreover, compound <bold>217c</bold> decreases arterial pressure in the rats (6.5 mm H). Derivative <bold>219</bold> has shown to decrease blood pressure (7.8 mm H) and tachycardia effects. Compound <bold>220a</bold> decreases the heart rate (5.9%), at the same time derivative <bold>220b</bold> increases the heart rate (28.5%), both these compounds demonstrate decreasing arterial pressure (6.5 mm H). Al-Salahi et al. [<xref rid="B104-molecules-30-03506" ref-type="bibr">104</xref>] suggested that certain compounds could be tested as drugs blocking adrenaline receptors, while others appear to stimulate heart function or could be altered to improve blood pressure reduction.</p><p>A series of some previously obtained methylsulfanyl-triazoloquinazoline derivatives <bold>221</bold>&#8211;<bold>223</bold> (21 compounds, <xref rid="molecules-30-03506-f013" ref-type="fig">Figure 13</xref>) [<xref rid="B106-molecules-30-03506" ref-type="bibr">106</xref>] have been tested against Coxsackievirus B4 and Adenovirus type 7 [<xref rid="B107-molecules-30-03506" ref-type="bibr">107</xref>]. The antiviral activity of these compounds against Coxsackie B4 and Adeno type 7 was evaluated in BGM and Hep-2 cell lines. Most tested derivatives were found to possess weak effects on Coxsackie B4 and Adeno type 7, compounds <bold>223</bold> proved to be the most promising. High reduction percentages were observed to viral titers 63.3&#8211;83.3% by compounds <bold>223c</bold>, <bold>223b</bold>, and <bold>223d</bold>, which indicates promising effect against Coxsackie B4. The reduction of Adeno type 7 titters were 63.3, 50, and 66.6% demonstrated by <bold>223b</bold>, <bold>223c</bold>, and <bold>223d</bold>, respectively.</p><p>Screening and evaluation of antioxidant activity was conducted for the expanded series of 1,2,4-triazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives <bold>221</bold>&#8211;<bold>226</bold> (40 compounds) [<xref rid="B108-molecules-30-03506" ref-type="bibr">108</xref>]. The antioxidant activity of 1,2,4-triazolo[1,5-<italic toggle="yes">a</italic>]quinazolines was evaluated using the 1,1-diphenyl-2-picryl-hydrazyl (DPPH) reagent. The obtained findings were compared with a standard synthetic antioxidant, 2,6-bis(1,1-dimethylethyl)-4-methylphenol (BHT). All tested compounds exhibited antioxidant activity ranged from weak to moderate and high. It was found that triazoloquinazolines <bold>224</bold>, <bold>225a</bold>,<bold>b</bold>, <bold>226a</bold>,<bold>b</bold> demonstrated the highest capacity to deplete DPPH, and from them, derivatives <bold>224</bold>, <bold>226a</bold>,<bold>b</bold> showed percent inhibitions of 85.9, 91.0, and 91.2, respectively, when compared with BHT (93%).</p><p>Triazoloquinazolines <bold>227</bold> (14 compounds, <xref rid="molecules-30-03506-f014" ref-type="fig">Figure 14</xref>) were reported as a new class of potent &#945;-glucosidase inhibitors [<xref rid="B109-molecules-30-03506" ref-type="bibr">109</xref>]. All compounds were synthesized and characterized previously [<xref rid="B104-molecules-30-03506" ref-type="bibr">104</xref>,<xref rid="B106-molecules-30-03506" ref-type="bibr">106</xref>]. The structure of derivative <bold>229b</bold> was later confirmed by X-ray data [<xref rid="B89-molecules-30-03506" ref-type="bibr">89</xref>]. Abuelizz et al. [<xref rid="B109-molecules-30-03506" ref-type="bibr">109</xref>] assayed the enzymatic inhibitory activity of compounds <bold>227</bold> against &#945;-glucosidase.</p><p>Triazoloquinazolines <bold>227</bold> demonstrated significant activity with the IC<sub>50</sub> values ranging between 12.70 &#177; 1.87 and 180.34 &#177; 1.28 &#956;M. Among them, derivatives <bold>231</bold>, <bold>230</bold>, <bold>229a</bold>, <bold>229b</bold>, and <bold>228</bold> showed the highest inhibitory activity (IC<sub>50</sub> = 12.70 &#177; 1.87, 28.54 &#177; 1.22, 45.65 &#177; 4.28, 72.28 &#177; 4.67, and 83.87 &#177; 5.12 &#956;M, respectively) in relation to that of acarbose (IC<sub>50</sub> = 143.54 &#177; 2.08 &#956;M) as a reference drug (<xref rid="molecules-30-03506-t006" ref-type="table">Table 6</xref>). Molecular modeling study confirmed the importance of binding energy in the stability of complex formed between the docked triazoloquinazolines and the amino acid residues in the active site of the enzyme.</p></sec></sec><sec sec-type="conclusions" id="sec7-molecules-30-03506"><title>7. Conclusions</title><p>Looking at current research articles about the discovery of pyrrolo-, indolo-, and azolo[<italic toggle="yes">a</italic>]-quinazoline compounds shows that different types of these molecules have caught researchers&#8217; interest. Although these compounds exhibit markedly distinct structures, most featured molecules remain either unsubstituted at position 4 of the quinazoline nucleus or incorporate oxo-, amino, aryl, or alkoxy substituents.</p><p>Considerable prospects are associated with such synthons for [<italic toggle="yes">a</italic>]-annelated quinazolines as 2-(3-butenyl)quinazolin-4(3<italic toggle="yes">H</italic>)-ones, <italic toggle="yes">N</italic>&#8242;-phenyl-2-aminobenzohydrazides, 2-halogeno-benzamides, 2-halogenobenzaldehydes, 2-aminobenzonitriles, anthranilamide, isatoic anhydride, 2-hydrazinobenzoic acid, 2-aminoquinazolines, and 2-hydrazinoquinazolines.</p><p>A promising line of research is the discovery of new approaches such as cyclocondensations, three-component carbonylative cyclization, Pd-catalyzed domino synthesis or direct C&#8211;H arylation, metal-free base-promoted intramolecular C&#8211;N coupling reaction. Some green methods were applied, for example, deep eutectic solvent, mechanochemical activation, graphene oxide as mild heterogeneous carbocatalyst, acid functionalized nanoporous silica (SBA-Pr-SO<sub>3</sub>H) as a reusable catalyst.</p><p>Noteworthy, many [<italic toggle="yes">a</italic>]-annelated quinazoline derivatives have specific activities in addition to antitumor activity, for example, antibacterial, hypotensive, antidepressant. Pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines exhibit anxiolytic, antihyperalgesic and anti-inflammatory activity, whereas pyrido[2&#8242;,3&#8242;:3,4]pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline demonstrate anticancer, antibacterial, and antifungal activity. Isoindolo[<italic toggle="yes">a</italic>]- and imidazo[<italic toggle="yes">a</italic>]-annelated quinazolines show cytotoxic effect, while benzimidazo[1,2-<italic toggle="yes">a</italic>]quinazoline derivatives have been reported as anticancer, antimicrobial, and antitubercular agents. Different [1,2,4]-triazolo[4,3-<italic toggle="yes">a</italic>]quinazolines have proved to exhibit anticancer, antimicrobial, antitubercular, antidepressant, anticonvulsant, antihistaminic, sedative-hypnotic, and vascular-disrupting activities. Some [1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives demonstrated themselves as antimicrobial, antifungal, hypotensive agents or potent &#945;-glucosidase inhibitors.</p><p>We can conclude that quinazolines [4,3-<italic toggle="yes">a</italic>]-annelated by 1,2,4-triazole cycle exhibit more diverse types of biological activity than other quinazolines [<italic toggle="yes">a</italic>]-annelated by azoles.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, V.N.C.; methodology, G.N.L.; writing&#8212;original draft preparation, G.N.L.; writing&#8212;review and editing, E.V.N.; visualization, E.V.N. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors on request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">TFA</td><td align="left" valign="middle" rowspan="1" colspan="1">Trifluoroacetic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CPT</td><td align="left" valign="middle" rowspan="1" colspan="1">Camptothecin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NIS</td><td align="left" valign="middle" rowspan="1" colspan="1">N-iodosuccinimide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NBS</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">N</italic>-bromosuccinimide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NOE</td><td align="left" valign="middle" rowspan="1" colspan="1">Nuclear Overhauser effect</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMSO</td><td align="left" valign="middle" rowspan="1" colspan="1">Dimethyl sulfoxide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TBAB</td><td align="left" valign="middle" rowspan="1" colspan="1">Tetrabutylammonium bromide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PEG</td><td align="left" valign="middle" rowspan="1" colspan="1">Polyethylene glycol</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TFE</td><td align="left" valign="middle" rowspan="1" colspan="1">2,2,2-Trifluoroethanol</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LAG</td><td align="left" valign="middle" rowspan="1" colspan="1">Liquid-assisted grinding</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HTS</td><td align="left" valign="middle" rowspan="1" colspan="1">High-throughput screening </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMF</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-Dimethylformamide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GABA</td><td align="left" valign="middle" rowspan="1" colspan="1">Gamma-aminobutyric acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HCA</td><td align="left" valign="middle" rowspan="1" colspan="1">Hierarchical Cluster Analysis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ERK</td><td align="left" valign="middle" rowspan="1" colspan="1">Extracellular signal-regulated kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GBBR</td><td align="left" valign="middle" rowspan="1" colspan="1">Groebke&#8211;Blackburn&#8211;Bienaym&#233; reaction</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MES</td><td align="left" valign="middle" rowspan="1" colspan="1">Maximal electroshock</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATP</td><td align="left" valign="middle" rowspan="1" colspan="1">Adenosine triphosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SAR</td><td align="left" valign="middle" rowspan="1" colspan="1">Structure&#8211;activity relationship</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DFT</td><td align="left" valign="middle" rowspan="1" colspan="1">Density Functional Theory</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FMO</td><td align="left" valign="middle" rowspan="1" colspan="1">Frontier molecular orbital</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TfOH</td><td align="left" valign="middle" rowspan="1" colspan="1">Trifluoromethanesulfonic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PTSA, TsOH</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Toluenesulfonic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DCM</td><td align="left" valign="middle" rowspan="1" colspan="1">Dichloromethane</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DCE</td><td align="left" valign="middle" rowspan="1" colspan="1">1,2-Dichloroethane</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NMR</td><td align="left" valign="middle" rowspan="1" colspan="1">Nuclear magnetic resonance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MsOH</td><td align="left" valign="middle" rowspan="1" colspan="1">Methanesulfonic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMF-DtBA</td><td align="left" valign="middle" rowspan="1" colspan="1">Dimethylformamide-di-<italic toggle="yes">tert</italic>-butylacetate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PIFA</td><td align="left" valign="middle" rowspan="1" colspan="1">(Bis(trifluoroacetoxy)iodo)benzene</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DABCO</td><td align="left" valign="middle" rowspan="1" colspan="1">1,4-diazabicyclo[2.2.2]octane</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BOP</td><td align="left" valign="middle" rowspan="1" colspan="1">Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DPPH</td><td align="left" valign="middle" rowspan="1" colspan="1">1,1-diphenyl-2-picryl-hydrazyl</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MOF</td><td align="left" valign="middle" rowspan="1" colspan="1">Metal&#8211;organic frameworks</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NCI</td><td align="left" valign="middle" rowspan="1" colspan="1">National Cancer Institute</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HDAC</td><td align="left" valign="middle" rowspan="1" colspan="1">Histone deacetylase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VEGFR</td><td align="left" valign="middle" rowspan="1" colspan="1">Vascular endothelial growth factor receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HREI-MS</td><td align="left" valign="middle" rowspan="1" colspan="1">High-resolution electron ionization mass spectrometry</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor Necrosis Factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Thin-layer chromatography</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-molecules-30-03506"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shagufta</surname><given-names>I.A.</given-names></name></person-group><article-title>An insight into the therapeutic potential of quinazoline derivatives as anticancer agents</article-title><source>Med. Chem. Commun.</source><year>2017</year><volume>8</volume><fpage>871</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1039/C7MD00097A</pub-id><pub-id pub-id-type="pmid">30108803</pub-id><pub-id pub-id-type="pmcid">PMC6072504</pub-id></element-citation></ref><ref id="B2-molecules-30-03506"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halappanavar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Teli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sannakki</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Teli</surname><given-names>D.</given-names></name></person-group><article-title>Quinazoline scaffold as a target for combating microbial resistance: Synthesis and antimicrobial profiling of quinazoline derivatives</article-title><source>Results Chem.</source><year>2025</year><volume>13</volume><fpage>101955</fpage><pub-id pub-id-type="doi">10.1016/j.rechem.2024.101955</pub-id></element-citation></ref><ref id="B3-molecules-30-03506"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alagarsamy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chitra</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saravanan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Sulthana</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Narendhar</surname><given-names>B.</given-names></name></person-group><article-title>An overview of quinazolines: Pharmacological significance and recent developments</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>151</volume><fpage>628</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.03.076</pub-id><pub-id pub-id-type="pmid">29656203</pub-id></element-citation></ref><ref id="B4-molecules-30-03506"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Morris-Natschke</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.S.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.Z.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.H.</given-names></name></person-group><article-title>Biologically active quinoline and quinazoline alkaloids Part II</article-title><source>Med. Res. Rev.</source><year>2018</year><volume>38</volume><fpage>1614</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.1002/med.21492</pub-id><pub-id pub-id-type="pmid">29485730</pub-id><pub-id pub-id-type="pmcid">PMC6105521</pub-id></element-citation></ref><ref id="B5-molecules-30-03506"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lakshmi</surname><given-names>T.V.</given-names></name><name name-style="western"><surname>Nandur</surname><given-names>S.</given-names></name></person-group><article-title>4(3<italic toggle="yes">H)-</italic>Quinazolinone derivatives: Promising antibacterial drug leads</article-title><source>Eur. J. Med. Chem.</source><year>2019</year><volume>170</volume><fpage>157</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.03.018</pub-id><pub-id pub-id-type="pmid">30884322</pub-id></element-citation></ref><ref id="B6-molecules-30-03506"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakheit</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Abuelizz</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name></person-group><article-title>Crystallographic analysis, Hirshfeld surface investigation, and DFT calculations of 2-phenoxy-triazoloquinazoline molecule: Implications for drug design</article-title><source>J. Mol. Struct.</source><year>2025</year><volume>1319</volume><fpage>139436</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2024.139436</pub-id></element-citation></ref><ref id="B7-molecules-30-03506"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakheit</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Abuelizz</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name></person-group><article-title>A DFT study and Hirshfeld surface analysis of the molecular structures, radical scavenging abilities and ADMET properties of 2-methylthio(methylsulfonyl)-[1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolines: Guidance for antioxidant drug design</article-title><source>Crystals</source><year>2023</year><volume>13</volume><elocation-id>1086</elocation-id><pub-id pub-id-type="doi">10.3390/cryst13071086</pub-id></element-citation></ref><ref id="B8-molecules-30-03506"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Auti</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>George</surname><given-names>G.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>A.T.</given-names></name></person-group><article-title>Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids</article-title><source>RSC Advances</source><year>2020</year><volume>10</volume><fpage>41353</fpage><lpage>41392</lpage><pub-id pub-id-type="doi">10.1039/D0RA06642G</pub-id><pub-id pub-id-type="pmid">35516563</pub-id><pub-id pub-id-type="pmcid">PMC9057921</pub-id></element-citation></ref><ref id="B9-molecules-30-03506"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kushwaha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rashi</surname></name></person-group><article-title>One pot synthesis and mechanistic insights of quinazoline and related molecules</article-title><source>Tetrahedron</source><year>2025</year><volume>179</volume><fpage>134635</fpage><pub-id pub-id-type="doi">10.1016/j.tet.2025.134635</pub-id></element-citation></ref><ref id="B10-molecules-30-03506"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nosova</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Lipunova</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Permyakova</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Charushin</surname><given-names>V.N.</given-names></name></person-group><article-title>Quinazolines annelated at the N(3)&#8211;C(4) bond: Synthesis and biological activity</article-title><source>Eur. J. Med. Chem.</source><year>2024</year><volume>271</volume><fpage>116411</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2024.116411</pub-id><pub-id pub-id-type="pmid">38669910</pub-id></element-citation></ref><ref id="B11-molecules-30-03506"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abuelizz</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name></person-group><article-title>An overview of triazoloquinazolines: Pharmacological significance and recent developments</article-title><source>Bioorg. Chem.</source><year>2021</year><volume>115</volume><elocation-id>105263</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioorg.2021.105263</pub-id><pub-id pub-id-type="pmid">34426148</pub-id></element-citation></ref><ref id="B12-molecules-30-03506"><label>12.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jabeen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aslam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M.</given-names></name><name name-style="western"><surname>ul Haq</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Hussain</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>M.E.A.</given-names></name></person-group><article-title>Triazoloquinazoline: Synthetic strategies and medicinal importance</article-title><source>Recent Advances on Quinazoline</source><publisher-name>IntechOpen</publisher-name><publisher-loc>London, UK</publisher-loc><year>2023</year><fpage>1</fpage><lpage>27</lpage></element-citation></ref><ref id="B13-molecules-30-03506"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Rafiq</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aslam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saif</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Al-Hussain</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>M.E.A.</given-names></name></person-group><article-title>Recent approaches for the synthesis of imidazoquinazolines and benzimidazoquinazolines</article-title><source>Recent Advances on Quinazoline</source><publisher-name>IntechOpen</publisher-name><publisher-loc>London, UK</publisher-loc><year>2023</year><fpage>1</fpage><lpage>19</lpage></element-citation></ref><ref id="B14-molecules-30-03506"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Alex</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name></person-group><article-title>Pyrazoloquinazolines: Synthetic strategies and bioactivities</article-title><source>Eur. J. Med. Chem.</source><year>2015</year><volume>97</volume><fpage>444</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2014.11.051</pub-id><pub-id pub-id-type="pmid">25438709</pub-id></element-citation></ref><ref id="B15-molecules-30-03506"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name></person-group><article-title>Progress in synthesis and bioactivity evaluation of pyrazoloquinazolines</article-title><source>Lett. Drug Des. Discov.</source><year>2020</year><volume>17</volume><fpage>104</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.2174/1570180815666181017120100</pub-id></element-citation></ref><ref id="B16-molecules-30-03506"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaskevych</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Dekhtyar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vovk</surname><given-names>M.</given-names></name></person-group><article-title>Cyclizations of alkenyl(alkynyl)-functionalized quinazolinones and their heteroanalogues: A powerful strategy for the construction of polyheterocyclic structures</article-title><source>Chem. Rec.</source><year>2024</year><volume>24</volume><fpage>e202300255</fpage><pub-id pub-id-type="doi">10.1002/tcr.202300255</pub-id><pub-id pub-id-type="pmid">37830463</pub-id></element-citation></ref><ref id="B17-molecules-30-03506"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumitrascu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Georgescu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Georgescu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cairad</surname><given-names>M.R.</given-names></name></person-group><article-title>Chapter Three&#8212;Pyrroloquinolines, Imidazoquinolines, and Pyrroloquinazolines with a Bridgehead Nitrogen</article-title><source>Adv. Heterocycl. Chem.</source><year>2019</year><volume>129</volume><fpage>155</fpage><lpage>244</lpage></element-citation></ref><ref id="B18-molecules-30-03506"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasapalli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sammeta</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>Z.F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Boerth</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Golen</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Savinov</surname><given-names>S.N.</given-names></name></person-group><article-title>Synthesis of C-ring-substituted vasicinones and luotonins via regioselective aza-Nazarov cyclization of quinazolinonyl enones</article-title><source>Org. Lett.</source><year>2019</year><volume>21</volume><fpage>9824</fpage><lpage>9828</lpage><pub-id pub-id-type="doi">10.1021/acs.orglett.9b03586</pub-id><pub-id pub-id-type="pmid">31800251</pub-id></element-citation></ref><ref id="B19-molecules-30-03506"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasapalli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sammeta</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>Z.F.</given-names></name><name name-style="western"><surname>Golen</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Agama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pommier</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Savinov</surname><given-names>S.N.</given-names></name></person-group><article-title>Design and synthesis of C-aryl angular luotonins via a one-pot aza-Nazarov&#8211;Friedlander sequence and their topo-I inhibition studies along with C-aryl vasicinones and luotonins</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2021</year><volume>41</volume><elocation-id>127998</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmcl.2021.127998</pub-id><pub-id pub-id-type="pmid">33794318</pub-id><pub-id pub-id-type="pmcid">PMC8113096</pub-id></element-citation></ref><ref id="B20-molecules-30-03506"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaskevych</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Savinchuk</surname><given-names>N.O.</given-names></name><name name-style="western"><surname>Vaskevych</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Rusanov</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Grygorenko</surname><given-names>O.O.</given-names></name><name name-style="western"><surname>Vovk</surname><given-names>M.V.</given-names></name></person-group><article-title>PIFA-Initiated oxidative cyclization of 2-(3-butenyl)quinazolin-4(3<italic toggle="yes">H</italic>)-ones&#8212;An efficient approach to 1-(Hydroxymethyl)-2,3-dihydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(1<italic toggle="yes">H</italic>)-ones</article-title><source>Beilstein J. Org. Chem.</source><year>2021</year><volume>17</volume><fpage>2787</fpage><lpage>2794</lpage><pub-id pub-id-type="doi">10.3762/bjoc.17.189</pub-id><pub-id pub-id-type="pmid">34900009</pub-id><pub-id pub-id-type="pmcid">PMC8630437</pub-id></element-citation></ref><ref id="B21-molecules-30-03506"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaskevych</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Savinchuk</surname><given-names>N.O.</given-names></name><name name-style="western"><surname>Vaskevych</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Rusanov</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Vovk</surname><given-names>M.V.</given-names></name></person-group><article-title>Chalcogenation/Pyrrolo(Pyrido)Annulation of 2-(3-butenyl)quinazolin-4(3<italic toggle="yes">H</italic>)-ones by Arylsulfenyl(Selenyl) Chlorides</article-title><source>Tetrahedron</source><year>2022</year><volume>111</volume><fpage>132722</fpage><pub-id pub-id-type="doi">10.1016/j.tet.2022.132722</pub-id></element-citation></ref><ref id="B22-molecules-30-03506"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaskevych</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Savinchuk</surname><given-names>N.O.</given-names></name><name name-style="western"><surname>Vaskevych</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Rusanov</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Bylina</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Kyrylchuk</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Vovk</surname><given-names>M.V.</given-names></name></person-group><article-title>Proton- and halogen-induced cyclizations of 2-(3-butenyl) quinazolin-4(3<italic toggle="yes">H</italic>)-ones in the synthesis of pyrrolo[2,1-<italic toggle="yes">b</italic>]- and pyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolinone derivatives</article-title><source>J. Heterocycl. Chem.</source><year>2023</year><volume>60</volume><fpage>431</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1002/jhet.4598</pub-id></element-citation></ref><ref id="B23-molecules-30-03506"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>N.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>P.</given-names></name></person-group><article-title>Regioselective Bronsted Acid-Catalyzed Annulation of Cyclopropane Aldehydes with N&#8217;-Aryl Anthranil Hydrazides: Domino Construction of Tetrahydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(1<italic toggle="yes">H</italic>)-ones</article-title><source>J. Org. Chem.</source><year>2020</year><volume>85</volume><fpage>3393</fpage><lpage>3406</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.9b03170</pub-id><pub-id pub-id-type="pmid">31958951</pub-id></element-citation></ref><ref id="B24-molecules-30-03506"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grinev</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Amalchieva</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Egorova</surname><given-names>A.Y.</given-names></name></person-group><article-title>Features of Reaction of Substituted 4-Oxobutanoic Acids and 3H-Furan-2-ones with 1,3-binucleophiles</article-title><source>Russ. J. Org. Chem.</source><year>2017</year><volume>53</volume><fpage>1669</fpage><lpage>1674</lpage><pub-id pub-id-type="doi">10.1134/S1070428017110094</pub-id></element-citation></ref><ref id="B25-molecules-30-03506"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferraris</surname><given-names>D.V.</given-names></name></person-group><article-title>Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic</article-title><source>J. Med. Chem.</source><year>2010</year><volume>53</volume><fpage>4561</fpage><pub-id pub-id-type="doi">10.1021/jm100012m</pub-id><pub-id pub-id-type="pmid">20364863</pub-id></element-citation></ref><ref id="B26-molecules-30-03506"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Sreenivasulu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jafar</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Rambabu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kapavarapu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shivakumar</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A new three-component reaction: Green synthesis of novel isoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline derivatives as potent inhibitors of TNF-&#945;</article-title><source>Chem. Commun.</source><year>2011</year><volume>57</volume><fpage>5010</fpage><lpage>5012</lpage><pub-id pub-id-type="doi">10.1039/c1cc10715a</pub-id><pub-id pub-id-type="pmid">21445417</pub-id></element-citation></ref><ref id="B27-molecules-30-03506"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotipalli</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kavala</surname><given-names>V.</given-names></name><name name-style="western"><surname>Janreddy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>C.-W.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>T.-S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.-N.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>C.-F.</given-names></name></person-group><article-title>Syntheses of indolo[1,2-<italic toggle="yes">a</italic>]quinazolinone derivatives via palladium-catalyzed intramolecular C&#8211;H amidation</article-title><source>RSC Adv.</source><year>2014</year><volume>4</volume><fpage>2274</fpage><lpage>2283</lpage><pub-id pub-id-type="doi">10.1039/C3RA44798G</pub-id></element-citation></ref><ref id="B28-molecules-30-03506"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matsubara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>K.</given-names></name></person-group><article-title>Ullmann N-Arylation/2-Amidation Cascade by Self-Relay Copper Catalysis: One-pot Synthesis of Indolo[1,2-<italic toggle="yes">a</italic>]quinazolinones</article-title><source>Org. Chem. Front.</source><year>2017</year><volume>4</volume><fpage>2124</fpage><lpage>2127</lpage><pub-id pub-id-type="doi">10.1039/C7QO00549K</pub-id></element-citation></ref><ref id="B29-molecules-30-03506"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badigenchala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sekar</surname><given-names>G.</given-names></name></person-group><article-title>NIS-mediated cross-coupling of C(sp<sup>2</sup>)&#8211;H and N&#8211;H bonds: A transition metal-free approach towards indolo[1,2-<italic toggle="yes">a</italic>]quinazolinones</article-title><source>J. Org. Chem.</source><year>2017</year><volume>82</volume><fpage>7657</fpage><lpage>7665</lpage><pub-id pub-id-type="doi">10.1021/acs.joc.7b01080</pub-id><pub-id pub-id-type="pmid">28682077</pub-id></element-citation></ref><ref id="B30-molecules-30-03506"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name></person-group><article-title>Efficient Pd-catalyzed domino synthesis of 1-phenyl-1<italic toggle="yes">H</italic>-indol-2-amine and 5-amino-indolo[1,2-<italic toggle="yes">a</italic>]quinazoline derivatives</article-title><source>Org. Biomol. Chem.</source><year>2015</year><volume>13</volume><elocation-id>10122</elocation-id><pub-id pub-id-type="doi">10.1039/C5OB01642H</pub-id><pub-id pub-id-type="pmid">26377704</pub-id></element-citation></ref><ref id="B31-molecules-30-03506"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sashidhara</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Palnati</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Dodda</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Avula</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Swami</surname><given-names>P.</given-names></name></person-group><article-title>Studies on novel synthetic methodologies, part XII: An efficient one-pot access to 6,6a-dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-diones and 5-phenylisoindolo[2,1-<italic toggle="yes">a</italic>]quinazolin-11(6a<italic toggle="yes">H</italic>)-ones</article-title><source>Synlett</source><year>2013</year><volume>24</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1055/s-0032-1317761</pub-id></element-citation></ref><ref id="B32-molecules-30-03506"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Chary</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>M.</given-names></name></person-group><article-title>&#946;-Cyclodextrin-mediated MCR in water: Synthesis of dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-dione derivatives under microwave irradiation</article-title><source>Tetrahedron Lett.</source><year>2013</year><volume>54</volume><fpage>6744</fpage><lpage>6746</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2013.09.138</pub-id></element-citation></ref><ref id="B33-molecules-30-03506"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esmaeili-Marandi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Saeedi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yavari</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shafiee</surname><given-names>A.</given-names></name></person-group><article-title>Synthesis of novel isoinodolo[2,1-<italic toggle="yes">a</italic>]quinazolinedione derivatives containing a 1,2,3-triazole ring system</article-title><source>Helv. Chim. Acta</source><year>2016</year><volume>99</volume><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/hlca.201500122</pub-id></element-citation></ref><ref id="B34-molecules-30-03506"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lotfi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Saeedi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kianmehr</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shafiee</surname><given-names>A.</given-names></name></person-group><article-title>Synthesis of novel fused quinazolinone derivatives</article-title><source>Mol. Divers.</source><year>2016</year><volume>20</volume><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1007/s11030-016-9675-x</pub-id><pub-id pub-id-type="pmid">27209476</pub-id></element-citation></ref><ref id="B35-molecules-30-03506"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madhubabu</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Shankar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M.V.B.</given-names></name><name name-style="western"><surname>Akula</surname><given-names>R.</given-names></name></person-group><article-title>Metal-catalyst-free green and efficient synthesis of five and six-membered fused N-heterocyclic quinazoline derivatives</article-title><source>Tetrahedron Lett.</source><year>2016</year><volume>57</volume><fpage>5033</fpage><lpage>5037</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2016.09.094</pub-id></element-citation></ref><ref id="B36-molecules-30-03506"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbasian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kabirifard</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mahdavi</surname><given-names>M.</given-names></name></person-group><article-title>The synthesis of 2,3-dihydroquinazoline-4(1<italic toggle="yes">H</italic>)-one and dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-dione derivatives in the presence of imidazolium ionic liquid sulfonic acid functionalized SBA-15: A novel feature of SBA-15</article-title><source>Arkivoc</source><year>2018</year><volume>3</volume><fpage>302</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.24820/ark.5550190.p010.448</pub-id></element-citation></ref><ref id="B37-molecules-30-03506"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rayatzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haghipour</surname><given-names>S.</given-names></name></person-group><article-title>Efficient synthesis of 6,6a-dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-dione derivatives catalyzed by functionalized nanoporous silica</article-title><source>Monatshefte Chem.</source><year>2021</year><volume>152</volume><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1007/s00706-020-02720-4</pub-id></element-citation></ref><ref id="B38-molecules-30-03506"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devi</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Garande</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bhate</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Sirisha</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ganapathi</surname><given-names>T.</given-names></name></person-group><article-title>Synthesis of isoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline, isoindolo[2,1-<italic toggle="yes">a</italic>]pyrrolo[2,1-<italic toggle="yes">c</italic>]quinoxalinone, and indolo[1,2-<italic toggle="yes">a</italic>]isoindolo[1,2-<italic toggle="yes">c</italic>]quinoxalinone derivatives in a deep eutectic solvent</article-title><source>Synlett</source><year>2016</year><volume>27</volume><fpage>2807</fpage><lpage>2810</lpage></element-citation></ref><ref id="B39-molecules-30-03506"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khachatryan</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Belus</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Misyurin</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Baryshnikova</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Kolotaev</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Matevosyan</surname><given-names>K.R.</given-names></name></person-group><article-title>Synthesis and properties of 1,2-dihydro-4(3<italic toggle="yes">H</italic>)-quinazolinones</article-title><source>Russ. Chem. Bull.</source><year>2017</year><volume>66</volume><fpage>1044</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1007/s11172-017-1852-2</pub-id></element-citation></ref><ref id="B40-molecules-30-03506"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lohar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mane</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kamat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumbhar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salunkhe</surname><given-names>R.</given-names></name></person-group><article-title>Trifluoroethanol and liquid-assisted grinding method: A green catalytic access for multicomponent synthesis</article-title><source>Res. Chem. Intermed.</source><year>2017</year><volume>44</volume><fpage>1919</fpage><lpage>1933</lpage><pub-id pub-id-type="doi">10.1007/s11164-017-3206-y</pub-id></element-citation></ref><ref id="B41-molecules-30-03506"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>R.-Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.-T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.-S.</given-names></name></person-group><article-title>Iodine-catalyzed synthesis of H-phthalazino[1,2-<italic toggle="yes">b</italic>]quinazoline and isoindolo[2,1-a]quinazoline derivatives via chemoselective reaction of 2-aminobenzohydrazide and 2-formylbenzoic acid in ionic liquids</article-title><source>Tetrahedron Lett.</source><year>2016</year><volume>57</volume><fpage>2515</fpage><lpage>2519</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2016.04.101</pub-id></element-citation></ref><ref id="B42-molecules-30-03506"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodhak</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hazra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pramanik</surname><given-names>A.</given-names></name></person-group><article-title>Graphene oxide: An efficient carbocatalyst for the facile synthesis of isoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-diones via domino condensation under solvent-free conditions</article-title><source>ChemistrySelect</source><year>2018</year><volume>3</volume><fpage>7707</fpage><lpage>7712</lpage><pub-id pub-id-type="doi">10.1002/slct.201801322</pub-id></element-citation></ref><ref id="B43-molecules-30-03506"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name></person-group><article-title>One-pot three-component selective synthesis of isoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline derivatives via a palladium-catalyzed cascade cyclocondensation/cyclocarbonylation sequence</article-title><source>Org. Biomol. Chem.</source><year>2017</year><volume>15</volume><fpage>3674</fpage><lpage>3680</lpage><pub-id pub-id-type="doi">10.1039/C7OB00256D</pub-id><pub-id pub-id-type="pmid">28398450</pub-id></element-citation></ref><ref id="B44-molecules-30-03506"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolotaev</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Matevosyan</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Osipov</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Khachatryan</surname><given-names>D.S.</given-names></name></person-group><article-title>Synthesis of new quinazoline-containing hydroxamic acids as potential HDAC/VEGFR inhibitors. Unusual rearrangements with pyrrolidone ring opening and dehydration of 3-N-hydroxyquinazoline fragment containing tetracycles</article-title><source>Tetrahedron Lett.</source><year>2019</year><volume>60</volume><fpage>151315</fpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2019.151315</pub-id></element-citation></ref><ref id="B45-molecules-30-03506"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mondal</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.A.</given-names></name></person-group><article-title>Mechanistic insight into the acid-catalyzed, one-pot synthesis of isoindole-fused quinazolin-4-ones</article-title><source>J. Chem. Sci.</source><year>2020</year><volume>132</volume><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1007/s12039-020-01768-3</pub-id></element-citation></ref><ref id="B46-molecules-30-03506"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orvieto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Branca</surname><given-names>D.</given-names></name><name name-style="western"><surname>Giomini</surname><given-names>C.</given-names></name></person-group><article-title>Identification of substituted pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-one as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors</article-title><source>Bioorg. Med. Chem.</source><year>2009</year><volume>19</volume><fpage>4196</fpage><lpage>4200</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2009.05.113</pub-id><pub-id pub-id-type="pmid">19541484</pub-id></element-citation></ref><ref id="B47-molecules-30-03506"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kasatochkin</surname><given-names>A.</given-names></name></person-group><article-title>Synthesis of 6,7,8,9-tetrahydropyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines containing a 5-phenylamine fragment</article-title><source>Russ. J. Org. Chem.</source><year>2013</year><volume>49</volume><fpage>1250</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1134/S1070428013080307</pub-id></element-citation></ref><ref id="B48-molecules-30-03506"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferraguti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shigemoto</surname><given-names>R.</given-names></name></person-group><article-title>Metabotropic Glutamate Receptors</article-title><source>Cell. Tissue Res.</source><year>2006</year><volume>326</volume><fpage>483</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1007/s00441-006-0266-5</pub-id><pub-id pub-id-type="pmid">16847639</pub-id></element-citation></ref><ref id="B49-molecules-30-03506"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taliani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pugliesi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Barresi</surname><given-names>E.</given-names></name></person-group><article-title>Phenylpyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-one: A suitable scaffold for the development of noncamptothecin topoisomerase I (Top1) inhibitors</article-title><source>J. Med. Chem.</source><year>2013</year><volume>56</volume><fpage>7458</fpage><lpage>7462</lpage><pub-id pub-id-type="doi">10.1021/jm400932c</pub-id><pub-id pub-id-type="pmid">23987476</pub-id><pub-id pub-id-type="pmcid">PMC3982121</pub-id></element-citation></ref><ref id="B50-molecules-30-03506"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roopan</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Palaniraja</surname><given-names>J.</given-names></name></person-group><article-title>Synthesis of indazoloquinazoline system (microreview)</article-title><source>Chem. Heterocycl. Comp.</source><year>2016</year><volume>52</volume><fpage>93</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1007/s10593-016-1838-2</pub-id></element-citation></ref><ref id="B51-molecules-30-03506"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name></person-group><article-title>Water-mediated selective synthesis of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones and [1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-one via copper-catalyzed cascade reactions</article-title><source>Synth. Commun.</source><year>2015</year><volume>45</volume><fpage>2426</fpage><lpage>2435</lpage><pub-id pub-id-type="doi">10.1080/00397911.2015.1083032</pub-id></element-citation></ref><ref id="B52-molecules-30-03506"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gnanasekaran</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Muddala</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Bunce</surname><given-names>R.A.</given-names></name></person-group><article-title>Pyrazoloquinazolinones and pyrazolopyridopyrimidinones by a sequential N-acylation&#8211;S<sub>N</sub>Ar reaction</article-title><source>Tetrahedron Lett.</source><year>2015</year><volume>56</volume><fpage>1367</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2015.01.146</pub-id></element-citation></ref><ref id="B53-molecules-30-03506"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Annareddygari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kasireddy</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>J.</given-names></name></person-group><article-title>Transition-metal-free N-arylation: A general approach to aza-fused poly-heteroaromatics</article-title><source>J. Heterocycl. Chem.</source><year>2019</year><volume>56</volume><fpage>3267</fpage><lpage>3276</lpage><pub-id pub-id-type="doi">10.1002/jhet.3722</pub-id></element-citation></ref><ref id="B54-molecules-30-03506"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Regioselective synthesis of indazolo[2,3-<italic toggle="yes">a</italic>]quinazolines enabled by I<sub>2</sub>/S-facilitated annulation relay dehydrogenative aromatization of cyclohexanones</article-title><source>Chem. Commun.</source><year>2023</year><volume>59</volume><fpage>13835</fpage><lpage>13838</lpage><pub-id pub-id-type="doi">10.1039/D3CC04698B</pub-id><pub-id pub-id-type="pmid">37921123</pub-id></element-citation></ref><ref id="B55-molecules-30-03506"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.-Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.-A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.-L.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Discovery of pyrazolo[1,5-<italic toggle="yes">a</italic>]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2017</year><volume>27</volume><fpage>3201</fpage><lpage>3204</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2017.05.002</pub-id><pub-id pub-id-type="pmid">28539219</pub-id></element-citation></ref><ref id="B56-molecules-30-03506"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kov&#225;cs</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moln&#225;r-T&#243;th</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blask&#243;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fejes</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nyerges</surname><given-names>M.</given-names></name></person-group><article-title>Synthesis of new pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives</article-title><source>Synth. Commun.</source><year>2015</year><volume>45</volume><fpage>1675</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1080/00397911.2015.1040511</pub-id></element-citation></ref><ref id="B57-molecules-30-03506"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerrini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ciciani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ciattini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Crocetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Daniele</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Melani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vergelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>M.P.</given-names></name></person-group><article-title>Pyrazolo[1,5-a]quinazoline scaffold as 5-deaza analogue of pyrazolo[5,1-<italic toggle="yes">c</italic>][1,2,4]benzotriazine system: Synthesis of new derivatives, biological activity on GABA<sub>A</sub> receptor subtype and molecular dynamic study</article-title><source>J. Enzym. Inhib. Med. Chem.</source><year>2016</year><volume>31</volume><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.3109/14756366.2015.1014475</pub-id><pub-id pub-id-type="pmid">25792503</pub-id></element-citation></ref><ref id="B58-molecules-30-03506"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerrini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ciciani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Crocetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Daniele</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghelardini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Iacovone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mannelli</surname><given-names>L.D.C.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vergelli</surname><given-names>C.</given-names></name></person-group><article-title>Identification of a new pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline ligand highly affine to &#947;-aminobutyric type A (GABAA) receptor subtype with anxiolytic-like and antihyperalgesic activity</article-title><source>J. Med. Chem.</source><year>2017</year><volume>60</volume><fpage>9691</fpage><lpage>9702</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01151</pub-id><pub-id pub-id-type="pmid">29125291</pub-id></element-citation></ref><ref id="B59-molecules-30-03506"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Kadh</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Abou-Amra</surname><given-names>E.S.</given-names></name></person-group><article-title>New fused pyrazolopyrimidine derivatives; heterocyclic styling, synthesis, molecular docking and anticancer evaluation</article-title><source>J. Heterocycl. Chem.</source><year>2020</year><volume>57</volume><fpage>2704</fpage><lpage>2721</lpage><pub-id pub-id-type="doi">10.1002/jhet.3979</pub-id></element-citation></ref><ref id="B60-molecules-30-03506"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerrini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vergelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cantini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Daniele</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mascia</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>C.</given-names></name></person-group><article-title>Synthesis of new GABAA receptor modulator with pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline (PQ) scaffold</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><fpage>1438</fpage><pub-id pub-id-type="doi">10.3390/ijms20061438</pub-id><pub-id pub-id-type="pmid">30901916</pub-id><pub-id pub-id-type="pmcid">PMC6470557</pub-id></element-citation></ref><ref id="B61-molecules-30-03506"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerrini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Crocetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Daniele</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lacovone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cantini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Melani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vergelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>M.P.</given-names></name></person-group><article-title>New 3,6-disubstituted pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines as ligands to GABA<sub>A</sub> receptor subtype</article-title><source>J. Heterocycl. Chem.</source><year>2019</year><volume>56</volume><fpage>1571</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1002/jhet.3535</pub-id></element-citation></ref><ref id="B62-molecules-30-03506"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chimichi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cosimelli</surname><given-names>B.</given-names></name><name name-style="western"><surname>Costanzo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guerrini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Selleri</surname><given-names>S.</given-names></name></person-group><article-title>A new entry to pyrazolo[1,5-<italic toggle="yes">a</italic>]pyrido[3,4-<italic toggle="yes">e</italic>]pyrimidine derivatives</article-title><source>Heterocycles</source><year>1990</year><volume>31</volume><fpage>1141</fpage><pub-id pub-id-type="doi">10.3987/COM-90-5471</pub-id></element-citation></ref><ref id="B63-molecules-30-03506"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crocetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guerrini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cantini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vergelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Melani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mascia</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>M.P.</given-names></name></person-group><article-title>&#8216;Proximity frequencies&#8217;: A new parameter to evaluate the profile of GABA<sub>A</sub>R modulators</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2021</year><volume>34</volume><elocation-id>127755</elocation-id><pub-id pub-id-type="doi">10.1016/j.bmcl.2020.127755</pub-id><pub-id pub-id-type="pmid">33359444</pub-id></element-citation></ref><ref id="B64-molecules-30-03506"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crocetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guerrini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Melani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vergelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mascia</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>M.P.</given-names></name></person-group><article-title>GABA<sub>A</sub> receptor modulators with a pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline core: Synthesis, molecular modelling studies and electrophysiological assays</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>13032</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232113032</pub-id><pub-id pub-id-type="pmid">36361842</pub-id><pub-id pub-id-type="pmcid">PMC9658275</pub-id></element-citation></ref><ref id="B65-molecules-30-03506"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crocetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guerrini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Melani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mascia</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>M.P.</given-names></name></person-group><article-title>3,8-Disubstituted pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline as GABA<sub>A</sub> receptor modulators: Synthesis, electrophysiological assays, and molecular modelling studies</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>10840</elocation-id><pub-id pub-id-type="doi">10.3390/ijms251910840</pub-id><pub-id pub-id-type="pmid">39409169</pub-id><pub-id pub-id-type="pmcid">PMC11477267</pub-id></element-citation></ref><ref id="B66-molecules-30-03506"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>Design, synthesis, and biological screening of a series of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives as SIRT6 activators</article-title><source>Eur. J. Pharm. Sci.</source><year>2023</year><volume>185</volume><fpage>106424</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2023.106424</pub-id><pub-id pub-id-type="pmid">36918058</pub-id></element-citation></ref><ref id="B67-molecules-30-03506"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name></person-group><article-title>Discovery of potent small-molecule sirt6 activators: Structure-activity relationship and anti-pancreatic ductal adenocarcinoma activity</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><fpage>10474</fpage><lpage>10495</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01183</pub-id><pub-id pub-id-type="pmid">32787077</pub-id></element-citation></ref><ref id="B68-molecules-30-03506"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crocetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Khlebnikov</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Guerrini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schepetkin</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Melani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>M.T.</given-names></name></person-group><article-title>Anti-inflammatory activity of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines</article-title><source>Molecules</source><year>2024</year><volume>29</volume><elocation-id>2421</elocation-id><pub-id pub-id-type="doi">10.3390/molecules29112421</pub-id><pub-id pub-id-type="pmid">38893295</pub-id><pub-id pub-id-type="pmcid">PMC11173647</pub-id></element-citation></ref><ref id="B69-molecules-30-03506"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Swaroop</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Punna</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sirisha</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ganapathi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Narsaiah</surname><given-names>B.</given-names></name></person-group><article-title>Synthesis of Novel Pyrido[2&#8242;,3&#8242;:3,4]Pyrazolo[1,5-<italic toggle="yes">a</italic>]Quinazoline Derivatives, Their Biological Evaluation and Molecular Modelling Studies</article-title><source>ChemistrySelect</source><year>2018</year><volume>3</volume><fpage>7813</fpage><lpage>7821</lpage><pub-id pub-id-type="doi">10.1002/slct.201801186</pub-id></element-citation></ref><ref id="B70-molecules-30-03506"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>Substrate controlled [5+1] annulation of 5-amino-1<italic toggle="yes">H</italic>-phenylpyrazoles with alkenes: Divergent synthesis of multi-substituted 4,5-dihydropyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines</article-title><source>Eur. J. Org. Chem.</source><year>2020</year><fpage>3997</fpage><lpage>4003</lpage><pub-id pub-id-type="doi">10.1002/ejoc.202000536</pub-id></element-citation></ref><ref id="B71-molecules-30-03506"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>Design, Synthesis, and Insecticidal Activities of Novel 5-Substituted 4,5-Dihydropyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline Derivatives</article-title><source>Pest. Man. Sci.</source><year>2021</year><volume>77</volume><fpage>1013</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1002/ps.6113</pub-id><pub-id pub-id-type="pmid">33002298</pub-id></element-citation></ref><ref id="B72-molecules-30-03506"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>Structural optimization based on 4,5-dihydropyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline scaffold for improved insecticidal activities</article-title><source>Pest. Biochem. Physiol.</source><year>2023</year><volume>195</volume><elocation-id>105533</elocation-id><pub-id pub-id-type="doi">10.1016/j.pestbp.2023.105533</pub-id><pub-id pub-id-type="pmid">37666607</pub-id></element-citation></ref><ref id="B73-molecules-30-03506"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.-J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.-F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.-P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>An</surname><given-names>J.-X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.-J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.-Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.-Q.</given-names></name></person-group><article-title>Design, synthesis, and biological evaluation of novel berberine derivatives against phytopathogenic fungi</article-title><source>Pest. Manag. Sci.</source><year>2022</year><volume>78</volume><fpage>4361</fpage><lpage>4376</lpage><pub-id pub-id-type="doi">10.1002/ps.7055</pub-id><pub-id pub-id-type="pmid">35758905</pub-id></element-citation></ref><ref id="B74-molecules-30-03506"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Dao</surname><given-names>P.D.Q.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.S.</given-names></name></person-group><article-title>Microwave-Assisted Synthesis of Benzo[4,5]imidazo[1,2-<italic toggle="yes">a</italic>]pyrimidines from &#946;-Bromo-&#945;,&#946;-unsaturated Aldehydes and 2-Aminobenzimidazoles</article-title><source>Synlett</source><year>2017</year><volume>28</volume><fpage>1811</fpage><lpage>1815</lpage><pub-id pub-id-type="doi">10.1055/s-0036-1588834</pub-id></element-citation></ref><ref id="B75-molecules-30-03506"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Dao</surname><given-names>P.D.Q.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.S.</given-names></name></person-group><article-title>Synthesis of Pyrimidine- and Quinazoline-Fused Benzimidazole-4,7-diones Using Combinatorial Cyclocondensation and Oxidation</article-title><source>ACS Omega</source><year>2018</year><volume>3</volume><fpage>17456</fpage><lpage>17465</lpage><pub-id pub-id-type="doi">10.1021/acsomega.8b02755</pub-id><pub-id pub-id-type="pmid">31458351</pub-id><pub-id pub-id-type="pmcid">PMC6643376</pub-id></element-citation></ref><ref id="B76-molecules-30-03506"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dao</surname><given-names>P.D.Q.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>H.-S.</given-names></name></person-group><article-title>Microwave-assisted Copper Powder-Catalyzed Synthesis of Azole-Fused Pyrimidinones</article-title><source>Curr. Org. Chem.</source><year>2018</year><volume>22</volume><fpage>85</fpage><lpage>93</lpage></element-citation></ref><ref id="B77-molecules-30-03506"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>B.</given-names></name></person-group><article-title>Heterogeneous Amorphous Cu&#8211;MOF-74 Catalyst for C&#8211;N Coupling Reaction</article-title><source>ChemistrySelect</source><year>2018</year><volume>3</volume><fpage>10694</fpage><lpage>10700</lpage><pub-id pub-id-type="doi">10.1002/slct.201802837</pub-id></element-citation></ref><ref id="B78-molecules-30-03506"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumpulainen</surname><given-names>E.T.T.</given-names></name><name name-style="western"><surname>Hognasbacka</surname><given-names>A.</given-names></name></person-group><article-title>Modular Approach to Tricyclic Heterocycles through Copper Catalysis and Functionalization by Palladium-Catalyzed C&#8211;H Arylation</article-title><source>Eur. J. Org. Chem.</source><year>2017</year><volume>2017</volume><fpage>2610</fpage><lpage>2614</lpage><pub-id pub-id-type="doi">10.1002/ejoc.201700356</pub-id></element-citation></ref><ref id="B79-molecules-30-03506"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Bahadur</surname><given-names>V.</given-names></name><name name-style="western"><surname>Len</surname><given-names>C.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>N.G.J.</given-names></name><name name-style="western"><surname>Parmar</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Van der Eycken</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>B.K.</given-names></name></person-group><article-title>Microwave Assisted Metal Free, Base mediated C&#8211;N Bond Formation/Cleavage: Synthesis of Benzimidazo[1,2-<italic toggle="yes">a</italic>]quinazoline Derivatives</article-title><source>ACS Sust. Chem. Eng.</source><year>2016</year><volume>4</volume><fpage>2206</fpage><lpage>2210</lpage><pub-id pub-id-type="doi">10.1021/acssuschemeng.5b01669</pub-id></element-citation></ref><ref id="B80-molecules-30-03506"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>H.</given-names></name></person-group><article-title>Synthesis and characterization of a new compound 4-(2-chlorobenzyl)imidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(<italic toggle="yes">4H</italic>)-one: DFT study, crystal structure, MEP, and HOMO&#8211;LUMO values</article-title><source>J. Struct. Chem.</source><year>2021</year><volume>62</volume><fpage>1285</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1134/S0022476621080163</pub-id></element-citation></ref><ref id="B81-molecules-30-03506"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Design, synthesis and biological evaluation of novel triazoloquinazolinone and imidazoquinazolinone derivatives as allosteric inhibitors of SHP2 phosphatase</article-title><source>J. Enzyme Inhibit. Med. Chem.</source><year>2022</year><volume>37</volume><fpage>1495</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1080/14756366.2022.2078968</pub-id><pub-id pub-id-type="pmid">35635145</pub-id><pub-id pub-id-type="pmcid">PMC9176666</pub-id></element-citation></ref><ref id="B82-molecules-30-03506"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghashghaei</surname><given-names>O.</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sintes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rev&#233;s</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kielland</surname><given-names>N.</given-names></name><name name-style="western"><surname>Estarellas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Luque</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Avi&#324;&#559;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eritja</surname><given-names>R.</given-names></name><name name-style="western"><surname>Serna-Gallego</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Multiple Multicomponent Reactions: Unexplored Substrates, Selective Processes, and Versatile Chemotypes in Biomedicine</article-title><source>Chem. Eur. J.</source><year>2018</year><volume>24</volume><fpage>14513</fpage><lpage>14521</lpage><pub-id pub-id-type="doi">10.1002/chem.201802877</pub-id><pub-id pub-id-type="pmid">29974986</pub-id></element-citation></ref><ref id="B83-molecules-30-03506"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shlenev</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Filimonov</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Tarasov</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Danilova</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Agat&#8217;ev</surname><given-names>P.A.</given-names></name></person-group><article-title>Synthesis of New Sulfonamide Derivatives of Thiazolo[3,2-<italic toggle="yes">a</italic>]quinazolin-5-one</article-title><source>Russ. J. Org. Chem.</source><year>2016</year><volume>52</volume><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1134/S1070428016010139</pub-id></element-citation></ref><ref id="B84-molecules-30-03506"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Z.S.</given-names></name></person-group><article-title>Synthesis and anticonvulsant activity of substituted[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolines</article-title><source>Chin. J. Org. Chem.</source><year>2011</year><volume>31</volume><fpage>2082</fpage><lpage>2087</lpage></element-citation></ref><ref id="B85-molecules-30-03506"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.-B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.-N.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>L.-P.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Z.-S.</given-names></name></person-group><article-title>Synthesis and Anticonvulsant Activity Evaluation of 4-Phenyl[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(<italic toggle="yes">4H</italic>)-one and Its Derivatives</article-title><source>Arch. Pharm. Chem. Life Sci.</source><year>2015</year><volume>348</volume><fpage>564</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1002/ardp.201500115</pub-id><pub-id pub-id-type="pmid">26053879</pub-id></element-citation></ref><ref id="B86-molecules-30-03506"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.-B.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Z.-S.</given-names></name></person-group><article-title>Synthesis and antidepressant activities of 4-(substituted-phenyl)triazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones and their derivatives</article-title><source>Mol. Divers.</source><year>2015</year><volume>19</volume><fpage>817</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1007/s11030-015-9623-1</pub-id><pub-id pub-id-type="pmid">26251313</pub-id></element-citation></ref><ref id="B87-molecules-30-03506"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alagarsamy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Raja</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Dhanabal</surname><given-names>K.</given-names></name></person-group><article-title>Synthesis and pharmacological evaluation of some 3-phenyl-2-substituted-3<italic toggle="yes">H</italic>-quinazolin-4-one as analgesic, anti-inflammatory agents</article-title><source>Bioorg. Med. Chem.</source><year>2007</year><volume>15</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2006.09.065</pub-id><pub-id pub-id-type="pmid">17079148</pub-id></element-citation></ref><ref id="B88-molecules-30-03506"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>X.-B.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.-W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>N.-M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.-B.</given-names></name></person-group><article-title>Identification of new NIK inhibitors by discriminatory analysis-based molecular docking and biological evaluation</article-title><source>Arch. Pharm. Chem. Life Sci.</source><year>2019</year><volume>352</volume><fpage>e1800374</fpage><pub-id pub-id-type="doi">10.1002/ardp.201800374</pub-id><pub-id pub-id-type="pmid">31116887</pub-id></element-citation></ref><ref id="B89-molecules-30-03506"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abuelizz</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ghabbour</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Marzouk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdellatif</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name></person-group><article-title>DFT calculation, Hirshfeld analysis and X-ray crystal structure of some synthesized N-alkylated (S-alkylated) [1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolines</article-title><source>Crystals</source><year>2021</year><volume>11</volume><fpage>1195</fpage><pub-id pub-id-type="doi">10.3390/cryst11101195</pub-id></element-citation></ref><ref id="B90-molecules-30-03506"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Danylchenko</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Drushlyak</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Kovalenko</surname><given-names>S.M.</given-names></name></person-group><article-title>Formation of 1-methyl[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones by reaction of 2-hydrazinoquinazolin-4(3<italic toggle="yes">H</italic>)-ones with acetylacetone</article-title><source>Heterocycl. Commun.</source><year>2015</year><volume>21</volume><fpage>195</fpage><lpage>197</lpage></element-citation></ref><ref id="B91-molecules-30-03506"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gobinath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Alagarsamy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nivedhitha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>V.R.</given-names></name></person-group><article-title>Synthesis of 1-Substituted-4-(Pyridin-4-yl) [1,2,4]Triazolo[4,3-<italic toggle="yes">a</italic>]Quinazolin-5(4<italic toggle="yes">H</italic>)-ones as a New Class of H<sub>1</sub>-Antihistaminic Agents</article-title><source>Trop. J. Pharm. Res.</source><year>2015</year><volume>14</volume><fpage>271</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.4314/tjpr.v14i2.12</pub-id></element-citation></ref><ref id="B92-molecules-30-03506"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gobinath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Alagarsamy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nivedhitha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>V.R.</given-names></name></person-group><article-title>Design and Synthesis of 1-Substituted-4-(4-Nitrophenyl)-[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones as a New Class of Antihistaminic Agents</article-title><source>Russ. J. Bioorg. Chem.</source><year>2020</year><volume>46</volume><fpage>403</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1134/S1068162020030085</pub-id></element-citation></ref><ref id="B93-molecules-30-03506"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name></person-group><article-title>Synthesis, crystal structure, and density functional theory study of a new compound 4-(2-chlorobenzyl)-1-(5-fluoro-2-hydroxy-3-(thiomorpholinomethyl)phenyl)[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-one</article-title><source>J. Heterocycl. Chem.</source><year>2021</year><volume>58</volume><fpage>2102</fpage><lpage>2108</lpage><pub-id pub-id-type="doi">10.1002/jhet.4333</pub-id></element-citation></ref><ref id="B94-molecules-30-03506"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z.-X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.-M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.-Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.-H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.-G.</given-names></name></person-group><article-title>Synthesis, crystal structure, DFT, molecular docking and antitumor activity of 4-(2-chlorobenzyl)-1-(5-fluoro-2-hydroxy-3-((4-methylpiperidin-1-yl)methyl)phenyl)[1,2,4]-triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-one</article-title><source>Res. Chem. Intermed.</source><year>2021</year><volume>47</volume><fpage>3609</fpage><lpage>3627</lpage><pub-id pub-id-type="doi">10.1007/s11164-021-04491-x</pub-id></element-citation></ref><ref id="B95-molecules-30-03506"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name></person-group><article-title>Design, synthesis, and biological evaluation of novel triazoloquinazolinone derivatives as SHP2 protein inhibitors</article-title><source>J. Enzym. Inhib. Med. Chem.</source><year>2021</year><volume>36</volume><fpage>2170</fpage><lpage>2182</lpage><pub-id pub-id-type="doi">10.1080/14756366.2021.1986491</pub-id><pub-id pub-id-type="pmcid">PMC8583937</pub-id><pub-id pub-id-type="pmid">34749564</pub-id></element-citation></ref><ref id="B96-molecules-30-03506"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Yadava</surname><given-names>U.</given-names></name><name name-style="western"><surname>Upadhyay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M.L.</given-names></name></person-group><article-title>Synthesis, biological evaluation and molecular docking studies of novel quinazolinones as antitubercular and antimicrobial agents</article-title><source>Bioorg. Chem.</source><year>2021</year><volume>108</volume><elocation-id>104611</elocation-id><pub-id pub-id-type="pmid">33484939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioorg.2020.104611</pub-id></element-citation></ref><ref id="B97-molecules-30-03506"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#352;vajger</surname><given-names>U.</given-names></name><name name-style="western"><surname>Horvat</surname><given-names>&#381;.</given-names></name><name name-style="western"><surname>Knez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ro&#382;man</surname><given-names>P.</given-names></name><name name-style="western"><surname>Turk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gobec</surname><given-names>S.</given-names></name></person-group><article-title>New antagonists of toll-like receptor 7 discovered through 3D ligand-based virtual screening</article-title><source>Med. Chem. Res.</source><year>2015</year><volume>24</volume><fpage>362</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1007/s00044-014-1127-5</pub-id></element-citation></ref><ref id="B98-molecules-30-03506"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Driowya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leclercq</surname><given-names>J.</given-names></name><name name-style="western"><surname>Verones</surname><given-names>V.</given-names></name><name name-style="western"><surname>Barczyk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lecoeur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Renault</surname><given-names>N.</given-names></name><name name-style="western"><surname>Flouquet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ghinet</surname><given-names>A.</given-names></name><name name-style="western"><surname>Berthelot</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lebegue</surname><given-names>N.</given-names></name></person-group><article-title>Synthesis of triazoloquinazolinone based compounds as tubulin polymerization inhibitors and vascular disrupting agents</article-title><source>Eur. J. Med. Chem.</source><year>2016</year><volume>115</volume><fpage>393</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2016.03.056</pub-id><pub-id pub-id-type="pmid">27031215</pub-id></element-citation></ref><ref id="B99-molecules-30-03506"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#193;lvarez</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.-E.</given-names></name><name name-style="western"><surname>Toti</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Krausz</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bang</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.S.</given-names></name></person-group><article-title>Identification of a new heterocyclic scaffold for inhibitors of the polo-box domain of polo-like kinase 1</article-title><source>J. Med. Chem.</source><year>2020</year><volume>63</volume><fpage>14087</fpage><lpage>14117</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01669</pub-id><pub-id pub-id-type="pmid">33175530</pub-id><pub-id pub-id-type="pmcid">PMC7769008</pub-id></element-citation></ref><ref id="B100-molecules-30-03506"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Sarg</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Bayoumi</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>El-Deebb</surname><given-names>M.A.</given-names></name></person-group><article-title>Synthesis and anticancer evaluation of some novel 5-amino[1,2,4]triazole derivatives</article-title><source>J. Heterocycl. Chem.</source><year>2018</year><volume>55</volume><fpage>1450</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1002/jhet.3184</pub-id></element-citation></ref><ref id="B101-molecules-30-03506"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdelhamid</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Abdelmoniem</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ghozlan</surname><given-names>S.A.S.</given-names></name><name name-style="western"><surname>Butensch&#246;n</surname><given-names>H.</given-names></name></person-group><article-title>Hydrazononitriles as precursors for 4-aminotriazoles and 3-aminoisoxazoles: One pot synthesis of triazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives</article-title><source>J. Heterocycl. Chem.</source><year>2016</year><volume>53</volume><fpage>1251</fpage><lpage>1258</lpage><pub-id pub-id-type="doi">10.1002/jhet.2426</pub-id></element-citation></ref><ref id="B102-molecules-30-03506"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marzouk</surname><given-names>M.S.</given-names></name></person-group><article-title>Synthesis of novel 2-phenoxy-benzo[<italic toggle="yes">g</italic>][1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazoline and its derivatives starting with diphenyl-N-cyanoimidocarbonate</article-title><source>Russ. J. Gen. Chem.</source><year>2016</year><volume>86</volume><fpage>1741</fpage><lpage>1746</lpage><pub-id pub-id-type="doi">10.1134/S1070363216070331</pub-id></element-citation></ref><ref id="B103-molecules-30-03506"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Abuelizz</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Wadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>El Dib</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Alotaibi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Marzouk</surname><given-names>M.</given-names></name></person-group><article-title>Antimicrobial activity of synthesized 2-methylthiobenzo[g][1,2,4]-triazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives</article-title><source>Medicinal Chem.</source><year>2016</year><volume>12</volume><fpage>760</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.2174/1573406412666160502155106</pub-id><pub-id pub-id-type="pmid">27140181</pub-id></element-citation></ref><ref id="B104-molecules-30-03506"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name><name name-style="western"><surname>El-Tahir</surname><given-names>K.-E.</given-names></name><name name-style="western"><surname>Alswaidan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lolak</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hamidaddin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marzouk</surname><given-names>M.</given-names></name></person-group><article-title>Biological effects of a new set 1,2,4-triazolo[1,5-<italic toggle="yes">a</italic>]quinazolines on heart rate and blood pressure</article-title><source>Chem. Cent. J.</source><year>2014</year><volume>8</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/1752-153X-8-3</pub-id><pub-id pub-id-type="pmid">24428932</pub-id><pub-id pub-id-type="pmcid">PMC3903009</pub-id></element-citation></ref><ref id="B105-molecules-30-03506"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakheit</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Abuelizz</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name></person-group><article-title>Hirshfeld surface analysis and density functional theory calculations of 2-benzyloxy-1,2,4-triazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-one: A comprehensive study on crystal structure, intermolecular interactions, and electronic properties</article-title><source>Crystals</source><year>2023</year><volume>13</volume><fpage>1410</fpage><pub-id pub-id-type="doi">10.3390/cryst13101410</pub-id></element-citation></ref><ref id="B106-molecules-30-03506"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Geffken</surname><given-names>D.</given-names></name></person-group><article-title>Synthesis of novel 2-methylsulfanyl-4H-[1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5-one and derivatives</article-title><source>Synth. Commun.</source><year>2011</year><volume>41</volume><fpage>3512</fpage><lpage>3523</lpage><pub-id pub-id-type="doi">10.1080/00397911.2010.518780</pub-id></element-citation></ref><ref id="B107-molecules-30-03506"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Al-Omar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Alswaidan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Marzouk</surname><given-names>M.</given-names></name><name name-style="western"><surname>El-Senousy</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Amr</surname><given-names>A.E.-G.E.</given-names></name></person-group><article-title>Antiviral activities of some synthesized methylsulfanyltriazoloquinazoline derivatives</article-title><source>Res. Chem. Intermed.</source><year>2015</year><volume>41</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1007/s11164-013-1177-1</pub-id></element-citation></ref><ref id="B108-molecules-30-03506"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Anouar</surname><given-names>E.-H.</given-names></name><name name-style="western"><surname>Marzouk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Taie</surname><given-names>H.A.A.</given-names></name><name name-style="western"><surname>Abuelizz</surname><given-names>H.A.</given-names></name></person-group><article-title>Screening and evaluation of antioxidant activity of some 1,2,4-triazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives</article-title><source>Future Med. Chem.</source><year>2017</year><volume>10</volume><fpage>379</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.4155/fmc-2017-0224</pub-id><pub-id pub-id-type="pmid">29145730</pub-id></element-citation></ref><ref id="B109-molecules-30-03506"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abuelizz</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Anouar</surname><given-names>E.-H.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Azman</surname><given-names>N.I.I.N.</given-names></name><name name-style="western"><surname>Marzouk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Al-Salahi</surname><given-names>R.</given-names></name></person-group><article-title>Triazoloquinazolines as a new class of potent &#945;-glucosidase inhibitors: In vitro evaluation and docking study</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0220379</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0220379</pub-id><pub-id pub-id-type="pmid">31412050</pub-id><pub-id pub-id-type="pmcid">PMC6693780</pub-id></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Schemes and Tables</title><fig position="float" id="molecules-30-03506-f001" orientation="portrait"><label>Figure 1</label><caption><p>Polycyclic quinazolines of nature origin, which can be regarded as prototypes of biologically important [<italic toggle="yes">a</italic>]-annelated quinazolines.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g001.jpg"/></fig><fig position="float" id="molecules-30-03506-f002" orientation="portrait"><label>Figure 2</label><caption><p>Types of polycyclic quinazolines considered in current review.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g002.jpg"/></fig><fig position="float" id="molecules-30-03506-sch001" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Synthetic approach to [<italic toggle="yes">a</italic>]- or [<italic toggle="yes">b</italic>]-annelated quinazolinones <bold>2</bold> and <bold>3</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch001.jpg"/></fig><fig position="float" id="molecules-30-03506-sch002" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch002_Scheme 2</object-id><label>Scheme 2</label><caption><p>Synthesis of angular luotonins <bold>5a</bold>&#8211;<bold>l</bold>. <bold>1</bold>, <bold>4</bold>, <bold>5</bold>: R = H (<bold>a</bold>), 4-OMe (<bold>b</bold>), 4-Cl (<bold>c</bold>), 3-OMe (<bold>d</bold>), 3,4,5-(OMe)<sub>3</sub> (<bold>e</bold>), 4-Br (<bold>f</bold>), 4-F (<bold>g</bold>), 4-CF<sub>3</sub> (<bold>h</bold>), 3-Br (<bold>i</bold>), 4-SMe (<bold>j</bold>), 2-Me (<bold>k</bold>), 4-Me (<bold>l</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch002.jpg"/></fig><fig position="float" id="molecules-30-03506-sch003" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch003_Scheme 3</object-id><label>Scheme 3</label><caption><p>Synthesis of 2,3-dihydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(1<italic toggle="yes">H</italic>)-ones <bold>7</bold>. <bold>7</bold>: R = H (<bold>a</bold>), 5-NO<sub>2</sub> (<bold>b</bold>), 5-F (<bold>c</bold>), 6-Me (<bold>d</bold>), 6-OMe (<bold>e</bold>), 6-Cl (<bold>f</bold>), 6-NO<sub>2</sub> (<bold>g</bold>), 6,7-(OMe)<sub>2</sub> (<bold>h</bold>), 7-Cl (<bold>i</bold>), 8-Me (<bold>j</bold>), 8-Br (<bold>k</bold>), 8-F (<bold>l</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch003.jpg"/></fig><fig position="float" id="molecules-30-03506-sch004" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch004_Scheme 4</object-id><label>Scheme 4</label><caption><p>Synthetic approach to pyrroloquinazolinones <bold>10</bold>, <bold>12</bold>, <bold>13</bold>. R = H (<bold>a</bold>), 5-F (<bold>b</bold>), 6-Cl (<bold>c</bold>), 7-Cl (<bold>d</bold>), 8-Me (<bold>e</bold>), 6-OMe (<bold>f</bold>), 6-NO<sub>2</sub> (<bold>g</bold>), 6,7-(OMe)<sub>2</sub> (<bold>h</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch004.jpg"/></fig><fig position="float" id="molecules-30-03506-sch005" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch005_Scheme 5</object-id><label>Scheme 5</label><caption><p>Synthesis of tetrahydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(1<italic toggle="yes">H</italic>)-ones <bold>16aa</bold>&#8211;<bold>ja</bold> from <bold>14a</bold> and <bold>15a</bold>&#8211;<bold>j</bold>. <bold>16aa</bold>: Ar = 4-MeOC<sub>6</sub>H<sub>4</sub>, 85%, 34:66; <bold>16ba</bold>: Ar = Ph, 83%, 35:65; <bold>16ca</bold>: Ar = 4-MeC<sub>6</sub>H<sub>4</sub>, 82%, 32:68; <bold>16da</bold>: Ar = 3,4-(MeO)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>, 81%, 40:60; <bold>16ea</bold>: Ar = 4-FC<sub>6</sub>H<sub>4</sub>, 82%, 35:65; <bold>16fa</bold>: Ar = 4-ClC<sub>6</sub>H<sub>4</sub>, 82%, 35:65; <bold>16ga</bold>: Ar = 4-BrC<sub>6</sub>H<sub>4</sub>, 81%, 35:65; <bold>16ha</bold>: Ar = 1-naphthyl, 78%, 36:64; <bold>16ia</bold>: Ar = styryl, 79%, 35:65; <bold>16ja</bold>: Ar = 2-furyl, 82%, 35:65.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch005.jpg"/></fig><fig position="float" id="molecules-30-03506-sch006" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch006_Scheme 6</object-id><label>Scheme 6</label><caption><p>Synthesis of tetrahydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolin-5(1<italic toggle="yes">H</italic>)-ones <bold>16ab</bold>&#8211;<bold>ag</bold> from <bold>14a</bold>&#8211;<bold>g</bold> and <bold>15a</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch006.jpg"/></fig><fig position="float" id="molecules-30-03506-sch007" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch007_Scheme 7</object-id><label>Scheme 7</label><caption><p>Synthesis of 1-R-4,5-dihydropyrrolo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>17</bold> from 2-(aminomethyl)aniline and furanones. R = Ph (<bold>a</bold>), 4-MeC<sub>6</sub>H<sub>4</sub> (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch007.jpg"/></fig><fig position="float" id="molecules-30-03506-sch008" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch008_Scheme 8</object-id><label>Scheme 8</label><caption><p>Synthetic approach to indolo[1,2-<italic toggle="yes">a</italic>]quinazolinone derivatives <bold>20</bold> from 2-iodobenzamides <bold>18</bold> and indoles. R = H, Cl, (MeO)<sub>2</sub>; R<sup>1</sup> = Me, Et, iso-Pr, Bn, Ph, Ar; R<sup>2</sup> = H, OMe, OBn, Cl, Br.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch008.jpg"/></fig><fig position="float" id="molecules-30-03506-sch009" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch009_Scheme 9</object-id><label>Scheme 9</label><caption><p>Synthesis of indolo[1,2-<italic toggle="yes">a</italic>]quinazolinones <bold>23</bold> and <bold>25</bold> from 2-bromobenzamides <bold>21</bold> and indole derivatives <bold>22</bold>. <bold>23</bold>: R = H, MeO, Cl, Br; R<sup>1</sup> = H, Me, Bn, Ph; R<sup>2</sup> = H, Me, Cl; <bold>25</bold>: R = H, Me, Et, Bn, Ar; R<sup>1</sup> = H, Me; R<sup>2</sup> = H, Me, Et, MeO, Cl, Br.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch009.jpg"/></fig><fig position="float" id="molecules-30-03506-sch010" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch010_Scheme 10</object-id><label>Scheme 10</label><caption><p>Synthesis of 5-amine-indolo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>27</bold> from 2-aminobenzonitriles <bold>26</bold> and 2-(2-bromophenyl)acetonitriles. R = H, Me, F, CF<sub>3</sub>; R<sup>1</sup> = H, F, MeO; EWG = CN, COOEt.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch010.jpg"/></fig><fig position="float" id="molecules-30-03506-sch011" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch011_Scheme 11</object-id><label>Scheme 11</label><caption><p>Synthetic approach to 6,6a-dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-dione derivatives <bold>29</bold>, <bold>31</bold>. <bold>29</bold>: R = H, Me, Et, <italic toggle="yes">n</italic>-Pr, (CH<sub>2</sub>)<sub>2</sub>-OH, (CH<sub>2</sub>)<sub>3</sub>-OH, (CH<sub>2</sub>)<sub>3</sub>-COOH; <bold>31</bold>: Ar = Ph, 2-Me-C<sub>6</sub>H<sub>4</sub>, 4-F-C<sub>6</sub>H<sub>4</sub>, 2-Cl-C<sub>6</sub>H<sub>4</sub>, 2-Br-C<sub>6</sub>H<sub>4</sub>, 2-NO<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>, 2,3-Cl<sub>2</sub>-C<sub>6</sub>H<sub>3</sub>, 3,4-Cl<sub>2</sub>-C<sub>6</sub>H<sub>3</sub>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch011.jpg"/></fig><fig position="float" id="molecules-30-03506-sch012" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch012_Scheme 12</object-id><label>Scheme 12</label><caption><p>Synthetic approach to isoinodolo[2,1-<italic toggle="yes">a</italic>]quinazolino[1,2-<italic toggle="yes">c</italic>]quinazolinones <bold>33</bold>. R = (CH<sub>2</sub>)<sub>2</sub>Ph, cyclopentyl, cyclopropyl, allyl, hexyl, butyl, propyl, ethyl.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch012.jpg"/></fig><fig position="float" id="molecules-30-03506-sch013" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch013_Scheme 13</object-id><label>Scheme 13</label><caption><p>Synthesis of dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-dione derivatives <bold>34</bold>, <bold>35</bold>, <bold>36</bold>. <bold>34</bold>: R = Me, Bu, prop-2-yne, cyclopropyl, (CH<sub>2</sub>)<sub>2</sub>Ph, 1-Nf, Bn-4-Cl, Bn-4-OMe, Bn-2,4-Cl<sub>2</sub>, 4-Me-C<sub>6</sub>H<sub>4</sub>, 4-CN-C<sub>6</sub>H<sub>4</sub>, 2-MeO-C<sub>6</sub>H<sub>4</sub>, 2,3-(Me)<sub>2</sub>-C<sub>6</sub>H<sub>3</sub>, 2-Cl,3-Me-C<sub>6</sub>H<sub>3</sub>, 4-COOMe-C<sub>6</sub>H<sub>4</sub>, 4-<italic toggle="yes">t</italic>-Bu-C<sub>6</sub>H<sub>4</sub>; <bold>35</bold>: R = propen-2-yl-methyl, Bn, Bn-2-Cl, Bn-4-Cl, furan-2-yl-methyl, Py-2-yl-methyl; X = H, 2,3-(MeO)<sub>2</sub>; <bold>36</bold>: R = propen-2-yl, <italic toggle="yes">n</italic>-Pr, <italic toggle="yes">n</italic>-Bu, cyclopropyl, Bn, Bn-4-Me, Bn-2-OMe, Ph, 4-Me-C<sub>6</sub>H<sub>4</sub>, 4-MeO-C<sub>6</sub>H<sub>4</sub>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch013.jpg"/></fig><fig position="float" id="molecules-30-03506-sch014" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch014_Scheme 14</object-id><label>Scheme 14</label><caption><p>Synthetic approach to dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazolin-5,11-diones <bold>38</bold>, <bold>39</bold> from 2-aminobenzamides <bold>37</bold> (in blue) and 2-formylbenzoic acids (in red). <bold>37</bold>: R = H, Alk, Bn, Ar; <bold>38</bold>: R = H (<bold>a</bold>), Bn (<bold>b</bold>), Me (<bold>c</bold>), Ph (<bold>d</bold>), 4-Me-C<sub>6</sub>H<sub>4</sub> (<bold>e</bold>), 3-Me-C<sub>6</sub>H<sub>4</sub> (<bold>f</bold>), 4-MeO-C<sub>6</sub>H<sub>4</sub> (<bold>g</bold>), 4-ClC<sub>6</sub>H<sub>4</sub> (<bold>h</bold>), 4-BrC<sub>6</sub>H<sub>4</sub> (<bold>i</bold>), 4-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub> (<bold>k</bold>), 3-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub> (<bold>l</bold>), 2-Nf (<bold>m</bold>), cyclohexyl (<bold>n</bold>), Bu (<bold>o</bold>); <bold>39</bold>: R<sup>2</sup> = R<sup>1</sup> = H (<bold>a</bold>), R<sup>2</sup> = R<sup>1</sup> = OMe (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch014.jpg"/></fig><fig position="float" id="molecules-30-03506-sch015" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch015_Scheme 15</object-id><label>Scheme 15</label><caption><p>Synthetic approach to dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-diones <bold>41</bold>, <bold>43</bold>. <bold>41</bold>: R, R<sup>1</sup> = Me, 5-Br (<bold>a</bold>); H, 5-Me (<bold>b</bold>); Me, H (<bold>c</bold>); Cl, 5-Br (<bold>d</bold>); H, H (<bold>e</bold>); H, 5-Cl (<bold>f</bold>); Me, 4-Cl (<bold>g</bold>); <bold>43</bold>: R = NHAr, CH<sub>2</sub>Ar, allyl, cyclopropyl, etc.; R<sup>1</sup> = H, Br, Cl.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch015.jpg"/></fig><fig position="float" id="molecules-30-03506-sch016" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch016_Scheme 16</object-id><label>Scheme 16</label><caption><p>Synthesis of dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-dione derivatives <bold>45</bold>. <bold>42</bold>, <bold>45</bold>: R = H, Bn, NHPh; R<sup>1</sup> = Me, MeO, Cl; <bold>44</bold>, <bold>45</bold>: R<sup>2</sup> = Me, OMe, F, Cl, CF<sub>3</sub>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch016.jpg"/></fig><fig position="float" id="molecules-30-03506-sch017" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch017_Scheme 17</object-id><label>Scheme 17</label><caption><p>Synthetic approach to dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazoline-5,11-diones <bold>49a</bold>,<bold>b</bold>. <bold>46</bold>: X = H, R = H (<bold>a</bold>), OMe (<bold>b</bold>); <bold>47</bold>: X = OH, R = H (<bold>a</bold>), OMe (<bold>b</bold>); <bold>49</bold>: R = H (<bold>a</bold>), OMe (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch017.jpg"/></fig><fig position="float" id="molecules-30-03506-sch018" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch018_Scheme 18</object-id><label>Scheme 18</label><caption><p>Synthetic approach to dihydroisoindolo[2,1-<italic toggle="yes">a</italic>]quinazolin-5,11-diones <bold>50a</bold>,<bold>b</bold>. <bold>48</bold>, <bold>50</bold>: R = H (<bold>a</bold>), OMe (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch018.jpg"/></fig><fig position="float" id="molecules-30-03506-sch019" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch019_Scheme 19</object-id><label>Scheme 19</label><caption><p>Synthesis of isoindolo[2,1-<italic toggle="yes">a</italic>]quinazolin-5(11<italic toggle="yes">H</italic>)-ones <bold>52a</bold>&#8211;<bold>d</bold> from anthranilamides <bold>51a</bold>&#8211;<bold>d</bold> (in blue) and <italic toggle="yes">o</italic>-phthalaldehyde (in red). <bold>51</bold>, <bold>52</bold>: R<sup>1</sup>, R<sup>2</sup> = H, H (<bold>a</bold>); 3-NO<sub>2</sub>, H (<bold>b</bold>); 3-Br, H (<bold>c</bold>); Br, Br (<bold>d</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch019.jpg"/></fig><fig position="float" id="molecules-30-03506-sch020" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch020_Scheme 20</object-id><label>Scheme 20</label><caption><p>Synthetic approach to pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>54</bold> and <bold>56</bold>. <bold>54</bold>: R<sup>1</sup> = H, Cl, OMe, NO<sub>2</sub>; R<sup>2</sup> = H, Me, CN, Ph, cyclopropyl, 2-thienyl; <bold>56</bold>: R = H, NO<sub>2</sub>; R<sup>1</sup> = H, Me, COOEt, cyclopropyl, 4-MeC<sub>6</sub>H<sub>4</sub>, 2-thienyl; R<sup>2</sup> = H, CN.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch020.jpg"/></fig><fig position="float" id="molecules-30-03506-sch021" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch021_Scheme 21</object-id><label>Scheme 21</label><caption><p>Synthesis of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>58</bold>, indazolo[2,3-<italic toggle="yes">a</italic>]quinazoline <bold>59</bold>, 10-azaindazolo[2,3-<italic toggle="yes">a</italic>]quinazoline <bold>60</bold>. <bold>57</bold>, <bold>58</bold>: R = H, Br, CF<sub>3</sub>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch021.jpg"/></fig><fig position="float" id="molecules-30-03506-sch022" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch022_Scheme 22</object-id><label>Scheme 22</label><caption><p>Synthesis of indazolo[2,3-<italic toggle="yes">a</italic>]- and pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>62</bold>, <bold>63</bold>. <bold>62</bold>: R = H, F, OH, Cl, Br, Me, CN; R<sup>1</sup> = H, Me, Et, <italic toggle="yes">n</italic>-Pr, CF<sub>3</sub>, OMe, COOEt, Ph, cyclohexyl-4-Pr; Ar = Ph, substituted Ar, naphthalene-2-yl, antracen-9-yl, hetaryl; <bold>63</bold>: R<sup>2</sup> = H, CONH<sub>2</sub>, CN, COOEt.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch022.jpg"/></fig><fig position="float" id="molecules-30-03506-f003" orientation="portrait"><label>Figure 3</label><caption><p>Chemical structures of compounds <bold>A</bold> and <bold>64a</bold>&#8211;<bold>t</bold>. <bold>64a</bold>&#8211;<bold>l</bold>: X = N, R = 8-Cl (<bold>a</bold>), 7-NO<sub>2</sub> (<bold>b</bold>), 8-CF<sub>3</sub> (<bold>c</bold>), H (<bold>d</bold>), 8-Me (<bold>e</bold>); X = CH, R = H (<bold>f</bold>), 8-MeSO<sub>2</sub> (<bold>g</bold>), 8-CF<sub>3</sub> (<bold>h</bold>), 9-CF<sub>3</sub> (<bold>i</bold>), 8-NO<sub>2</sub> (<bold>j</bold>), 9-NH<sub>2</sub> (<bold>k</bold>), 8-NH<sub>2</sub> (<bold>l</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g003.jpg"/></fig><fig position="float" id="molecules-30-03506-f004" orientation="portrait"><label>Figure 4</label><caption><p>3D docking model of compound <bold>64r</bold> in active pocket of KDM4D. Compound <bold>64r</bold> is color coded with carbon atom by green, nitrogen atom by blue, and oxygen atom by red; Fe(II) is in orange and residues of KDM4D are in light blue. Reproduced with permission of Elsevier [<xref rid="B55-molecules-30-03506" ref-type="bibr">55</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g004.jpg"/></fig><fig position="float" id="molecules-30-03506-sch023" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch023_Scheme 23</object-id><label>Scheme 23</label><caption><p>Synthesis of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives <bold>66</bold>&#8211;<bold>69</bold>. <bold>65</bold>&#8211;<bold>69</bold>: R<sup>1</sup> = H, Me; R<sup>2</sup> = H, Me, Br; R<sup>3</sup> = H, Me, OMe; R<sup>4</sup> = H, Me; R<sup>5</sup> = H, Me; <bold>68</bold>, <bold>69</bold>: n = 1, 2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch023.jpg"/></fig><fig position="float" id="molecules-30-03506-sch024" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch024_Scheme 24</object-id><label>Scheme 24</label><caption><p>Synthetic approach to pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>70</bold>, <bold>72</bold>, <bold>73</bold>&#8211;<bold>75</bold>, <bold>76</bold>, <bold>77</bold>, <bold>78</bold>, <bold>79</bold>. <bold>70</bold>: R = OMe (<bold>a</bold>), H (<bold>b</bold>), O(CH<sub>2</sub>)<sub>2</sub>OMe (<bold>c</bold>); <bold>72</bold>: R = OMe (<bold>a</bold>), H (<bold>b</bold>); <bold>76</bold>: R = OMe (<bold>a</bold>), H (<bold>b</bold>); <bold>77</bold>: R = OMe, R<sup>1</sup> = CH<sub>2</sub>Ph (<bold>a</bold>), CH<sub>2</sub>-(2-OMe)Ph (<bold>b</bold>), CH<sub>2</sub>-2-thienyl (<bold>c</bold>), CH<sub>2</sub>-2-furyl (<bold>d</bold>), CHMe<sub>2</sub> (<bold>e</bold>); <bold>78</bold>: R = H, R<sup>1</sup> = CH<sub>2</sub>Ph (<bold>a</bold>), CH<sub>2</sub>-(2-OMe)Ph (<bold>b</bold>), CH<sub>2</sub>-2-thienyl (<bold>c</bold>); <bold>79</bold>: R<sup>1</sup> = CH<sub>2</sub>Ph (<bold>a</bold>), CH<sub>2</sub>-(2-OMe)Ph (<bold>b</bold>), CH<sub>2</sub>-2-furyl (<bold>d</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch024.jpg"/></fig><fig position="float" id="molecules-30-03506-sch025" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch025_Scheme 25</object-id><label>Scheme 25</label><caption><p>Synthetic approach to pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>80</bold>, <bold>82</bold>, <bold>83</bold>, <bold>87</bold>. <bold>80</bold>: R = H, R<sup>1</sup> = Ph (<bold>a</bold>), 2-thienyl (<bold>b</bold>), 3-thienyl (<bold>c</bold>); R = OMe, R<sup>1</sup> = 2-thienyl (<bold>d</bold>), 3-thienyl (<bold>e</bold>), CO-(2-OMe)-Ph (<bold>f</bold>), 2-CO-2-thienyl (<bold>g</bold>), CO-3-thienyl (<bold>h</bold>); <bold>82</bold>: R = H, Ar/Het = Ph (<bold>a</bold>), 2-thienyl (<bold>b</bold>), 3-thienyl (<bold>c</bold>); R = OMe, Ar/Het = 2-thienyl (<bold>d</bold>), 3-thienyl (<bold>e</bold>), 2-MeOPh (<bold>f</bold>), 3-furyl (<bold>g</bold>), 1-Boc-2-pyrrolyl (<bold>h</bold>), <italic toggle="yes">1H</italic>-2-pyrrolyl (<bold>i</bold>); <bold>83</bold>: R = OMe, Ar/Het = (2-MeO)Ph (<bold>a</bold>), 2-thienyl (<bold>b</bold>), 3-thienyl (<bold>c</bold>), (4-MeO)Ph (<bold>d</bold>), 2-furyl (<bold>e</bold>), 2(<italic toggle="yes">1H</italic>)-pyrrolyl (<bold>f</bold>), 2-(1-methyl)pyrrolyl (<bold>g</bold>); <bold>86</bold>: X = Br (<bold>a</bold>), I (<bold>b</bold>); <bold>87</bold>: Ar/Het = 2-MeOPh (<bold>a</bold>), 2-thienyl (<bold>b</bold>), 4-MeOPh (<bold>d</bold>), 2-furyl (<bold>e</bold>), 2(<italic toggle="yes">1H</italic>)-pyrrolyl (<bold>f</bold>), 2-(1-methyl)pyrrolyl (<bold>g</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch025.jpg"/></fig><fig position="float" id="molecules-30-03506-sch026" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch026_Scheme 26</object-id><label>Scheme 26</label><caption><p>Synthetic approach to pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>89</bold>&#8211;<bold>94</bold>, <bold>96</bold>, <bold>97</bold>. <bold>89</bold>: R = CN (<bold>a</bold>), COOEt (<bold>b</bold>); <bold>90</bold>: R, R<sup>1</sup> = CN, CH<sub>2</sub>Ph (<bold>a</bold>), COOEt, Me (<bold>b</bold>); <bold>91</bold>: R = CH<sub>2</sub>Ph (<bold>a</bold>), CH<sub>2</sub>(2-OMe-Ph) (<bold>b</bold>), CH<sub>2</sub>-2-furyl (<bold>c</bold>); <bold>92</bold>: R = CH<sub>2</sub>Ph (<bold>a</bold>), CH<sub>2</sub>(2-OMe-Ph) (<bold>b</bold>), CH<sub>2</sub>-2-furyl (<bold>c</bold>), Et (<bold>d</bold>); <bold>94</bold>: R = H (<bold>a</bold>), CH<sub>2</sub>Ph (<bold>b</bold>); <bold>96</bold>: R = H (<bold>a</bold>), CH<sub>2</sub>Ph (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch026.jpg"/></fig><fig position="float" id="molecules-30-03506-f005" orientation="portrait"><label>Figure 5</label><caption><p>Chemical structures of compounds <bold>98</bold>, <bold>99</bold>, <bold>100</bold>&#8211;<bold>107</bold>. <bold>98</bold>, <bold>99</bold>: R = H (<bold>a</bold>), CHMe<sub>2</sub> (<bold>b</bold>), cyclohexyl (<bold>c</bold>), CH<sub>2</sub>cyclohexyl (<bold>d</bold>), Ph (<bold>e</bold>), CH<sub>2</sub>Ph (<bold>f</bold>), CH<sub>2</sub>(2-OMe)Ph (<bold>g</bold>), CH<sub>2</sub>(2-furyl) (<bold>h</bold>), CH<sub>2</sub>(2-thienyl) (<bold>i</bold>); <bold>100</bold>: R = CH<sub>2</sub>(2-OMe)Ph (<bold>a</bold>), CH<sub>2</sub>(2-thienyl) (<bold>b</bold>), t-Bu (<bold>c</bold>); <bold>101</bold>: R = CH<sub>2</sub>(2-OMe)Ph (<bold>a</bold>), CH<sub>2</sub>(2-thienyl) (<bold>b</bold>), Et (<bold>c</bold>); <bold>102</bold>: R = CH<sub>2</sub>(2-OMe)Ph (<bold>a</bold>), CH<sub>2</sub>(2-thienyl) (<bold>b</bold>), <italic toggle="yes">t</italic>-Bu (<bold>c</bold>); <bold>103</bold>: R = CH<sub>2</sub>(2-OMe)Ph (<bold>a</bold>), CH<sub>2</sub>(2-thienyl) (<bold>b</bold>), Et (c); <bold>104</bold>: R<sup>1</sup> = H (<bold>a</bold>), Me (<bold>b</bold>); <bold>106</bold>: R<sup>1</sup> = H (<bold>a</bold>), Me (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g005.jpg"/></fig><fig position="float" id="molecules-30-03506-f006" orientation="portrait"><label>Figure 6</label><caption><p>Chemical structures of compounds <bold>108</bold>&#8211;<bold>113</bold>. <bold>108</bold>: R = Me (<bold>a</bold>), CH<sub>2</sub><italic toggle="yes">c</italic>Pr (<bold>b</bold>), propyne (<bold>c</bold>), CH<sub>2</sub>Ph (<bold>d</bold>), CH<sub>2</sub>(2-MePh) (<bold>e</bold>), CH<sub>2</sub>(2-MeOPh) (<bold>f</bold>), CH<sub>2</sub>(pyridin-4-yl) (<bold>g</bold>); <bold>109</bold>: R<sup>7</sup> = H, R<sup>8</sup> = NO<sub>2</sub> (<bold>a</bold>), R<sup>7</sup> = NO<sub>2</sub>, R<sup>8</sup> = H (<bold>b</bold>); <bold>110</bold>: R<sup>7</sup> = H, R<sup>8</sup> = NO<sub>2</sub> (<bold>a</bold>), R<sup>7</sup> = NO<sub>2</sub>, R<sup>8</sup> = H (b); <bold>111</bold>: R<sup>7</sup> = H, R<sup>8</sup> = NO<sub>2</sub>, R = CH<sub>2</sub>(2-MeOPh) (<bold>a</bold>), R<sup>7</sup> = H, R<sup>8</sup> = NO<sub>2</sub>, R = CH<sub>2</sub>-thien-2-yl (<bold>b</bold>), R<sup>7</sup> = NO<sub>2</sub>, R<sup>8</sup> = H, R = CH<sub>2</sub>(2-MeOPh) (<bold>c</bold>), R<sup>7</sup> = NO<sub>2</sub>, R<sup>8</sup> = H, R = CH<sub>2</sub>-thien-2-yl (<bold>d</bold>); <bold>113</bold>: R = CH<sub>2</sub>(2-MeOPh) (<bold>a</bold>), CH<sub>2</sub>-thien-2-yl (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g006.jpg"/></fig><fig position="float" id="molecules-30-03506-f007" orientation="portrait"><label>Figure 7</label><caption><p>Hydrogen bonds among agonist <bold>112</bold> (blue), antagonist <bold>108d</bold> (red), and &#947;Thr142, &#945;His102, and &#945;Ser205 in the binding site. Reproduced with permission of MDPI [<xref rid="B65-molecules-30-03506" ref-type="bibr">65</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g007.jpg"/></fig><fig position="float" id="molecules-30-03506-sch027" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch027_Scheme 27</object-id><label>Scheme 27</label><caption><p>Synthesis of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives <bold>115a</bold> (a-f), <bold>115b</bold> (a-o). <bold>115c</bold> (a-g); <bold>116a</bold> (a-o), <bold>116b</bold> (a-y), <bold>116c</bold> (a-j); <bold>117a</bold> (a-h), <bold>117b</bold> (a-h), <bold>117ca</bold> (a-h). R<sup>1</sup> = H (<bold>a</bold>), Me (<bold>b</bold>), <italic toggle="yes">t</italic>Bu (<bold>c</bold>); R<sup>2</sup> = Ar, Ar-Ar, Ar-O-Ar, thiazolyl, benzothiazolyl, benzooxazolyl, pyrazinyl etc.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch027.jpg"/></fig><fig position="float" id="molecules-30-03506-sch028" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch028_Scheme 28</object-id><label>Scheme 28</label><caption><p>Synthesis of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives <bold>118a</bold>&#8211;<bold>d</bold>, <bold>119a</bold>&#8211;<bold>d</bold>, <bold>120a</bold>&#8211;<bold>e</bold>, <bold>121a</bold>&#8211;<bold>c</bold>, <bold>122</bold>, <bold>123a</bold>&#8211;<bold>e</bold>, <bold>124</bold>, <bold>125</bold>, <bold>126</bold>. <bold>118</bold>&#8211;<bold>121</bold>: R<sup>7</sup>, R<sup>8</sup> = H, H (<bold>a</bold>); H, Cl (<bold>b</bold>), H, NO<sub>2</sub> (<bold>c</bold>); NO<sub>2</sub>, H (<bold>d</bold>); H, OMe (<bold>e</bold>); <bold>123</bold>: R = Me (<bold>a</bold>), CH<sub>2</sub>-Ph (<bold>b</bold>), CH<sub>2</sub>-4-SMe-Ph (<bold>c</bold>), CH<sub>2</sub>-2-Cl-Ph (<bold>d</bold>), CH<sub>2</sub>-3-Cl-Ph (<bold>e</bold>), CH<sub>2</sub>-4-Br-Ph (<bold>f</bold>), CH<sub>2</sub>-2-Me-Ph (<bold>g</bold>), CH<sub>2</sub>-3-OMe-Ph (<bold>h</bold>), CH<sub>2</sub>-4-SO<sub>2</sub>NH<sub>2</sub>-Ph (<bold>i</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch028.jpg"/></fig><fig position="float" id="molecules-30-03506-sch029" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch029_Scheme 29</object-id><label>Scheme 29</label><caption><p>Synthetic approach to 9-(trifluoromethyl)-pyrido[2&#8242;,3&#8242;:3,4]pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives <bold>128</bold>&#8211;<bold>132</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch029.jpg"/></fig><fig position="float" id="molecules-30-03506-sch030" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch030_Scheme 30</object-id><label>Scheme 30</label><caption><p>Synthetic approach to 4,5-dihydropyrazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>133</bold>&#8211;<bold>136</bold>. <bold>133</bold>: R<sup>1</sup> = CF<sub>3</sub>, NO<sub>2</sub>, CN, Cl, Br, F, OCF<sub>3</sub>; R<sup>2</sup> = Et, Me; <bold>134</bold>: R<sup>2</sup> = Me, Et, <italic toggle="yes">n</italic>-Pr, cyclobutylmethyl, 4-chlorobenzyl; <bold>135</bold>: X = O, NH; R = Me, Et, CH<sub>2</sub>CF<sub>3</sub>, 2,4-Me<sub>2</sub>Ph, 2-Cl-5-Me-thiazole, 2-Cl-5-Me-Py; <bold>136</bold>: R<sup>1</sup> = esters, amides, acylsulfur; R<sup>2</sup> = H, esters; R<sup>3</sup> = SOCF<sub>3</sub> or SO<sub>2</sub>CF<sub>3</sub>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch030.jpg"/></fig><fig position="float" id="molecules-30-03506-sch031" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch031_Scheme 31</object-id><label>Scheme 31</label><caption><p>Synthetic approach to benzimidazo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>137</bold>, <bold>138</bold>. <bold>137</bold>: X = CH, R = H (<bold>a</bold>), Br (<bold>b</bold>), OMe (<bold>c</bold>), CF<sub>3</sub> (<bold>d</bold>), NO<sub>2</sub> (<bold>e</bold>); X = N, R = H (<bold>f</bold>), Br (<bold>g</bold>); <bold>138</bold>: R = F, Cl, Br, CF<sub>3</sub>, Me, OMe; R<sup>1</sup> = H, Cl, Me.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch031.jpg"/></fig><fig position="float" id="molecules-30-03506-sch032" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch032_Scheme 32</object-id><label>Scheme 32</label><caption><p>Synthetic approach to tetrahydrobenzo[4,5]imidazo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>140</bold>, <bold>141</bold>, benzimidazo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>144</bold>, and benzimidazole-4,7-dione derivatives <bold>142a</bold>&#8211;<bold>c</bold>, <bold>145</bold>. <bold>140</bold>: R, R<sup>1</sup> = H, H (<bold>a</bold>), H, Me (<bold>b</bold>), Me, H (<bold>c</bold>), Ph, H (<bold>d</bold>); <bold>141</bold>, <bold>142</bold>: R = H (<bold>a</bold>), Me (<bold>b</bold>), Ph (<bold>c</bold>); <bold>143</bold>&#8211;<bold>145</bold>: R = H (<bold>a</bold>), F (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch032.jpg"/></fig><fig position="float" id="molecules-30-03506-sch033" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch033_Scheme 33</object-id><label>Scheme 33</label><caption><p>Synthetic approach to tetrahydrobenzo[4,5]imidazo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>147</bold>, tetrahydroimidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5-one <bold>148</bold>, benzimidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>150a</bold>&#8211;<bold>c</bold>, <bold>151a</bold>, and imidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5-one <bold>151b</bold>. <bold>147</bold>: R, R<sup>1</sup> = Bz, H (<bold>a</bold>); Bu, H (<bold>b</bold>); Bz, Me (<bold>c</bold>); Bz, Ph (<bold>d</bold>); <bold>150</bold>: R = Bz (<bold>a</bold>), Bu (<bold>b</bold>), Ph (<bold>c</bold>); <bold>151a</bold>: R = <italic toggle="yes">n</italic>-Pr, benzimidazole; <bold>151b</bold>: R = <italic toggle="yes">n</italic>-Bu, imidazole.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch033.jpg"/></fig><fig position="float" id="molecules-30-03506-sch034" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch034_Scheme 34</object-id><label>Scheme 34</label><caption><p>Synthesis of imidazo[1,2-<italic toggle="yes">a</italic>]quinazolin-5-one <bold>153</bold> and benzimidazo[1,2-<italic toggle="yes">a</italic>]quinazolines <bold>156</bold>. <bold>154</bold>: R<sup>1</sup> = H, 5,6-Cl; <bold>155</bold>: X = F, Cl, Br, NO<sub>2</sub>; R = H, 4-F, 5-F, 4-Cl, 3-OMe, 5-Br, 4-Br, 3,6-Br.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch034.jpg"/></fig><fig position="float" id="molecules-30-03506-sch035" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch035_Scheme 35</object-id><label>Scheme 35</label><caption><p>Synthetic approach to 4-(2-chlorobenzyl)imidazole[1,2-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones <bold>159</bold>, <bold>161a</bold>&#8211;<bold>e</bold>, <bold>164</bold>. <bold>161</bold>: R = 4-Me-piperazino (<bold>a</bold>), pyrrolidinyl (<bold>b</bold>), piperidinyl (<bold>c</bold>), morpholino (<bold>d</bold>), thiomorpholino (<bold>e</bold>); <bold>164</bold>: R = cycloimines, cycloamines, arylamines.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch035.jpg"/></fig><fig position="float" id="molecules-30-03506-f008" orientation="portrait"><label>Figure 8</label><caption><p>Interaction of compound <bold>164</bold> (R = 3-(OCF<sub>3</sub>)C<sub>6</sub>H<sub>4</sub>NH) with SHP2 protein. Reproduced with permission of Taylor &amp; Francis [<xref rid="B81-molecules-30-03506" ref-type="bibr">81</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g008.jpg"/></fig><fig position="float" id="molecules-30-03506-sch036" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch036_Scheme 36</object-id><label>Scheme 36</label><caption><p>Synthesis of imidazo[1,2-<italic toggle="yes">a</italic>]quinazoline derivative <bold>166</bold>, diimidazo[1,2-<italic toggle="yes">a</italic>:1&#8242;,2&#8242;-<italic toggle="yes">c</italic>]quinazoline derivatives <bold>167</bold>, <bold>168</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch036.jpg"/></fig><fig position="float" id="molecules-30-03506-sch037" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch037_Scheme 37</object-id><label>Scheme 37</label><caption><p>Synthesis of benzo[4,5]thiazolo[3,2-<italic toggle="yes">a</italic>]quinazoline <bold>169</bold>, thiazolo[3,2-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>172</bold>. <bold>170</bold>, <bold>171</bold>: X, R<sup>1</sup> = F, H (<bold>a</bold>); Cl, H (<bold>b</bold>); Cl, Cl (<bold>c</bold>); Br, H (<bold>d</bold>); <bold>172</bold>: R<sup>1</sup> = H (<bold>a</bold>&#8211;<bold>c</bold>), Cl (<bold>d</bold>&#8211;<bold>f</bold>); R<sup>2</sup>R<sup>3</sup>N = morpholin-4-yl (<bold>a</bold>,<bold>d</bold>); R<sup>2</sup> = H, R<sup>3</sup> = Ph (<bold>b</bold>,<bold>e</bold>); R<sup>2</sup>R<sup>3</sup>N = piperidin-4-yl (<bold>c</bold>,<bold>f</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch037.jpg"/></fig><fig position="float" id="molecules-30-03506-sch038" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch038_Scheme 38</object-id><label>Scheme 38</label><caption><p>Synthesis of 4-aryl-[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(<italic toggle="yes">4H</italic>)-ones <bold>175</bold> (24 compounds), <bold>176</bold> (23 compounds) and <bold>177</bold>&#8211;<bold>180</bold>. <bold>174</bold>&#8211;<bold>176</bold>: R = H, <italic toggle="yes">o</italic>(<italic toggle="yes">p</italic>)-OMe, <italic toggle="yes">p</italic>-OC<sub>3</sub>H<sub>7</sub>, <italic toggle="yes">p</italic>-OC<sub>4</sub>H<sub>9</sub>, <italic toggle="yes">p</italic>-OC<sub>5</sub>H<sub>11</sub>, <italic toggle="yes">p</italic>-OC<sub>6</sub>H<sub>13</sub>, <italic toggle="yes">p</italic>-OC<sub>8</sub>H<sub>17</sub>, <italic toggle="yes">p</italic>-OC<sub>10</sub>H<sub>21</sub>, <italic toggle="yes">p</italic>-OC<sub>12</sub>H<sub>25</sub>, <italic toggle="yes">p</italic>-OC<sub>14</sub>H<sub>29</sub>, <italic toggle="yes">o</italic>(<italic toggle="yes">m</italic>,<italic toggle="yes">p</italic>)-F, <italic toggle="yes">o</italic>(<italic toggle="yes">m</italic>,<italic toggle="yes">p</italic>)-Cl, <italic toggle="yes">m</italic>(<italic toggle="yes">p</italic>)-Br, <italic toggle="yes">o</italic>(<italic toggle="yes">m</italic>,<italic toggle="yes">p</italic>)-Me, <italic toggle="yes">p</italic>-CF<sub>3</sub>, <italic toggle="yes">o</italic>,<italic toggle="yes">p</italic>-Cl<sub>2</sub>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch038.jpg"/></fig><fig position="float" id="molecules-30-03506-sch039" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch039_Scheme 39</object-id><label>Scheme 39</label><caption><p>Synthesis of 1-substituted-[1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones <bold>182</bold>, <bold>183</bold>, <bold>185a</bold>&#8211;<bold>e</bold>, <bold>186a</bold>&#8211;<bold>e</bold>. <bold>181</bold>: R = NHNH<sub>2</sub> (<bold>a</bold>), NH-<italic toggle="yes">i</italic>C<sub>5</sub>H<sub>11</sub> (<bold>b</bold>); <bold>184</bold>: R = pyridine-4-yl (<bold>a</bold>), 4-nitrophenyl (<bold>b</bold>); <bold>185</bold>, <bold>186</bold>: R<sup>1</sup> = H (<bold>a</bold>), Me (<bold>b</bold>), Et (<bold>c</bold>), <italic toggle="yes">n</italic>-Pr (<bold>d</bold>), CH<sub>2</sub>Cl (<bold>e</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch039.jpg"/></fig><fig position="float" id="molecules-30-03506-sch040" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch040_Scheme 40</object-id><label>Scheme 40</label><caption><p>Synthesis of 4-(2-chlorobenzyl)containing [1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones <bold>189</bold> and <bold>190</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch040.jpg"/></fig><fig position="float" id="molecules-30-03506-sch041" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch041_Scheme 41</object-id><label>Scheme 41</label><caption><p>Synthesis of [1,2,4]triazolo[4,3-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-one derivatives <bold>192</bold>, <bold>193</bold>, <bold>195</bold>. <bold>192</bold>: Ar = (furan-2-yl)methyl (<bold>1-6</bold>), (thiophen-2-yl)methyl (<bold>7</bold>&#8211;<bold>10</bold>), 2-chlorobenzyl (<bold>11</bold>), 4-fluorobenzyl (<bold>12</bold>&#8211;<bold>16</bold>, <bold>27</bold>), 4-methoxybenzyl (<bold>17</bold>&#8211;<bold>26</bold>, <bold>28</bold>); <bold>193</bold>, <bold>194</bold>: Ar = 4-fluorobenzyl (<bold>a</bold>), 4-methoxybenzyl (<bold>b</bold>); <bold>195</bold>: Ar, R<sup>1</sup> = 4-fluorobenzyl, 2-morpholinoacetyl (<bold>a</bold>), 4-methoxybenzyl, 2-morpholinoacetyl (<bold>b</bold>), 4-methoxybenzyl, 2-(pyrrolidin-1-yl)acetyl (<bold>c</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch041.jpg"/></fig><fig position="float" id="molecules-30-03506-f009" orientation="portrait"><label>Figure 9</label><caption><p>Interaction of compound <bold>195c</bold> with SHP2 protein. Compound <bold>195c</bold> was shown in colored sticks (green: carbon atom, blue: nitrogen atom, red: oxygen atom). Reproduced with permission of Taylor &amp; Francis [<xref rid="B81-molecules-30-03506" ref-type="bibr">81</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g009.jpg"/></fig><fig position="float" id="molecules-30-03506-f010" orientation="portrait"><label>Figure 10</label><caption><p>Chemical structures of compounds <bold>196</bold>, <bold>197</bold>, <bold>198a</bold>,<bold>b</bold>, and <bold>199</bold>. <bold>196</bold>: R = H (<bold>a</bold>), 4-OEt (<bold>b</bold>), 4-Me (<bold>c</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g010.jpg"/></fig><fig position="float" id="molecules-30-03506-f011" orientation="portrait"><label>Figure 11</label><caption><p>Chemical structures of compounds <bold>200</bold>, <bold>201</bold>, and <bold>202</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g011.jpg"/></fig><fig position="float" id="molecules-30-03506-sch042" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch042_Scheme 42</object-id><label>Scheme 42</label><caption><p>Synthesis of [1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>204</bold> and their aza-analogs <bold>205</bold>, [1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolines <bold>206</bold> and <bold>207</bold>. <bold>204</bold>, <bold>205</bold>: R<sup>1</sup> = H (<bold>a</bold>), Ph (<bold>b</bold>); <bold>206</bold>: R = H (<bold>a</bold>), Br (<bold>b</bold>), Me (<bold>c</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch042.jpg"/></fig><fig position="float" id="molecules-30-03506-sch043" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch043_Scheme 43</object-id><label>Scheme 43</label><caption><p>Synthesis of [1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5-ones <bold>209</bold> and <bold>211</bold>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch043.jpg"/></fig><fig position="float" id="molecules-30-03506-sch044" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-sch044_Scheme 44</object-id><label>Scheme 44</label><caption><p>Synthesis of 2-phenoxybenzo[<italic toggle="yes">g</italic>][1,2,4]triazolo[1,5-<italic toggle="yes">a</italic>]quinazolin-5(4<italic toggle="yes">H</italic>)-ones <bold>212</bold>&#8211;<bold>215</bold>. <bold>213</bold>: R = Et, allyl, 2(3)-Me-benzyl, 3-OMe-benzyl, 3(4)-CN-benzyl, 4-Cl-benzyl, 4-NO<sub>2</sub>-benzyl, 2-(piperidin-1-yl)ethyl, 2-morpholinoethyl, 2-(phtalimido-2-yl)propyl.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-sch044.jpg"/></fig><fig position="float" id="molecules-30-03506-f012" orientation="portrait"><label>Figure 12</label><caption><p>Chemical structures of the compounds <bold>217</bold>&#8211;<bold>220</bold>. <bold>217</bold>: R, R<sup>1</sup> = H, OPh (<bold>a</bold>); H, SMe (<bold>b</bold>); Me, OPh (<bold>c</bold>); H, SO<sub>2</sub>Me (<bold>d</bold>); <bold>218</bold>: R, R<sup>1</sup> = OPh, 4-NO<sub>2</sub>-Bn (<bold>a</bold>); OPh, Et (<bold>b</bold>); SO<sub>2</sub>Me, allyl (<bold>c</bold>); SO<sub>2</sub>Me, 4-NO<sub>2</sub>-Bn (<bold>d</bold>); <bold>220</bold>: R = Et (<bold>a</bold>), <italic toggle="yes">n</italic>-Pr (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g012.jpg"/></fig><fig position="float" id="molecules-30-03506-f013" orientation="portrait"><label>Figure 13</label><caption><p>Chemical structures of the compounds <bold>221</bold>, <bold>222</bold>, <bold>223a</bold>&#8211;<bold>d</bold>, <bold>224</bold>, <bold>225a</bold>,<bold>b</bold>, <bold>226a</bold>,<bold>b</bold>. <bold>223</bold>: R, R<sup>1</sup> = H, allyl (<bold>a</bold>); Me, Bn (<bold>b</bold>); H, Bn (<bold>c</bold>); H, 4-NO<sub>2</sub>-Bn (<bold>d</bold>); <bold>225</bold>: R<sup>1</sup>, R<sup>2</sup> = H, 3-Py (<bold>a</bold>); Me, 4-NO<sub>2</sub>-Ph (<bold>b</bold>); <bold>226</bold>: R<sup>1</sup> = allyl (<bold>a</bold>), cyclohexyl (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g013.jpg"/></fig><fig position="float" id="molecules-30-03506-f014" orientation="portrait"><label>Figure 14</label><caption><p>Chemical structures of compounds <bold>227</bold>, <bold>228</bold>, <bold>229a</bold>,<bold>b</bold>, <bold>230</bold>, and <bold>231</bold>. <bold>229</bold>: R<sup>1</sup> = Et (<bold>a</bold>), allyl (<bold>b</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03506-g014.jpg"/></fig><table-wrap position="float" id="molecules-30-03506-t001" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-t001_Table 1</object-id><label>Table 1</label><caption><p>Inhibitory activities of compounds <bold>A</bold>, <bold>64p</bold>, <bold>64r</bold>, and <bold>64s</bold> against KDM4D.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Inhibition Rate at 10 &#956;M</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> (&#956;M)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>A</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">73.33 &#177; 19.14</td><td align="center" valign="middle" rowspan="1" colspan="1">3.14 &#177; 0.18</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>64p</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">85.06 &#177; 3.54</td><td align="center" valign="middle" rowspan="1" colspan="1">4.03 &#177; 1.02</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>64r</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">88.82 &#177; 9.58</td><td align="center" valign="middle" rowspan="1" colspan="1">0.41 &#177; 0.03</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>64s</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78.06 &#177; 6.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.85 &#177; 0.14</td></tr></tbody></table></table-wrap><table-wrap position="float" id="molecules-30-03506-t002" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-t002_Table 2</object-id><label>Table 2</label><caption><p>BZR Ligand affinity of pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives <bold>72</bold>, <bold>77</bold>, <bold>78</bold> [<xref rid="B58-molecules-30-03506" ref-type="bibr">58</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-03506-i001.jpg"/>
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sup>1</sup></th><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Ki (nM)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>72a</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">OMe</td><td align="center" valign="middle" rowspan="1" colspan="1">Et</td><td align="center" valign="top" rowspan="1" colspan="1">102.4 &#177; 10.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>72b</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">Et</td><td align="center" valign="top" rowspan="1" colspan="1">529.3 &#177; 58.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>77a</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">OMe</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>Ph</td><td align="center" valign="top" rowspan="1" colspan="1">19.0 &#177; 1.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>77b</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">OMe</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>-(2-OMe)Ph</td><td align="center" valign="top" rowspan="1" colspan="1">0.27 &#177; 0.04</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>77c</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">OMe</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>-2-thienyl</td><td align="center" valign="top" rowspan="1" colspan="1">16.7 &#177; 0.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>77d</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">OMe</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>-2-furyl</td><td align="center" valign="top" rowspan="1" colspan="1">15.2 &#177; 1.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>77e</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">OMe</td><td align="center" valign="middle" rowspan="1" colspan="1">CHMe<sub>2</sub></td><td align="center" valign="top" rowspan="1" colspan="1">97.4 &#177; 13.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>78a</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>Ph</td><td align="center" valign="top" rowspan="1" colspan="1">25.9 &#177; 1.98</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>78b</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">H</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>-(2-OMe)Ph</td><td align="center" valign="top" rowspan="1" colspan="1">3.16 &#177; 0.54</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>78c</bold>
</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">H</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CH<sub>2</sub>-2-thienyl</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">13.2 &#177; 0.7</td></tr></tbody></table></table-wrap><table-wrap position="float" id="molecules-30-03506-t003" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-t003_Table 3</object-id><label>Table 3</label><caption><p>Binding at GABA<sub>A</sub>-R subtype of compounds <bold>89</bold>&#8211;<bold>94</bold>, <bold>96</bold> [<xref rid="B61-molecules-30-03506" ref-type="bibr">61</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-03506-i002.jpg"/>
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sup>1</sup></th><th align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">I, %</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>89a</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">CN</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>89b</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">COOEt</td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="top" rowspan="1" colspan="1">32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>90a</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">CN</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>Ph</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>90b</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">COOEt</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="center" valign="top" rowspan="1" colspan="1">19</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>91a</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">COOCH<sub>2</sub>Ph</td><td align="center" valign="top" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="center" valign="top" rowspan="1" colspan="1">14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>91b</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">COOCH<sub>2</sub>(2-OCH<sub>3</sub>Ph)</td><td align="center" valign="top" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="center" valign="top" rowspan="1" colspan="1">18</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>91c</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">COOCH<sub>2</sub>-2-furyl</td><td align="center" valign="top" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>92a</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">COOCH<sub>2</sub>Ph</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>92b</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">COOCH<sub>2</sub>(2-OCH<sub>3</sub>Ph)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">14</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>92c</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">COOCH<sub>2</sub>-2-furyl</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>92d</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">COOEt</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>93</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1,2,4-oxadiazol-3-yl-5-methyl</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>Ph</td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>94a</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">CONH<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">H</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>94b</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">CONH<sub>2</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>2</sub>Ph</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>96a</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1,2,4-triazol-3-yl</td><td align="center" valign="middle" rowspan="1" colspan="1">CH<sub>3</sub></td><td align="center" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>96b</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1,2,4-triazol-3-yl</td><td align="center" valign="top" rowspan="1" colspan="1">CH<sub>2</sub>Ph</td><td align="center" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>97</bold>
</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">I</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">CH<sub>2</sub>Ph</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">43.7</td></tr></tbody></table></table-wrap><table-wrap position="float" id="molecules-30-03506-t004" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-t004_Table 4</object-id><label>Table 4</label><caption><p>Antibacterial activity of pyrido[2&#8242;,3&#8242;:3,4]pyrazolo[1,5-<italic toggle="yes">a</italic>]quinazoline derivatives <bold>130</bold>&#8211;<bold>132</bold> (minimum inhibitory concentration MIC, &#956;g/mL) [<xref rid="B69-molecules-30-03506" ref-type="bibr">69</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus</italic><break/><italic toggle="yes">Aureus</italic> MTCC96</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Bacillus Subtilis</italic> MTCC121</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Staphylococcus Aureus</italic> MLS162940</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Micrococcus Luteus</italic> 2470MTCC</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Klebsiella Planticola</italic> MTCC530</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>130a</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>130b</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td><td align="center" valign="middle" rowspan="1" colspan="1">15.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>130c</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>130f</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>131a</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">15.6</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>132c</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>132d</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>132e</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">15.6</td><td align="center" valign="middle" rowspan="1" colspan="1">15.6</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>132f</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>132h</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8</td><td align="center" valign="middle" rowspan="1" colspan="1">&gt;125</td><td align="center" valign="middle" rowspan="1" colspan="1">7.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ciprofloxacin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.9</td></tr></tbody></table></table-wrap><table-wrap position="float" id="molecules-30-03506-t005" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-t005_Table 5</object-id><label>Table 5</label><caption><p>Inhibition rate of compounds <bold>161</bold> and <bold>164</bold> on melanoma cells A375 in vitro at 100 &#956;M [<xref rid="B81-molecules-30-03506" ref-type="bibr">81</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="6" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-03506-i003.jpg"/>
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">% Inhibition</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">% Inhibition</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>161</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">4-Methylpiperazin-1-yl</td><td align="center" valign="middle" rowspan="1" colspan="1">76.15</td><td align="center" valign="middle" rowspan="1" colspan="1">164</td><td align="center" valign="middle" rowspan="1" colspan="1">(3-MeOC<sub>6</sub>H<sub>4</sub>)NH</td><td align="center" valign="middle" rowspan="1" colspan="1">24.42</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>164</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3-(OCF<sub>3</sub>)C<sub>6</sub>H<sub>4</sub>NH</td><td align="center" valign="middle" rowspan="1" colspan="1">24.08</td><td align="center" valign="middle" rowspan="1" colspan="1">164</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-03506-i004.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">21.89</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>164</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">3-CF<sub>3</sub>C<sub>6</sub>H<sub>4</sub>NH</td><td align="center" valign="middle" rowspan="1" colspan="1">27.93</td><td align="center" valign="middle" rowspan="1" colspan="1">164</td><td align="center" valign="middle" rowspan="1" colspan="1">
<inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molecules-30-03506-i005.jpg"/>
</td><td align="center" valign="middle" rowspan="1" colspan="1">24.77</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SHP244</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorafenib</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.79</td></tr></tbody></table></table-wrap><table-wrap position="float" id="molecules-30-03506-t006" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03506-t006_Table 6</object-id><label>Table 6</label><caption><p>Medicinally important [1,2,4]-triazolo[4,3-<italic toggle="yes">a</italic>]quinazolines.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Substituents</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Biological Activity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">LC<sub>50</sub> Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>175</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">R = 4-Cl</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticonvulsant</td><td align="center" valign="middle" rowspan="1" colspan="1">88.02 mg/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B85-molecules-30-03506" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>175</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">R = 4-Br</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticonvulsant</td><td align="center" valign="middle" rowspan="1" colspan="1">94.60 mg/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B85-molecules-30-03506" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>176</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">R = 4-Me</td><td align="center" valign="middle" rowspan="1" colspan="1">Antidepressant</td><td align="center" valign="middle" rowspan="1" colspan="1">Percentage decrease in immobility duration 82.69% at a dose of 50 mg/kg</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B86-molecules-30-03506" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>193</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Ar = 4-MeOC<sub>6</sub>H<sub>4</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibitory activity against SHP2 protease</td><td align="center" valign="middle" rowspan="1" colspan="1">Percentage inhibition 28.20% at 100 &#956;M</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B81-molecules-30-03506" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>201</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">R<sup>1</sup> = R<sup>3</sup> = H, R<sup>2</sup> = Pr</td><td align="center" valign="middle" rowspan="1" colspan="1">PBD of Plk1 Inhibitory </td><td align="center" valign="middle" rowspan="1" colspan="1">1.03 &#956;M</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B88-molecules-30-03506" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>231</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#945;-Glucosidase inhibitor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.70 &#956;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-molecules-30-03506" ref-type="bibr">89</xref>]</td></tr></tbody></table></table-wrap></sec></back></article></pmc-articleset>